ANNUAL REPORTS IN MEDICINAL
CHEMISTRY
Volume 19
Academic Press Rapid Manuscript Reproduction
ANNUAL REPORTS IN ME...
16 downloads
1220 Views
22MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
ANNUAL REPORTS IN MEDICINAL
CHEMISTRY
Volume 19
Academic Press Rapid Manuscript Reproduction
ANNUAL REPORTS IN MEDICINAL CHEMISTRY Volume 19 Sponsored by the Division of Medicinal Chemistry of the American Chemical Society Editor-in-Chief: DENIS M. BAILEY STERLING-WINTHROP RESEARCH INSTITUTE RENSSELAER, NEW YORK
SECTION EDITORS BARRIE HESP WILLIAM T. COMER FRANK C. SCIAVOLINO BEVERLY A. PAWSON ROBERT W. EGAN RICHARD C. ALLEN
ACADEMIC PRESS, INC.
1984
(Harcouft Brace Jovanovich, Publishers)
ORLANDO SAN DIEGO NEW YORK LONDON TORONTO MONTREAL SYDNEY TOKYO
COPYRIGHT 0 1984, BY ACADEMIC PRESS,INC. ALL RIGHTS RESERVED. NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR A N Y INFORMATION STORAGE AND RETRIEVAL SYSTEM,WITHOUT PERMISSION IN WRITINQ FROM THE PUBLISHBB.
ACADEMIC PRESS,INC.
Orlando, Florida 32001
United Kingdom Edition published by ACADEMIC PRESS. INC. ( L O N D O N ) LTD.
24/20 Oval Road, London N W l 7DX
LIBRARY OF CONQRESS
CATALOG CARD NUMBER:
I SBN 0- 12-0405 19-9 PRINTED IN THE U N m STATES OF AMERICA 84 85 86 81
9 8 7 6 5 4 3 2 1
6 6 - 26 84 3
CONTRIBUTORS PREFACE
xi
...
Xlll
I.
CNS AGENTS
Section Editor: Barrie Hesp, Stuart Pharmaceuticals, Division of ICI Americas, Wilmington, Delaware 1.
Analgesics 0. William Lever, Jr., Kwen-Jen Chang, and John D. McDermed, Wellcome Research Laboratories, Burroughs Wellcome Co., Research Triangle Park, North Carolina
1
2 . Antianxiety Agents, Anticonvulsants, and Sedative-Hypnotics Joseph P. Yevich, James S. New, and Michael S. Eison, Bristol-Myers Research and Development, Evansville, Indiana
11
3. Antipsychotic Agents Tomas de Paulis and Sten Ramsby, Astra Lakemedal AB, Sweden
21
4. Cognitive Disorders Fred M. Hershenson and John G. Marriott, Warner Lambertl Parke-Davis, Ann Arbor, Michigan
31
5.
Adaptive Changes in Central Nervous System Receptor Systems B. Kenneth Koe and Fredric J . Vinick, Pfzer Central Research, Groton, Connecticut
6 . CNS Autoreceptors as Targets for Drug Design Pieter B. M. W. M. Timmermans, Department of Pharmacy, Division of Pharmacotherapy, University of Amsterdam, Plantage Muidergracht 24, 1018 TV Amsterdam, The Netherlands V
41
51
vi
Contents
11. PHARMACODYNAMIC AGENTS Section Editor: William T. Comer, Bristol-Myers Research and Development, 345 Park Avenue, New York, New York 7. Antihypertensive Agents Peter Sprague and James R. Powell, The Squibb Institute for Medical Research, Princeton, New Jersey
61
8. Cardiotonic Agents Bernd Wetzel and Norbert Hauel, Dr. Karl Thomae GmbH, 0-7950 Biberach, Federal Republic of Germany
71
9. Agents for the Treatment of Peptic Ulcer Disease David E. Bays and Roger Stables, Glaxo Group Research Ltd., Ware, Hertfordshire, England
81
10. Pulmonary and Antiallergy Agents John H. Musser, Anthony F. Kref, and Alan J . Lewis, Wyeth Laboratories, Inc., Philadelphia, Pennsylvania
93
111. CHEMOTHERAPEUTIC AGENTS
Section Editor: Frank C. Sciavolino, Pfizer Central Research, Groton, Connecticut 11, Antibacterial Agents E. S. Hamanaka and M. S. Kellogg, Pfizer Central Research, Groton, Connecticut
107
12. Antiviral Agents James L. Kelley, Wellcome Research Laboratories, Burroughs Wellcome Co., Research Triangle Park, North Carolina
117
13. Antifungal Chemotherapy Michael B. Gravestock and John F. Ryley, ICI Pharmaceuticals Division, Mereside, Alderley Park, Macclesfield, Cheshire, England
127
14. Antineoplastic Agents Terrence W. Doyle, Bristol-Meyers Pharmaceutical R & D Division, P.O. Box 4755, Syracuse, New York
137
15. Antiparasitic Agents Bernard J . Banks, Pfizer Central Research, Sandwich, Kent, England
147
Contents
vii
IV. METABOLIC DISEASES AND ENDOCRINE FUNCTION Section Editor: Beverly A. Pawson, Roche Research Center, Hoffmann-La Roche Inc., Nutley, New Jersey 16. Progress in the Development of Antiobesity Drugs Ann C. Sullivan, Susan Hogan, and Joseph Triscari, Roche Research Center, Hoffmann-La Roche Inc., Nutley, New Jersey 17. Aldose Reductase Inhibitors as a New Approach to the Treatment of Diabetic Complications Christopher A. Lipinski and Nancy J . Hutson, Pfizer Central Research, Groton, Connecticut 18.
Vitamin D: Metabolism and Mechanism of Action Hector F. DeLuca and Heinrich K . Schnoes, Department of Biochemistry, University of Wisconsin-Madison, College of Agricultural and Life Sciences, Madison, Wisconsin
19. Interleukin 2 John J . Farrar, William R. Benjamin, Lorraine Cheng, and Beverly A. Pawson, Roche Research Center, Hoffmann-La Roche Inc., Nutley, New Jersey
157
169
179
191
V. TOPICS IN BIOLOGY Editor: Robert W. Egan, Merck Institute for Therapeutic Research, Rahway, New Jersey 20. The Inactivation of Cytochrome P-450 Paul R. Ortiz de Montellano, Department of Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco, California
20 1
2 1. Phospholipases Eduardo G. Lapetina, Department of Molecular Biology, Wellcome Research Laboratories, Burroughs Wellcome Co., Research Triangle Park, North Carolina
213
22. Vaccine Synthesis by Recombinant DNA Technology Dennis G. Kleid, Department of Vaccine Development, Genentech Inc., 460 Point San Bruno Blvd., South San Francisco, California
223
23. Collagenases in Tumor Cell Extravasation T. Turpeenniemi-Hujanen, U . P. Thorgeirsson, and L. A . Liotta, Laboratory of Pathology, NCI, NIH, Bethesda, Maryland
23 1
viii
Contents
24. Biology of Leukotrienes William Kreutner and Marvin I . Siegel, Schering-Plough Corporation, Bloomfield, New Jersey
24 1
25. Endogenous Natriuretic Agents Mary Anna Napier and Edward H . Blaine, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey and West Point, Pennsylvania
25 3
VI. TOPICS IN CHEMISTRY AND DRUG DESIGN
Section Editor: Richard C. Allen, Hoechst-Roussel Pharmaceuticals Inc., Somerville, New Jersey 26. Enzymic Methods in Organic Synthesis Mark A. Findeis and George M . Whitesides, Department of Chemistry, Harvard University, Cambridge, Massachusetts
263
27. Stable Isotopes in Drug Metabolism and Disposition Thomas A. Baillie and Albert W, Rettenmeier, Department of Medicinal Chemistry, University of Washington, Seattle, Washington Lisa A. Peterson and Neal Castagnoli, Jr., Department of Pharmaceutical Chemistry, University of California, San Francisco, California
273
28. Drug Discovery at the Molecular Level: A Decade of Radioligand Binding in Retrospect Michael Williams and David C. U'Prichard, Nova Pharmaceutical Corporation, P,0. Box 21204, Wade Avenue, Baltimore, Maryland 29. Forskolin and Adenylate Cyclase: New Opportunities in Drug Design Kenneth B. Seamon, National Center for Drugs and Biologics, FDA, Bethesda, Maryland
30. Recent Progress in the Rational Design of Peptide Hormones and Neurotransmitters Victor J . Hruby, John L. Krstenansky, and Wayne L. Cody, Department of Chemistry, University of Arizona, Tucson, Arizona
VII.
WORLDWIDE MARKET INTRODUCTIONS
Section Editor: Richard C. Allen, Hoechst-Roussel Pharmaceuticals Inc., Sornerville, New Jersey
283
293
303
Contents
31.
To Market, to Market-1983 Richard C . Allen, Hoechst-Roussel Pharmaceuticals Inc., Somerville, New Jersey
COMPOUND NAME AND CODE NUMBER INDEX CUMULATIVE CHAPTER TITLES KEYWORD INDEX
ix
313
327 335
This Page Intentionally Left Blank
Allen. Richard C . . . . Baillie. Thomas A . . . Banks. Bernard J . . . . Bays. David E . . . . . Benjamin. William R . . . Blaine. Edward H . . . . Castagnoli. Neal. Jr . . . Chang. Kwen-Jen . . . . . . Cheng. Lorraine Cody. Wayne L . . . . DeLuca. Hector F. . . . de Paulis. Tomas . . . Doyle. Terrence W . . . Eison. Michael S . . . . Farrar. John J . . . . . Findeis. Mark A . . . . Gravestock. Michael B . . Hamanaka. E . S . . . . Hauel. Norbert . . . . Hershenson. Fred M . . . Hogan. Susan . . . . Hruby. Victor J . . . . Hutson. Nancy J . . . . Kelley. James L . . . . Kellogg. M . S . . . . . Kleid. Dennis G . . . . Koe. B . Kenneth . . . Kreft. Anthony F. . . . Kreutner. William . . . Krstenansky. John L . . . Lapetina. Eduardo G . . . Lever. 0. William. Jr. . .
. . . 313 . . . 273
Lewis. Alan J . . . . . . Liotta. L . A . . . . . . Lipinski. Christopher A . . . Marriott. John G . . . . . McDermed. John D . . . . Musser. John H . . . . . Napier. Mary Anna . . . New. James S . . . . . . Ortiz de Montellano. Paul R . . Pawson. Beverly A . . . . Peterson. Lisa A . . . . . Powell. James R . . . . . Ramsby. Sten . . . . . Rettenmeier. Albert W. . . Ryley. John F. . . . . . Schnoes. Heinrich K . . . . Seamon. Kenneth B . . . . Siegel. Marvin I . . . . . Sprague. Peter . . . . . Stables. Roger . . . . . Sullivan. Ann C . . . . . Thorgeirsson. U . P. . . . Timmermans. Pieter B.M. W.M. Triscari. Joseph . . . . . Turpeenniemi.Hujanen. T. . U’Prichard. David C . . . . Vinick. Fredric J . . . . . Wetzel. Bernd . . . . . . Whitesides. George M . . . Williams. Michael . . . . Yevich. Joseph P. . . . .
. . . 147 . . . 81 . . . 191
. . . 253 . . . 273 . . . 1 . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . .
. 191 . 303 . 179
. 21 . 137 .
11
. 191 . 263 . . . . . . .
. . . .
. . . .
. . .
127 107 71 31 157 303 169 117 107 223 41 93 241 303 21 3 1
xi
. .
93
. . 231 . . 169 . . 31 . .
1
. .
93 253 11 201 191 273 61 21 273 127 179 293 241 61 81 157 231 51 157 231 283 41 71 263 283 11
. . . .
. . . .
. . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . .
. . . .
This Page Intentionally Left Blank
PREFACE
Volume 19 of Annual Reports in Medicinal Chemistry contains 30 chapters organized in the traditional format of previous volumes-in sections titled CNS Agents, Pharmacodynamic Agents, Chemotherapeutic Agents, Metabolic Diseases and Endocrine Function, Topics in Biology, and Topics in Chemistry and Drug Design. In addition, this year the editors experiment with a new section that summarizes worldwide first market introductions of therapeutic agents during the previous calendar year. In the first six sections are included a mix of literature updates on a broad sweep of drug research areas, as well as reviews of highly specialized and newly emerging technologies. Topics covered for the first time include CNS autoreceptors, interleukin 2, endogenous natriuretic factors, and enzymic methods in organic synthesis. Phospholipases and collagenases, touched on in earlier Annual Reports, receive in-depth coverage in separate chapters in this volume. Reviews on recombinant DNA technology and the biology of leukotrienes bring the reader up to date in these highly important and active areas. In the new section, Worldwide Market Introductions, the chapter “To Market, to Market” presents an aspect lacking in the previous 18 volumes of Annual Reports-an organized follow-up on market introduction, the ultimate endpoint of the many agents reviewed. The accumulation of data for this chapter proved formidable and while a number of sources were used, it is inevitable that we missed some drugs. We hope we have not made a major omission! Finally, I want to extend my gratitude to the section editors and contributors whose time and effort made Volume 19 possible, and in particular to Martha Johnson, whose assistance was invaluable in preparing the final copy. Denis M . Bailey Rensselaer, New York M a y I984
...
XI11
This Page Intentionally Left Blank
Section I
-
CNS Agents
Editor: Barrie Hesp, Stuart Pharmaceuticals, Division of ICI Americas, Wilmington, DE 19897 Chapter 1.
Analgesics
0. William Lever, Jr., Kwen-Jen Chang and John D. McDermed Wellcome Research Laboratories, Burroughs Wellcome Co. Research Triangle Park, NC 27709 Efforts toward alleviation of pain continue at an intensive pace at the clinical, pre-clinical and basic research levels. In this review, recent research developments in opioid and non-opioid analgesia are presented, along with selected clinical highlights. Opioid Receptors and Ligands Endogenous opioids and their multiple receptors continue as the focus of vigorous research. The proceedings of the 1983 International Narcotic Research Conferenc were published,’ and reviews were recently p o ided on opioid peptides,2,$ opioid receptors and their functional roles, macology and therapeutic implications of enke halins and endorphins,Shycardiovascular effects of endogenous opioids, opioids and the adrenalpituit ry axis, opioids and the hippocampus,l2 substance in nociception,’$ potential therapeutic roles for opioid antagonists’‘, roles of opioid pept‘des in appetite control,l 5 and autoradiography of opioid receptors. 16
6-8
’’
Biosvnthesis and Metabolism of Opioid Peptideg - Opioid peptide biosynzhesis was summariz in our previous review nd additional overviews of the biosynthesis”-22 and distribution2o 9 7 2%25 of endogeneous opioids have appeared. Several inhibitors of enkephalin convertase, a carboxypeptidase which may liberate enkephalins from immediate precursors, Degradation of enkephalins by peptidases continues were described 2 6 9 2 7 to be s t ~ d i e d , ~ ~ , ~ the ~ analgesic properties of inhibitors of as28z54 Thiorphan, N-[(R,S)-3-mercapto-2-benzylproenkephalin metabolism. panoyllglycine, is an enkephalinase inhibitor (Ki = 3.5 nM) which also inhibits (Ki = 140 nM) angiotensin-converting enzyme (ACE).32 By contrast, the retro-inuerso isomer, retro-thiorphan [(R,S)-HS-CH2-CH(CH2Ph)- N H CO-CH2C02H], does not inhibit ACE but retains potent enkephalinase inhibition (Ki = 6 nM) and has an inuiuo analgesic potencs2(i.c.v.; mouse hot plate, mouse writhing) similar to that of thiorphan. Thiorphan was reported to reduce postmyelographic side effects (headache, nausea, sciatica) when administered (i.v.) to patients prior to m y e l ~ g r a p h y . ~ ~ Oral administration of D-phenylalanine, a carboxypeptidase inhibitor, was found to be of benefit in patients with certain chronic ain complaints; the drug was most effective after 3-5 weeks of therapy.38
’’
Opioid Receptors and Pharmacology - The previously defined opioid receptor sub-types ( P , ~ , K , E , U ) continue to be studied, and an additional binding site, designated the A site, was recently described in rat brain.35 The A
ANNUAL REPORTS IN MEDICINAL CHEMISTRY-I9
Copyright 0 1984 by Academic Press, Inc. All nghts of reproduction in any form reserved. ISBN 0-12-040519-9
-2
Sect. I
- CNS Agents
Hesp, Ed.
sites have a regional distribution in brain different from that of p receptors and have a high affinity for 4,5-epoxymorphinans (u., morphine, naloxone) and low affinity for non-epoxymorph‘nan p ligands, K ligands, 6 ligands, and “universal” ( p , 6 , ~ )ligands.j5 Evidence that u receptors may differ from phencyclidine receptors was provided by the report of a naloxone-inaccessible u receptor in rat brain and spinal cord which stereoselectively binds (+)-ethylketocyclazocine and (+)-N-allylnormetazocine [(+)-SKF 10,0471 and has drug selectivity and regiona13$istribution different from those of p, 6 and phencyclidine receptors. Additional studies on u agon t and on their phencyclidine-like behavioral effects were reported.jf-81The benzomorphan Mr 2034 [ ( - ) - N (2-tetrahydrofurfuryl)normetazocinel, originally proposed as a K liga d is more accurately described as a universal ( p , 6 , ~ , 0 ) opioid ligand.42 The nature of opioid binding continues to be e ~ p l o r e d . ~ ~In ’ ~rat ~ brain and spinal cord, p a@jl 6 sites predominate, and K sites represent Both 6 and p receptors mediate antinocionly 10% of total binding. pro il s of i.~and K agonists were ~ e p t i o n . ~ The ~ - ~antinociceptive ~ reported to be distinguishable inuiuo, 55,5‘ and the affinities of K agonists for p and 6 receptors invivo in the rat were assessed.55 Respiratory depression is caused by opioid agonists but may be mediat b a receptor population different from that producing antinociception.5‘-521 Evidence suggesting th t the p sites in mouse vas deferens and guinea pig ileum are different,60,g1 and support for the possibility that opio agonists and antagonists interact with different sites on )1 receptors? were also presented. The antitussive effects of opioids appear to arise from interaction with pharmacological receptors which are less st eoselective and less sensitive to naloxone than the analgesic c tors.g5 Attempts Additional data to purify opioid receptors have progressed slowly. were cited for the coexistence of allosterically coupled morphine an enkephalin receptors within an opioid receptor complex in rat brain.26,67
sQ*gFs
-
Newer Endonenous ODioid Peptides The number of endogenous opioid peptides continues to grow rapidly. Several fragments of proenkephalin A have received recent attention. A u-selective octapeptide fragment, Gly-Gly-Phe-Met-Arg-Arg-Val-NH2, has been isolated from bovine brain6”;nd from h y g n pheochromo~ytoma~~ and has been designated both as metorE, a 25-amino acid fragment, phamide and as a d r e n ~ r p h i n . ~Peptide ~ binds preferentially to 1.1 and K receptors but has minimal analgesic tail flick) in potency (i.c.v., The C-terminal heptapeptide fragmen mous: Met -enke h lin-Argg-Phe7, has e n found in human and rabbit pl sma,72, rat brain 75-iJ5and spinal c~rd,~‘,?~ and lung of several species.78 A unique high affinity binding site was described in rat lung membranes.78 The role of this peptide as a Met-enkephalin pr cursor or a transmitter is speculative. The fragment Met5-enkephalin-Arg&-Gly7-Leu8 is a p- and &-selective ligand which binds poorly to K receptors; synthetic extension to incorporate a Lys9 residue improved K affinity 10-fold but did not alter p or 6 binding or the p,6-~electivity.~~
-
Svnthetic ODioid PeDtide Analonues Structure-activity studies on analogues of the exceptionally selective ligand morphiceptin (TyrPro-Phe-Pro-NH2) were reported.g’ One of the most potent analgesics was PL017 ( Tyr-Pro-NMePhe-D-Pro-NH2). 6o A peptide containing the PL017 sequence at the N-terminus and the dyn-A -17) sequence at the C-terminus had high affinity for both p and K s i t e s 3 Analogues of 8-endorphin containing the dynorphin (5-13) or (6-13) sequences showed excitatory behavioral effects in the mouse t had no analgesic properties in the By contrast, a 8-endorphin analogue mouse tail flick assay (i.c.v. 1 with a dermorphin sequence (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser) in residues
.”
Chap. 1
Analgesics
Lever, Chang, McDermed
3
(1-7)wag2several-fold more potent than B-endorphin (mouse tail flick, A number of additional studies on the dermorphins, potent i.c.v.). Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) originally opioid heptapeptides (u., isolated from the skin o S th American frogs, and their synthetic analogues were reported.83-gH A heptapeptide is not required for high activity. The dermorphin (1-4) analogue H2N-C(NH)-Tyr-D-Ala-Phe-Gly-NHadamantyl, which contains a guanidino N-terminus and an N-adamantyl amide moiety, is a powerful p-agonist (mouse tail flick, i.c.v.) with potency 30,000 and 1000 times that of Met-enkephalin and morphine, r e ~ p e c t i v e l y . ~ ~ New &-selective li ands have emerged, including deltakephalin (TyrD-Thr-Gly-Phe-Leu-Thr),8g certain enkephalin dimers,l7vgo and cyclic enkephalin analogues containing disulfide-linked penicillamine and cystine residues.91 Possibly the most highly 6-selective ligands reported to date are the bis-penicillamine 14-membered cyclic disulfide-containing en~ kephalin analogues DPDPE (la) and DPLPE ( & ) , which gave 6 4 selectivity By contrast, ratios in isolated tissues of 3164 and 1088, respectively. the 14-membered cyclic enkephalin analogue 2, as well as a number of partial retro-inuerso modifications of this cyclic structure, are p-selective ligands 93 Other approaches to conformational restriction were reported 941 95 as were enkephalin analogues incorggrating dehydroamino cyclopropyl-containing amino acids, y g 9 p-nitro substitution in Phe4,100 ketomethylene replacement of the T r-Gly and Gly-Gly amide linka e lo' modifications at the C-terminus,182 S-oxidized m t io nine,'Oj'and phosphonate analogues of the C-terminal residues.7ob -
acid^,^^,^^
!Q
R1 = C02H, R 2 = H
lb
R1 = H, R 2 = C 0 2 H (DPLPE)
(DPDPE)
T y r -D -Ala-G Iy -P he- Leu - NH-C H, C H,-X
QN3
3 X=NH X = NHCO(CH2)2NH
4
NO z
New Ligands, SAR, Structural Studies - Irreversible opioid ligands are of interest as receptor probes. The photolabile enkephalin d r'vatives 3 and and the 2, lo5 the chloromethyl ketone Tyr-D-Ala-Gly-Phe-Leu-CH$l, fentanyl isothiocyanate 5Io7 all appear to label 6 receptors selectively, whereas the etonitazene isothiocyanate 61°7 appears to inactivate only p receptors. A variety of epoxymorphinans with alkylatin groups attached Both B-CNA (1) through amino groups at C-6 are opioid affinity labels.'ol and a-CNA (8) produce irreversible antagonism at p, K and 6 receptors, and a-CNA appears to have an additional irreversible agonist property in the guinea pig ileum assay.lo9 Further studies in the ileum with B-FNA ( 9 ) and B-FOA (lo) led to the suggestigs that 1.1 agonists and antagonists interact with distinct receptor sites. Comparisons of isolated tissue data for various epimeric antagonist affinity labels indicated that the chiralit at C-6 is an important determinant of receptor alkylating The configuration at C-6 was shown to determine the ring C ability.'lo solution conformations of the oxymorphamines: rinh C is a chair in the B-epimer 11 and a twist boat in the a-epimer 12.
4 -
Sect. I
- CNS Agents
Hesp, Ed.
7 -
R1= N(CH2CH2C11 R2=H, R 3 = C H 2 d 2‘
(P-CNA)
8
R’= H, R2= N(CH2CH2C1)2, R3= C H 2 U
(a-CNA)
9
R1= NHCOCH= CHC02Me, R2=H, R3= C H 2 - a
10 R 1 = NHCOCH= CHC02Me, R2: 11 R1= NH2, R2= H, R3= Me 12 R1= HI R2= NH2, R3=Me
H, R3= Me
(P-FNA)
( 0 ~ 0 ~ )
Of four pentazocine analogues in which the N-alkyl group was folded was the most potent ( . 5 X back into 6- or 7-membered riyj$,lFgmpound pentazocine, mouse writhing). . Conjugate addition of alkyl groups to the 8-position of codeinone gave a series of analgesics in which the 8 - a - e p i m ~were ~ ~ generally more potent (mouse tail flick) than the 8-BSyntheses of two isomeric groups of thiazolomorphans were epimers. reportjTd o which 14 was the most potent (10 X codeine, mouse writhing) 5:11g Compound 14 is a 9-B-epimer and is somewhat more potent than the 9-a-epimer, in contrast with precedents from the benzomorphans,
a
.
u
14
15
There wer r rts of further modifications of ring C of morphine and From a large series of active compounds oxet n codeine . 1’i7-ci88 was about 700 X more potent (mouse writhing, s.c.) than morphine. Translocation of the hydroxyl group from the 4- to the 1-position destroyed activity in N-meth lmorphinan-6-ones.120 S ntheses of r’ng-C-contracted 6,14-exo-ethen m rphinans,12’ 2‘-thiobenzomorphans,12’ morphinanones,82j and more exotic heterocyclic analogs12‘ were described without indications of biological activity. A series of fentanylenkephalin hybrids were essentially inactive in isolated tissue assays. 125
?18
The roles of hydrophobic and hydrophilic (amphiphilic) domains of the &endorphin surface in relation to ph s’cochemical,biochemical, analgesic and binding activities were explored. ‘2‘,127 Studies on four large synthetic peptides designed to simulate or modify the surface properties of &endorphin led to the conclusion that exact residue homology may be less important to bioactivity than the gross physicochemical properties of the binding surface. In a complementary approach, a 40-residue peptide designed to mimic the binding site of opioid receptors was synthesized. 128 It displayed modest but significant affinity for several opioid peptides and discriminated them from non-opioids. (Leu-enkephalin, KD = 5.8 x
Chap.
Analgesics
1
Lever, Chang, McDermed
2
Non-Opioid Analgesia Direct modulation of opioid pathways has been thetmajor focus of modern analgesic research, but other modalities for antinociception appear to involve such pathways only indirectly or not at all. Stress, of which traditional Chinese acupuncture and modern electroacupuncture may be considered special cases, is one such mode. Early reports of naloxone blockade of acupuncture analgesia suggested mediation by endogenous opioids.129 However, more recent studies contradict this hypothesis. 130 A superficially related clinical procedure for control of chronic pain is electrical transcutaneous or spinal cord nerve stimulation. A doubieblind placebo-control d study indicated that such analgesia is not The neurophysiological mechanisms mediating naloxone-reversible. stress-induced autoanalgesia complex and depend subtly on the paraElectrical stress-induced analge meters of the applied stress. tg3 animals apparently involves both opioid and non-opioid substrates. Front foot shocks in rats produced naloxone-blocked morphine-tolerant analgesia (tail flick) unaffected by h pophysectomy, and therefore describable as opioid, non-hormonal.13y However, similar shocks to the hind feet gave analgesia unaffected by naloxone, tolerance, or morphtS3 Moreover, the hypophysectomy and therefore non-opioid, non-hormonal. footshock regimen influenced the nature of antinociception: prolonged intermittent shocks produced opioid-dependent analgesia, whereas br'ef continuous shocks produced non-opioid analgesia (rat tail flick). 134 esions of the raphe nucleus attenuated the latter but not the ~ ~ ~ ~ though ~ ~ other ~ ' studies i 3 h have i licated the raphe nucleus in mediation of both types of analgesia. 1%
'3'
's5
79,
GABA-ergic mechanisms have been implicated in antinociception. In normal volunteers the GABA agonist THIP (16)produced analgesia against dental pain without tolerance, atory depression, or other characteristics of opiate therapy. resg3S In an open study of cancer patients with chronic pain refractory to mild analgesics, THIP (20 mg i.m.) gave subjective pain control, but side effects (blurred vision, sedation) were dose-limiting.137 The GABA;ergic benzodiazepine midazolam (IJ) given intrathecally to anaesthetized dogs strongly att n ated nociceptive sympathetic reflexes to electrical nerve stimulation,'38 Baclofen and other GABA agonists have a so en found to be central antinociceptives in exThese effects were generally naloxone-in perimental animals. sitive, though indi ct effects o opioid substrates may be present.785GABA analgesia may"? o r may not144 be cross-tolerant to morphine.
139-1''
*N \
16
17
HO
18 -
Intrathecal administration of the -agonist clonidine attenuated nociceptive responses in rats and cats.9L45 Attempts to characterize further the receptors involved as a l or a2 gave inconclusive results.146 Studies with monoamine depletors indicated that intact spinal adrenergic and serotonergic fibers are 'nvolved in a complex way in expression of morphine analgesia in rats. 147 Adrenergic systems may mediate foot shock analgesia (rats, tail flick).148 A study in terminal cancer patients
-6
Sect. I
- CNS Agents
Hesp, Ed.
indicated effective control of chronic pain by epidural labetalol, a mixed a- and 8-antagonist though the result might have been due to a local anaesthetic effect. Several studies indicate that opioids acti ate erotonergic neurons and increase 5-HT turnover in the spinal cord. 130-155 Intrathecal 5-HT produced antinociception in mice (tail flick).153 The role of serotonergic neurons in opioid analgesia may be modek-dependent.152. Central cholinergic fib rs may also mediate analgesia,l5 and both m ~ s c a r i n i c l ~ ~ and nicotinicl5' agonists produce analgesia in rodents by central mechanisms. There is evidence that cholinergic connections m d'ate the expression of both endogenous and exogenous opioid analgesia.754,157 Meptazinol is one drug in clinical use (videinfra) which appears to take fortuitous advantage of the opioid-cholinergic connection. In rodent antinociceptive models it displays ph r acology appropriate for an opiate partial agonist and a cholinomimetic.?58 The analgesic properties of cannabinoid derivatives are well known, though no such drugs have yet been demonstrated to be substantially free from the CNS side eff ct to which cannabissativa owes its popularity as a substance of abuse. 15% 7 Igo However, cannabinoid analgesia has appeal due t failure to induce to its opioi independent mechanism and its con dependence.1 g i . A series of preliminary reports'ig'"985 have described the syntheses of analgesics modelled on 9-nor-9-8-hydroxyhexa drocannabinol; compound 18 was the most potent member (>60 X morphine). %1 Clinical Hinhliahts ODioid Analgesics - Clinical evaluation of the newer opioi agonistantagonist ugs continues, and theirl@algesic efficacy,lg6 phar aand dependence profileslgl9 were cokinetics,%7 receptor pharmacology, recently revi w d. A review on the pharmacology and therapeutic efficacy of nalbuphin 778 and a compilation of clinical experiences with injectable meptazinol'71 were ovided. Human pharmacokinetic data for meptazi 01 were reported. 1729 lSi5 Efficacy studies with epidura pentazocine,174 epidural buprenorphine,175 and parenteral d e ~ o c i n e 'for ~ ~ postoperative pain relief were reported. Oral cirayadol was superior to codein relief of advanced cancer ain. 177 The clinical pharmacokinetics77p;nd applications in anesthesiaq7g of fentanyl and its derivatives were a1 additional reports on enkephalin analogues reviewed. 8 ' e % ' For relief of severe episiotomy pain, metkephamid appeared. 1 acetate (140 mg, i.m.) was superior to mepiridine (100 mg, i.m.) but minor side effects wer more frequent; a lower dose (70 mg, i.m.) of metkephamid was ineffegbive.'80 The preclinical pharmacology of metkephamid was Intrathecal administration of D-Ala2-D-Leu5-enkephalin described. (DADL) to a single patient showed that DADL could provide a powerful, long-lasting analgesic effect, and also is ?@able of producing profound, naloxone-reversible respiratory depression.
'
- Therapeutic appliNon-Ster%dal Antiinflammatory Drugs (NSA ' O f clinical pharmacokineticsq and mechanism of action189 cations, of the peri herally-acting N AIDS were reviewed, and the pharmacology of and suprofen19s were discussed in detail. Ibuprofen diflunisal (400 mg, p.0.) was more effective than z mepirac (100 mg, p . 0 . ) or aspirin (600 mg, p.0.) against episiotomy pain,182 and rectal indomethacin (100 mglgfight hourly) provided effective analgesia following thoraA dose-r sponse study with i.v. indoprofen for postoperative cotomy pain was reported,19f and in women with moderate to severe cancer pain, indoprofen (400mg, i.v.) appeared equivalent to morphine (10 mg,
-
.
Chap. 1
Analgesics
Lever, Chang, McDermed
1
i.m.). lg5 Additional studies with diflunisal,l g 6 9 l g 7 flurbiprofen,lg8 fendosal, Ig9 and diclofenac2” were reported. Therapeutic applications of 2@ were rsJ&ewed.201 f202 In preclinical NSAIDs in primary dysmenorrh were described as effective studies, propionic acids and 3 NSAIDs with reduced ulcerogenic properties.
Migraine - Headache is the most common pain syndrome for which analgesic medication is applied and is associated with a large number of disorders with different etiologies. Comments here will be restricted to vascular headache, particularly migraine, which is probably a symptom of a reactive compensatory mechanism occurring late in a poorly understoojofathogenetic A classisequence. A provocative review of this topic is available. cal migraine attack begins with a prodromal phase which i vol es regional cerebral vasoconstriction leading to hypoxi ischemia,209-208 and possibly reduced neuronal 5-HT synthesis.208’ Onset of the painful headache phase is marked by vasodilation,206 which may reflect a defective vascular homeostatic mechanism.209 Partly because of a dearth of animal models, treatment has evolved empirically from clinical experience and has traditionally consisted of symptom management.210,21 Most drug treatment in the past focused acutely on the painful vasodilation phase. The efficacy of dihydroergotamine212 apparently results from its vasoconstrictor effects. NSAIDs inhibit prostacyclin biosynthes’s a d reduce the intensity, but not the frequency, of attacks.213,214 Newer therapies have addressed prevention of attacks. The prophylactic effects of B-blockers have been established, though their mechanism of action remains speculative. In a long-term placebocontrolled study of propranolol in 245 migraineurs, more than 70% of the subjects had fewer and less severe attacks, and 46% reported th t their improvement was maintained after discontinuation of medication.$15 Nadolol was shown to similarly prophylactic, whereas pindolol and alprenolol were not.28g Calcium channel blockers are the most recent additions to migraine prophylaxis. Clinical studies with flunarizine, a Ca++ blocker with anti-vasoconstrictive and anti-hypoxic effects in animals, indicate that it is clearly ophylactic, though its effect on severity of attacks is marginal.217,28‘ Small clinical studies with nimodipine, nifedipine, and verapamil indicate efficacy for these also.219 Nimodipine appears to produce the fewest side effects, probably because of its high selectivity for cerebral vasculature. These agents appear to prevent migraine attacks by attenuating Ca++-dependent cerebrai vasoconstriction irrespective of the nature of the triggering constrictive stimulus.220’ References 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13.
F . Porreca and T.F. Burks, Eds., Life Sci., 33 Su 1 I pp 1-782 (1983). Opioid Peptides”, J. Hughes, Ed., Brit. M a . ’ B ~ r f , g1-106(1983). , J.W. Thompson, Brit. Med. J. 288 259 (1984). A. Grossman and V. Clement:JKes, Clin. Endocrinol. Metab.. 12,31 (1983). J.A. Gilbert and E. Richelson. Mol. Cell. Biochem. 55 83 ( 1 9 8 3 r A. Herz, J. Neural. Transm. (Suppl.),3 , 2 2 7 (198i)-’ D.L. Copolov and R.D. Helme, Dru s 26 503 (1983). F.E. Bloorn.Ann. Rev. Pharmaeol.%&Zbl., 23,151 (1983). V. Clement-Jonesand G.M. Besser, Brit. MexBull. 39 95 (1983). J.W. Holaday, Biochem. Pharmacol., 32,573 (1983)’fim Rev. Pharmacol. Toxicol., 23,541 (1983). S. Mousa and D. Couri. Subst. Alcohornctions Misuse 4 1 (1983). W.A. Corrigall, Pharmacol. Biochem. Behav. 18 255 {&3), B. Pernow, Pharmacolog. Rev., 35,85 (1983).’-’
-8 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59: 60. 61. 62. 63. 64. 65. 66. 67. 68. 69.
70.
71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87.
Sect. I
-
CNS Agents
Hesp, Ed.
L.F. McNicholasand W.R. Martin, Drugs 27 81 (1984). (a)J.E. Morley and A.S. Levine, Lancet, 1: g 8 (1983);(b) J.E. Morley, A S . Levine, G.K. Yimand M.T. Lowy, Neurosci. Biobehav. Rev., 1,281 (1983). J.K. Wamsley, Pharmacolog. Rev., 35,69 (1983). O.W. Lever,Jr., K.-J. ChangandJ.bMcDermed.Ann. Rep. Med. Chem.,8,51(1983). J.L. Marx, Science, 220,395 (1983). R.V. Lewis and A.S.=ern, Ann. Rev. Pharmacol. Toxicol. 23 352 (1983). S. Udenfriend and D.L. Kilpatrick, Arch. Biochem. Bioph;CiZl, 309 (1983). H. Imura, Y. Nakai, K. Nakao. S. Oki, I. Tanaka, H. J i n g a m i , m o s h i m a s a . T. Tsukada, Y. Ikeda, M. Suda and M. Sakamoto, J. Endocrinol. Invest., ti, 139 (1983). J.Hughes, Brit. Med. Bull., 39,17(1983J. S.F. Atweh and M.J. Kuhar,%t. Med. Bull. 39 47 (1983). D.G. Smyth, Brit. Med. Bull., 2 , 2 5 (1983). ’ -’ A.C. Cuello, Brit. Med. Bull., 39, 11 (1983). L.D. Fricker and S.H. Snyder,T Biol. Chem., 258,10950 (1983). L.D. Fricker,T.H. Plummer. Jr. and S.H. Snyder, Biochem. Biophys. Res. Commun., 111,994(1983). J.-C. Schwartz, S. de la Baume, C.C. Yi. P. Chaillet. H. Marcais-Collado and J. CostenG, J. Neural Transm. (Suppl.), 18,235 (1983). “Degradayon of Endogenous Opioids: Its Relevance in Human Pathology and Therapy,” S. Ehrenpreis and F. Sicuteri, Eds., Raven Press, New York, 1983. P. Chaillet, H. Marcais-Collado. J. Constentin, C.C. Yi, S. de la Baume and J.-C. Schwartz, Eur. J . Pharmacol., 86,329 (1983). KBorin, P. Giustiand L. Cima, Life Sci., 33,1575 (1983). B.P. Roques, E. Lucas-Soroca, P. Chaillet,T Costentin and M:C. Fournie-Zaluski, Prw. Natl. Acad. Sci. USA, 80 3178 (1983). ‘PTbloras, A.M. Bidabe, J.M. Caille, G. Simonnet, J.M. Lecomte and M. Sabathie, Am. J. Neuroradiol., 5,653 I1 ~QRRI ____,.
R.C. Balagot, S. Ehrenpreis, J. Greenberg and M. Hyodo, in Ref. 29, p. 207. J. Grevel and W. Sadee, Science, 221,1198 (1983). S.W. Tam, Proc. Natl. Acad. Sci..m6703(1983). D.B. Vaupel, Eur. J. Pharmacol., 269 (1983). B.L. Slifer and R.L. Balster, J. Pharmacol. Exp. Ther., 225,522 (1983). H.E. Shannon, J. Pharmacol. Ex Ther., 225,144 ( 1 9 8 r J.M. White and S.G. Holtzman, Ikychopharrnacol., 80, 1 (1983), J. Pharmacol. Exp. Ther., =,95 (1983). J.M. Moerschbaecher and D.M. Thompson, J. Pharmacol. Exp. Ther., 2 , 7 3 8 (1983). N. Johnson and G.W. Pasternak. Life Sci., 33,985 (1983). J.E. Leysen, W. Gommeren and C.J. Niemegeers, Eur. J. Pharmacol., 87,209 (1983). J.W. Villiger, L.J. Ray and K.M. Taylor, Neuropharmacol., 22,447 (1983). J.-C. Meunier, Y. Kouakou, A. Puget and C. Moisand, Mol. Karmacol., 3 , 2 3 (1983). H.H. Osborne and A. Herz, Eur. J. Pharmacol., 86,373 (1983). E. Castanas, P. Girand, K. Audigier, R. Drissi, rBondouresque, B. Conte-Devolx and C. Oliver, Mol. Pharmacol., 25,38 (1984). K.J. Mack, ATkillian and J.A. Weyhenmeyer, Life Sci., g, 281 (1983). S.L. Hart, H. Slusarczyk and T. W. Smith, Eur. J. Pharmacol., 95,283 (1983). G.S.Ling and G.W. Pasternak, Brain Res., 271, 152 (1983). T.L. Yaksh, J. Pharmacol. Exp. Ther., 226.303 (1983). L.F. Tseng, Life Sci., 32,2545(1983). N. U ton, R.D. Sewe1KndP.S. S ncer, Arch. Int. Pharmacodyn. Ther., 262,199(1983). S.J. &ard and A.E. Takemori, J.!?harmacol. Exp. Ther., 224,525 (1983).P.L. Wood, D. Sanscha in, J W.Richard and M.ThakurFPharmacol. Exp. Ther., 226,545 (1983). A. Pazos and J. Florez,%ur. J: Pharmacol.,Q, 309 (1983). S.J. WardandA.E. Takemori, Eur. J. Pharmacol.,Q, l(1983). G.S. Ling, K. Spie el, S L Nishimura and G.W. Pasternak, Eur. J. Pharmacol., g, 487 (1983). J.W. Holaday, Pasternak and A.I. Faden, Neurosci. Lett., 37,199(1983). K.-J. Chang, E.T. Wei, A. Killian and J.K. Chan J Pharmacomxp. Ther., 227,403 (1983). L.M. Sayre, P.S. Portoghese and A.E. Takemori,%ur. J. Pharmacol., %,159(1983). P.S. Portoghese and A.E. Takemori, J. Med. Chem., 26,1341 (1983). T.T. Chau, F.E. Carter and L.S. Harris, J. PharmacorExp. T h e r . , g , 108(1983). T. Chow and R.S. Zukin, Mol. Pharmacol., @, 203 (1983). T.M. Cho, B.L. Ge, C. Yamato, A.P. Smithand H.H. Loh, Proc. Natl. Acad. Sci. USA, &,5176(1983). R. Rothman andT.C. Westfall, J. Eu’eurobiol.,14,341 (1983). R. Rothman andT.C. Westfall, Neurochem. Res., 8,913 (1983). E. Weber, F.S. Esch, P. Bohlen, S. Paterson, A.D. Corbett, A.T. McKnight, H.W. Kosterlitz, J.D. Barchas and 7362(1983). C.J. Evans, Proc. Natl. Acad. Sci. USA, H. Matsuo, A. Mi ata and K. Mizuno, Nzure, 3 ,721 (1983). M. Westphal, Li, E.P.Heimer and J. Meie9ofer, Biochem. Biophys. Res. Commun., 114,1084 (1983). E.P. Heimer, T.J. Lambros, A.M. Felix, G. Fleminger, C.H. Li, M. Westphal and J. M e i e n h z r , Arch. Biochem. Bio hys., 225,518(1983). J. Cphou, J x n and E Costa, Life Sci. $?, 2589 (1983). H.Y. Yang, P. #anula,J. Tang and E. Costa, J. Neurochem., 3 , 9 6 9 (1983). R.G. Williams and G.J. Dockray, Neurosci., 2,563 (1983). P. Giraud, E. Castanas, G. Patey, C. Oliver and J. Rossier, J. Neurochem. 41 154 (1983). E.A. Majane, M.J. Iadarola and H.-Y.T. Yang, Brain Res.. 264,336 (1983):-’ J. Tang, J. Chou, H.-Y.T. Yan and E Costa. Neuropharmacbl., 22,1147 (1983). J. Tang, J. Chou, A.Z. Zhang, fi.-T. Yan andE. Costa, Life S c i . , B , 2371 (1983). ues Eur. J. P h a r m a c x , a , 147(1983). J.M. Zajac, N. Ling, J. Rossier and B.P. K.-J. Chan and J.-K. Chang, Life Sci., !$%up&. I, 267. (1983). C.H. Li, D.kamashiro, P. Ferrara, L.-FTseng and E.L. Way, Int. J. Peptide Protein Res., 2l,331 (1983) D. Yamashiro, P. Nicolas and C.H. Li, Int. J. Peptide Protein Res., 21,219 (1983). S. Salvadori, G.P. Sarto and R. Tomatis, Eur. J. Med. Chem., 18 483(1983). S. Safvadori, M. Marastoni, R. Tomatis and G.Sarto, FarmacoTS, 153 (1983). K. Darlak, Z. Grzonka, P. Janicki, A. Czlonkowski and S.W. Gumulka, J. Med. Chem., 26,1445 (1983). R. de Castiglione and G. Perseo. Int. J. Peptide Protein Res., 21,471 (1983). G. Feuerstgin and A I. Faden, J. Pharmaiol. Exp. Ther., 226,r51(1983).
s,
-
G.8,
a,
C.d
Chap. 88.
89 90. 91.
1
Analgesics
Lever, C h a n g , McDermed
2
E.C. Degli-Uberti, G. Trasforini. S. Salvadori, R. Tomatis, A. Margutti, M. Bianconi, C. Rotola and R. Pansini, J Clin. Endocrinol. Metab. 56 1032 (1983). J.-M. Zajac, G. G a d , F. k&t, P. Dodey, P. Rossignol and B P. Roques, Biochem. Biophys. Res. Commun., 111, 390 (1983). D. Rodbard, T. Costa, Y Shimohigashi and S. Krumins, J. Rece t Res 3 21 (1983). H.I. Mosberg, R. Hurst, V.J. Hruby, J.J.Galligan, T.F. Burks, 8 . G e e H’dH.I. Yamamura, Life Sci., 32,2565 1l l1 l 0 ~ 9 ) ” ” , .
92 93 94. 95. 96. 97. 98. 99 100. 101. 102 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. ii7. 118. 119. 120. 121. 122.
123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156.
H.I. Mosberg, R. Hurst, V.J. Hruby, K. Gee, H.I. Yamamura, J.J.Ga1liganandT.F. Burks, Proc Natl. Acad. Sci. USA. 80,5871 (1983). J.M.Berman, M. Goodman, T.M.-D. Nguyen and P.W. Schiller, Biochem. Biophys. Res. Commun ,115,864 (\-””-,. lam T.S. Sudha and P. Balaram, Int. J. Peptide Protein Res., Zl,381 (1983). T. Deeks. P.A. Crooks and R.D. Waigh, J. Med. Chem., 26,762 (1983) Y. Shimohiagashi and C.H. Stammer, J. Chem. Soc., Pe& I. 803 (1983). Y. Shimohigashi, C.H. Stammer, T. Costa and P.F. Vonvoigtlander. Int. J Peptide Protein Res., 22.489 (1983) H. Kimura, C.H. Stammer, Y. Shimohigashi, C. Ren-Lin a n d J . Stewart, Biochem. Biophys. Res.Fommun., 115, 112 (1983). N. Muthukumaraswamy, A.R. Day, D. Pinon, C.S. Liao and R.J. Freer, Int. J . Peptide Protein Res., 22,305 IIBR.?) ,. - - -,.
J.-L. Fauchere, S. Pfenninger, K.Q. Do, C. Lemieux and P W. Schiller, Helv. Chim. Acta, 66, 1053 (1983). R.G. A1mouist.C.M. Olsen. E.T. Uvenoand L.Toll. J. Med Chem.. 27.115(1984). L Nadasdi, D Yamashiro, C H Lland P Huidobro-Toro. Int J P e z d e Protein Res .21.344 (1983) . _. J.A. Kiritsy-Roy, S.K. Chan and E.T. Iwamoto. Life Sci., 32,889 (1983). L. Kupczyk-Subotkowskaand P. Mastalerz, Int. J. PeptiGProtein Res. 21 485 (1983);P. Mastalerz, L. Kupczyk-Subotkowska. Z.S. Herman and G. Laskawiec. Saturwiss.. 6 r k 6 (1982). C. Zioudiou, D. Varoucha, S. Loukas, N. Nicolaou, R.A. Streaty and W : r K l e e , J. Biol. Chem., 258,10934 (19831. M.Szucs, S.Benyhe, A. Borsodi, M.Wolleman, G.Jancso, J. Szecsi and K. Medzihradszky, Life Sci ,32,2777 (1983). K.C. Rice, A.E. Jacobson, T.R. Burke, Jr., B.S. Bajwa, R.A. Streaty and W.A. Klee, Science.=,314 (1983). P.S. Portoghese and A.E. Takemori, in ”The Chemical Regulation of Biological Mechanisms,” A.M. Creighton and S. Turner, Eds., Royal SocietyofChemistry S ecial Publication No. 42, p. 181 (1983). L.M. Sayre, A.E. Takemori and P.S. Portoghese, J! Med. Chem. 26 503 (1983). L.M. Sayre, D.L. Larson, D.S. Fries.A.E. Takemori andP.S. PorGghese,J. Med.Chem ,26,1229(1983). R.C. Crouch, A.V. Bhatia and O.W. Lever, Jr., Tetrahedron Lett. 24 4801 (1983). M. Hori, T. Kataoka, H. Shimizu, E. Imai, Y. Suzuki and N. Kaw;&ra, Heterocycles, 20,1979 (1983). M. Hori. T. Kataoka, H. Shimizu, E. Imai, Y. Suzuki, N.Kawamura, H. Fujimura, M.h&aki and M.Niwa, Chem. Pharm. Bull. Jap., 31,2520 (1983). F. Ghozland, P. Maroni, I.Tiloria and J. Cros, Eur. J . Med. Chem., Is,22 (1983). K. Katsuura, M. Ohta and K. Mitsuhashi, Chem. Pharm. Bull. J a , 3 0 , 4 3 7 8 (1982). K. Katsuura, K. Yama chi S. Sakaiand K Mitsuhashi, Chem. {harm. Bull. Jap., 3 l , 1518 (1983). D.L. Leland and M.P. J. Org. Chem. ‘48 1813 (1983). M.P. Kotick, J. Org. Chem., 48,1819 (1983).’-’ M.P. Kotick, D.L. Leland, J . r P o l a z z i , J.F. Howesand A. Bousquet, J. Med. Chem., 26.1050(1983). H. Schmidhammer and A. Brossi, J . Org. Chem. 48 1469 (1983). A. Ghosh, D. Portlock, H. Dalzell, C. Malmberg.’P-Herlihy and R. Razdan, J. Org. Chem, 48,4137 (1983). M. Hori, M. Ban, E. Imai, N. Iwata, Y. Baba, H. Fujimura, M. Nozaki and M. Niwa, Heterocycles, 20,2359 (1983). M. BOs, W. Fleischhacker and P. Tschany, Heterocycles, 20,1077 (1983). J. Bosch, A. Doming0 and R. Granados, J. Heterocyclic Chem., 20,887 (1983). M.Y.H. Essawi and P.S. Portoghese, J. Med. Chem., 26,348 (1983). J.W. Taylor, R.J. Miller and E.T. Kaiser, J. Biol. Chem., 258,4464(1983). J . P . Blanc, J.W. Taylor, R.J. Miller and E.T. Kaiser, J. B X C h e m . , *,8277(1983). W. Kullmann, J. Med. Chem. 27 106 (1984). D.J. Mayer, D.D. Price and A: ~ i iBrain , Res., 121,368 (1977). C.R. Chapman, C. Benedetti, Y. Colpitts and R. G l a c h , Pain, 16,13 (1983). T.B. Freeman, J.N. Campbelland D.M. Long,Pain,l7,189(198n. G.W. Terman. J.W. Lewis and J.C. Liebeskind, Brain Res. ’ -’ 260 147 (1983). L.R. Watkins and D.J. Mayer, Science, 216,1185 (1982). J.T. Cannon, J.W. Lewis, V.E. Weinberg and J.C. Liebeskind, Brain Res., 269,231 (1983). L.R. Watkins, E. Young, I. Kinsheck and D.J. Mayer, SOC. Neurosci. Abstr , 340 (1981). T. Lindeburg, S. Folsgard. H. S i l k e n , E. Jacobsen and H. Kehlet, Acta Anaesthesiol. Scand., 27,10(1983). M.Kjaer and H. Nielsen, Br. J . Clin. Pharmacol. 16 477 (1983). D. Niv, J.G. Whitwam and L. Loh, Br. J. Anaest<e&I., 55,541 (1983). J. Sawynok, Naunyn-Schmiedeber s Arch. PharmacoL-323 54 (1983). T.F. Murray, W. McGill and D.L. Cfeney, Eur. J. P h a r m a ’ . , 90,179(1983). P. Kro sgaard-Larsen, P. Jacobsen, E. Falch and H. Hjeds. in ‘memica1 Regulation of Biological Mechanisms,” A.M. Ctreighton and S. Turner, Eds., Royal SOC. Chem. Special Publ. 42, London, 1982, p. 92. F.V. DeFeudis, Pharmacol. Res. Commun., 14,383 (1982). T. Andree, D.A. Kendall and S.J.Enna, Lifexi., 32,2265 (1983). S.P. Sivam and I.K. Ho, Neuropharmacol., 22,76n1983). S. Yasuoka andT.L. Yaksh, Neuropharmacol., 22,309 (1983). J.R. Howe, J . Y . Wang and T.L. Yaksh, J. Pharmacol. Exp. Ther., 224,552 (1983). Y. Kuraishi, Y. Harada, S. Aratani, M. Satoh and H. Takagi, BraiTRes., 273,245 (1983). W.T. Chance, Life Sci. 33 2241 (1983). E. Margaria, M. Gagli&i’’, L. Palieri. S. Treves and E. Fanzago. Int. J. Clin. Pharmacol. Ther. Toxicol., 2 , 4 7 (1983). J.W. Commisiong, J. Neurochem., 41.1313 (1983). C.A. Johnston and K.E. Moore, J . NTural Transm., =,65 (1983). 0.G.Ber e K Hole and S 0 Ogren, Brain Res., m , 5 1 ( 1 9 8 3 ) . J.L.K. H y f d h a n d G.L. Wiicox, LifeSci. 33 789(1983). R. Dirksen andG.M. Ni‘huis, Eur. J. Ph&’acol.. 91,215 (1983). J.A. Romano and T.M. dhih, Neuropharmacol. 2 2 3 2 7 (1983). M.D. Aceto, H. Awaya, B.R. Martin and E.L. d y ’ B r . J. Pharmacol., 79,869 (1983).
z,
10 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174.
175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188.
189. 190. 191. 192. 193.
194. 195.
196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 2ii. 212. 213. 214. 215. 216. 217. 218. 219. 220.
Sect. I
- CNS Agents
Hesp, Ed.
J.W. Lewis, J.T. Cannon and J.C. Liebeskind, Brain Res., 270,289 (1983). D.J. Bill, J.E. Hartley, R.J. Ste hensand A.M. Thompson,=. J. Pharmacol., 79,191 (1983). R.K. Razdan and J.F. Howes, d e d . Res. Rev., 2,119(1983). L. Lemberger, Ann. Rev. Pharmacol. Toxicol., 20,151 (1980). L.S. Harris, in "The Therapeutic Potential of X r i h u a n a , " S. Cohen and R.C. Stillman, eds., Plenum, New York, 1976, p. 299. L. Melvin, M. Johnson and G. Milne, Am. Chem. Soc. 186th Nat. Mt Abstr , Medi. 22,1983. M. Johnson, J. Eggler, L. Melvin and G. Milne, Am. Chem. Soc. 186% Nat. Gtg. Abstr., Medi. 1, 1983. L. Melvin, M.Johnson and G. Milne, Am. Chem. Soc. 186th Nat. Ytg. Abstr., Medi. 2,1983. L. Melvin, M. Johnson, C. Harbert, G . Milne and A. Weissman, J. Med. Chem., 2'7,67 (1984). E.M. Zola and D.C. McLeod, Drug Intell. Clin. Pharm. 17,411 (1983). R.E.S. Bullin ham, H.J. McQuay and R.A. Moore, ClinTharmacokinet., 8,332 (1983). S.R. Hameroa, Contemp. Anesth. Pract., 27 (1983). W.L. Woolverton and C.R. Schuster, Pharmacol. Rev., %,33 (1983). J.E. Errick and R.C. Heel, Drugs, 26,191 (1983). "Clinical Experience with Injectabx Meptazinol-a New Strong Analgesic. Proceedings of a Symposium," Postgrad. Yed. J., 59 (Su pl I). pp: 1-94 (1983). G. Davies, A.J. Sinxair, 8.J;Warrington, R. Franklin, T. Frost, A. Latham and P.J. Robson, Eur. J. Clin. Pharmacol., 3 , 5 3 5 (1982). H.M. Norbury, R.A. Franklinand D.F. Graham, Eur. J. Clin. Pharrnacol., 25,77 (1983). P.K. Kalia, R. Yadan, R. Saksena, R.K. Batra and G.R. Gode, Anesth. AnaE., 62,949 (1983). J. Cahill, D. Murphy, D.OBrien, J. Mulhall and G. Fitz atrick, Anaesthesia, 3% 760 (1983). B.T. Finucane, d.B. Floyd, D.J. Petro and R. Braswell, &n. Anaesth. SOC. J. 2 r 5 0 0 (1982). J.E. Stambau h J r J McAdamsand G. Freeland, Clin. Pharmacol. Ther., 33,i98(1983). L.E. Mather, 8lik ]iiharmacokinet., 8,422 (1983). J.D. Borel, Contem Anesth. Pract.? l(1983). S.S. Bloomfield, T.I?Barden and J. M%chell, Clin. Pharmacol. Ther., 34,240 (1983). R.C. Frederickson. C.J. Parli, G.W. DeVaneand M.D. Hynes, Natl. Inst. DrugAbuse Monogr. Ser., 43,150 (1983). B.M. Onofrio and T.L. Yaksh, Lancet, I, 1386 (1983). N. Gilchrist, J.E. Bolton, R.A. Donald, J.H. Livesey, H.K. R0udandM.G. Nicholls, Br. J. Clin. P h a r m a c o l . , s , 465 (1983). A. Roby, J.-C. Willer and B. Bussel, Neuropharmacol., 22,1121 (1983). G. Nuki, Brit. Med. J., 287,39 (1983). S.A. Cooper, Ann. Rev.xarmacol. Toxicol., 23,617 (1983). H.L. Crossley, S.A. Bergman and R.L. WynnJ. Am. Dent. Assoc. 106 61 (1983). R.K. Verbeeck, J.L. Blackburn and G.R. Loewen, Clin. PharmacokG'l., 8,297 (1983). R.J. Capetola, Y.E. Rosenthale, B. Dubinsky and J.L. McGuire, J. Clin. Pharmacol., 23,545 (19831. R.O. Davies, Pharmacother., 9(2, pt. 2). 9 s (1983). Pharmacol.. 27 (Su 1 ), p 1 96 (1983). uns ine,x.Z. 8Eon, b M : Laska, I. Zighelboim, A. decastroand C. desarrarin, Clin. Pharmacol. Ther., 34, :5:(198h). D.J.M. Keenan, K. Cave, L. Langdon and R.E. Lea, Brit. Wed. J., 287,1335 (1983). G. Rigamonti, E. Zanella, R. Lampugnani, D.Marrano, 0.Campione, 0.Bruni, V. Mandelli and G. Sacchetti, Br. J. Anaesth., 55,513 (1983). A. Pellegrini, B.Wassidda, P. Pelle ini, E. Defraia, A. Usai, L. Parrinello, G. Bruni, G. Rigamonti and C. Sacchetti, Int. J. Clin. Pharmacol. &er. Toxicol., 21,483 (1983). E.R. Umbenhauer, Pharmacother., 2,55S (1983). J.A. Forbes, A.L. Kolodny, W.T. Beaver, R.W. Shackelford and V.R. Scarlett, Pharmacother., 2,47S (1983). A. Sunshine, N.Z. Olson, E.M. Laska, I. Zighelboim, A. DeCastro and C. DeSarrazin, Pharmacother., 2,177 (1983). P.J. Desjardins, S.A. Cooper, C.M. Ruderman, L.T. Gallegos, D.C. Reynolds andG.0. Kruger, Pharmacother., 3, 52 (1983). E.C. Huskisson and R.Bryans, Curr. Med. Res. Opinion 8 350 (1983). N.J. Wenzloff and L. Shimp, Dru Intell Clin. Pharm., i6'2Z (1984). W.Y. Chan, Ann. Rev. Pharmacof. Toxicol., 23,131 (1983. A. Marzo, G. Quadro, G. Bruno, E. Treffner.F'L. Reali, G. Borrelli and R. Stradi, Arzneim.-Forsch.. 3 ( 1 ) , 198 (1983). K. Hino H. Nakamura, Y.Nagai H. Uno and H. Nishimura, J. Yed. Chem., 222 (1983). J.R. Gra'ham, Headache, 21,243 (1981). E. Skinhoj, Arch. Neurol.79,95 (1973). 83 (1982). W.K. Arner Cephalalgia M. Botney, keadache, i7b (1981). R.J. McCaffrey and W. Isaac, Headache, 23,152 (1983). R. Peatfield, Dru s 26 364 (1983). J.E. Sutherland, !m?am. Physician, 27,137 (1983). N. Martucci, V. Manna, P. Mattesi, G. n o i a n i , G . Manzoni, M. Lanfranchi, G . Bono and G . Micieli, Cephalalgia, 3(Su pl I), 151 (1983). B.H.$eters, C.J. Fraimand B.E. Masel, Am. J. Wed., 74,36(1983). R.C. Peatfield, R.G. Petty and F.C. Rose, Ce halalgia 3 129 (1983). S. Diamiond, L. Kudrow. J. Stevens and D.{hapiro. HGdache, 22 268 (1982). R.E. Ryan, Sr., R.E. Ryan, Jr., and A. Sudilovsky, Headache, &$6 (1983). P. Louis, Headache, 21.235 (1981). W.K. Amery, Headaxe, 23,70(1983). J.S. Meyer and J. HardenGrg, Headache, 23,266 (1983). S.J. Peroutka, Headache, 23,278 (1983).
z,
z,
a,
Chapter 2 .
Anti-Anxiety Agents, Anticonvulsants & Sedative-Hypnotics
Joseph P. Yevich, James S. New and Michael S. Eison Bristol-Myers Research and Development, Evansville, Indiana 47721
-
Introduction The prevalence of anxiety and the diverse utility of existing anxiolytic drugs continues to promote a broad spectrum of research in the anxiolytic area. The challenging basic science of anxiolytic drug action and the potential for compounds with profiles different from the traditional antianxiety drugs has focused attention upon more selective structure activity relationships. Several excellent review articles emphasizing medications currently used, approaches to new drug discovery, newer agents and theories, side-effects and hazards 4-8 and the use of benzodiazepines (BZ) as preoperative medications’ have been published. Insights into the GABAergic effects of these drugs and their anticonvulsant properties continue to grow. Animal Models - Conflict tests play a prominent role in anxiolytic research, and may be used to demonstrate proconflict, anticonflict, and anxiolytic anta onist actions.l5 A chronic conflict paradigm has been described. The effects of drugs upon deprivation-induced drinking should be considered to avoid false-positive indications.l 7 The susceptability of compounds’ anticonflict effects to blockade by BZ antagonists appears to distinguish BZ receptor binders from nondisplacers. The use of anticonvulsant activity and effects upon BZ binding as indices to dissociate pro-drug from directly acting BZ effects has been described,lg as has a chronic epilepsy model in rats.2 o Drug-discrimination techni ues have revealed that the diazepam stimulus complex is specific.” It has been proposed that drug discrimination techniques can detect anxiogenic BZ withdrawal effects.22 923 In other behavioral tests, the increase in response rates induced by BZ’s to rewarding electrical brain stimulation i s facilitated by GABA antagonist^,^^ and is observed even in rats trained on a DRL schedule (rewarding low rates of response).25’26 Conditioned startle,27 defensive burying,28 and social intera c t i o n ~ ~continue ~ ’ ~ ~ to be used to investigate anxiolytic and BZ anta onist activity. Quantitative EEG activity in animals31 and man3! complement cellular electrophysiological investigations of anxiol tic drug Effects of BZs upon memory,35 and electrically-induced head turning37 have been investisleep gated, as have effects upon feeding and d r i n I ~ i n g . ~ ~ -A~ protective O action of diazepam against gastric ulceration in rats induced by water-immersion or by immobilization stress has been described.41 Tolerance developing to anxiolytic drugs ,42 ’ 4 3 and models of physical dependence to BZs in rat44 and dog45 have been reported.
,I6
Benzodiazepine Receptor Neurochemistry and Pharmacology - The concept of heterogeneous benzodiazepine (BZ) receptor sites has stimulated considerable research in the development of drugs which may be more anxioselective than the BZ class. The functional linking of a
ANNUAL REPORTS IN MEDICINAL CHEMISTRY- 19
Copyright 0 1984 by Academic Press, Inc. All rights of reproduction in any form reserved. ISBN 0-12-0405 19-9
12
Sect. I
- CNS Agents
Hesp, Ed.
chloride ionophore, BZ and GABA receptor sites is substantiated by their isolation in a supramolecular complex in which GABA stimulation of [ 3H]flunitrazepam binding (FLU, &) remains intact.4 6 Affinity chromatography has also led to the successful isolation of a homogeneous GABA/BZ receptor complex from bovine cerebral cortex.4 7 Data continues to accrue indicating GABA, and its agonists, enhance the binding of the BZs to these receptors; diazepam (DZ, ) & l enhances ~O the binding of GABA and muscimol but has no effect on T € I I P . ~ ~ - The presence of a single class of saturable [3H] muscimol binding sites (KD = 23 nM) on a purified BZ receptor is evident.51 The potentiation of [ 3H]DZ binding is also elicited by ethylenediamine analogues in a process mediated predominantly by a change in receptor number and not receptor affinitye5* Both [3H]DZ and [3H]GABA binding are enhanced by the hypnotics (+)etomidate and pentobarbital, presumabl through a similar mechanism, which is blocked by GABA antagonists. 545 GABAergic ligands were also observed to protect soluble BZ receptors from heat inactivation.54 BZ Type 1 and Type 2 receptors, initially defined on the basis of their different affinities for CL 218,872, have been further characterized in rat cerebellum and cerebral cortex. CL 218,872 preferentially displaced [3H]FLU from Type 1 receptors; Type 1 R' R' R' Et'Y receptor binding is H F H O la NO. CHI stimulated in a Y lb CI CHI H H H O chloride H F H S Ra & CI CHzCFa manner byion ImMdependent sodium Id CI CHI H H C I O pentobarbital, while H H O le CI CHzCCFa H OH CI H 0 Type 2 sites remain If CI H relatively ~naffected.'~~ 1g CI H COOH H H 0 Distinction between l h CI (CH~)ZN(CZHI)Z H F H 0 R OH H H O 11 CI CHI Type 1 and Type 2 -1 H H H O 1j NO' H receptor populations is reported to be possible through their differential sensitivity to detergent solubilization techniques.56 The effects of GABA agonists on [3H]FLU binding to these sites in both cerebellar and hi pocampal membranes were found to be broadly similar in one study.5q Alternatively, the effect of GABA on FLU binding to [3H]FLU and [3H]f3-CCP (2a) labelled Type 1 and 2 receptors was found to involve different degrees of GABA regulation dependent on the specific brain region.58 SAR studies have examined the f3-carbolines as templates in the desi n of more specific, high affinity ligands for the BZ recep[3H)DMCM (b)interacts with high affinity BZ receptors with binding properties different. from those of [ 3H]FLU and $-CCP which may reflect a subclass selectivity within these receptors Intraventricular injections of $-CCE (g)increased the number of [3H]DZ binding sites in a variety of brain regions but, in a different study, decreased the total number of [3H]GABA binding sites in rats habituated to handling procedure^.^*'^^ f3-CCM (&) has been shown to antagonize the anxiolytic effects of the BZs, possess convulsant properties, and exhibit anxiogenic properties.6 4 [ 3H]$-CCE binds to a homogenous population of recognition sites in rat brain and is completely dissociable by low concentrations of B Z S . ~ The ~ $-carboline FG 7142 (2f) was found to induce severe anxiety in man.66 Pharmacokinetic factors were studied as a para-
Chap. 2
Anti-Anxiety Agents
Yevich, New, Eison
meter controlling the convulsant activity of fi-CCM, DMCM, and the n~nconvulsantproperties of fi-CCE in the rat; a slow rate of degradation of these compounds by rat plasma vitro) paralleled their potencies as convulsants.67
(s
BZ receptor heterogeneity has been further delineated from the differential affinities observed between pairs of ligands for these sites. Subpopulations of [3H]DZ receptor sites are defined by their interactions in bicuculline/GABA or barbiturate/pyrazolopyridine binding studies.6 8 Discrimination between these subtypes was also possible with RO 15-1788 but not with CGS 8216.68 A study of various BZ receptor ligands, with different biological activities, yielded no simple correlation between their biological activity and the observed temperature dependence of their binding.69
(z),
The non-homogeneity of BZ-receptors has generated several models which attempt to rationalize their binding characteristics with a structurally diverse group of ligands. Kinetic studies suggest these receptors exist as a single population in two distinct conformational states whose interconversion is affected by BZ agonists, GABA, chloride ion, temperature, and the BZ antagonist RO 15-1788.70 An allosteric model for BZ receptor function suggests the intrinsic activity of an agonist reflects its ability to induce a conformational change in the receptor. This approach predicts that ligands with high affinity for a binding domain on both the ground state and activated conformations o f the receptor will be anxioselective agents.71 A definition of the BZ receptor as a coupling unit between the GABA receptor and chloride channel, is used to explain its interaction with the BZ tranquilizers, the f3-carbolines,RO 15-1788, and phenobarbitone. BZ agonists enhance the coupling role of the BZ receptor while f3-carbolines block the access of BZ agonists to this coupling site. This actually results in a reduced coupling mechanism in the receptor and elicits opposing pharmacological effects. The - and f$-CCM ( g ) ,are referred to as "inverse fi-carbolines, DMCM (2b)
R'
R
'
~
c
R' H
-2
o
R
R' -
2a OnCIH, H OCHI H CZH,
R' -
H H
R'
H OCHI H 2d OCzH, H H H 2e OCzHs CHzOCH' OCHzCaHm H 2f NHCH, H H H 2'C
-
R'
H OCHI H H H H
agonists" in this scheme. This distinguishes them from pure antagonists such as RO 15-1788, which blocks the access of both inverse agonists and agonists to the receptor, without inducing a functionally relevant change in it.72 Ethanol and pentobarbital may modulate the BZ binding component in the chloride ionophore-BZ-GABA receptor complex via the picrotoxinin sensitive site, and a thirsty rat conflict model indicates the anticonflict actions of pentobarbital might be mediated through BZ receptors.73' 74 A peptidoaminobenzophenone, 450088-S($), was found to effectively inhibit the labeling of BZ CHz I
CI 0
CHI
CHI
i
13
14
Sect. I
- CNS
Agents
Hesp, Ed.
receptors by [3H]FLU in vivo despite a lack of in vitro activit and quazepam (2) preferentially binds to BZ Type 1 Several lines of evidence indicate RO 15-1788 may not be a strict BZ antagonist but may also have some partial agonist properties; it abolishes the sedativelataxic effects of DZ, but slows the development of kindled seizures, suggesting an anticonvulsant action in its p h a r m a ~ o l o g y . ~Ro ~ 15-1788 is effective in reversing the anticonvulsant effects of DZ and CL 218,872,64’78 and is shown to block the cognitive, amnesic, psychomotor and subjective effects of DZ in man, without altering the bioavailability of this drug.79 Psychometric tests sensitive to the effects of BZs showed no intrinsic pharmacolo ical activity associated with RO 15-1788 in man up to 600 mg orally.l0 The convulsant BZ RO 5-3663 (5) and RO 15-1788, both antagonized the anticonflict effect of chlordiazepoxide, but while RO 5-3663 was distinctly anxiogenic, RO 15-1788 displayed some anticonflict properties.81 RO 5-4864 (Id), a ligand selective for the BZ low affinity (micromolar) and peripheral receptors, registered significant anxiogenic action in the social. interaction test which was reversed by phenytoin, a ligand €or the low affinity receptors.82
-
A critical review examined the Benzodiazepine Anxiolytic Agents concept that multiple BZ receptors underlie the diverse behavioral effects which are observed with this chemical class.83 A study examining the effects of rapidly increasing doses of halazepam and DZ on severely anxious hospitalized patients was reported84 and effects of DZ on short term memory” and information processingg6 were examined. DZ was found to potentiate the behavioral effect of neuroleptics in rats,87 to produce some improvement in neuroleptic resistant schizophrenics,88 and to alleviate symptoms of tardive d y s k i n e ~ i a . ~The ~ effects of long term DZ therapy and drug withdrawal effects were also Clobazam (6) and DZ were compared in their differential effects on psychomotor performance9* and anxiolytic responses .93 Lorazepam (If)was evaluated for its effects on psychomotor performance vs. clobazams4 and DZ;s5 clear performance decrements were associated with its use. 96 Several has anxiolytic efficacy comparable studies indicate alprazolam (2) to DZ but at a lower dose and with a lower incidence of sedaHalazepam and clorazepate (la) were shown to not be significantly different from each other in treating symptoms of n anxiety or tension.99
(e)
713,R = H -
7b, R = C1
-
-a
-9
Sedative -Hypnotics Midazolam (8) continues to receive substantial support as an effective hypnoticToo with neither tolerance effects nor rebound insomnia on drug withdrawal.lol A series of papers has addressed safetylo2 and psychomotor performance aspects of this drug.lo3’l o 4 The clinical literature concerning the hypnotic effi-
Chap. 2
Anti-Anxiety Agents
Yevich, New, Eison
(s),
(a).
cacy of flurazepam temazepam and triazolam (2) has been reviewed. Triazolam has been researched as a hypnotic for geriatric patients.105-107 Considerable differences were reported for the pharmacokinetics of five BZ hypnotics in healthy subjects.lo8 There is no distinguishable difference between the nocturnal effects of triazolam or flurazepam, however, the "hangover" effects of these two drugs are still under evaluation.log' 110 Triazolam appeared superior to nitrazepam (Q) in an overall evaluation of sleep.lll The h notic loprazolam ( 9 ) was found not to be potentiated by alcohol,llYPbut no direct correlation was found between its pharmacokinetic data and various sleep parameters which were scrutinized. Initial indications suggest temazepam may have less hangover potential than nitrazepam, and both nitrazepam and flunitrazepam were well tolerated in elderly patients.'15 Non-Benzodiazepines Anxiolytic Agents - Further neurochemical and/or behavioral evaluations have been reported for 10-13a which have previously been shown to exhibit anxiolytic activity in animal models. Electrophysiological and receptor binding studies suggest that etazolate
(e)
N-N-CHIPX
R'
ClH. l o p , R' N =C(CHdr, R' lob, R' = n-CeHm, R' -
E
H =H
CHi
12~1,X = CHI, Y -
CF~
11 -
-
12b, X = NH, Y
= NH CHz
1 3 ~X . 13b, X -
= CI = H
enhances BZ binding and the effects of GABA by interaction at a site distinct from the GABA and BZ recognition sites.l16 The bicucullineand picrotoxin-sensitive blockade of electrically-induced head turning in the rat by tracazolate indicates the drug's GABAmimetic a~tivity.~? Antagonism of the DZ-induced righting reflex in mice by C1 218,872 (11) has been interpreted as evidence for its partial agonist activity at the BZ receptor.ll? The quinoline derivatives PK 8165 (12a) and PK 9084 have also been hypothesized as partial B Z X c e p t o r agonists based on their antagonism of the anticonvulsant effects of DZ and their competitive inhibition of [3H]FLU binding.'18 PK 9084 showed a partial anxiolytic profile in a social interaction paradigm in rats, while PK 8165 was ineffective at the doses tested.2 9 In a pentylenetetrazol-saline discrimination model, CGS 9896 (13a) exhibited DZ-like activity which was blocked by pretreatment with the BZ antagonist CGS 8216 (=).l"
(e)
(e)
Several clinical studies have shown buspirone (=)to have anxiolytic efficacy equivalent to that of DZ with significantly less sedation. 120-122 Rats trained to discriminate oxazepam or pentobarbital from vehicle did not generalize to buspirone.123 At doses above those which :)($(CHZ)~-G?~ are anxiolytically relevant in man, the drug caused a dose-related elevation of plasma 0 prolactin in male subjects, and like the B Z ' s 14p, R, R = -(CHZ)C also increased growth hormone levels.124 Mb, R = CHa Buspirone elicits a dose-dependent rise in rat striatal dopamine (DA) metabolite and may do so by selective antagonism of presynaptic DA autoreceptors with minimal postsynaptic effects.127 Its catalepsy-reversal effects may occur
2
16 -
Sect. I
- CNS
Agents
Hesp, Ed.
via a DA-independent mechanism. 128 The drug increases rat locus coeruleus noradrenergic neuronal activity,129 binds to calf hippocampus serotonin type-1 receptors,130 enhances L3H]FLU ginding after oral dosing iq+rats,131 causes an increase in the K -depolarized into synaptosomes,132 and affords significant brain uptake of 45Ca levels of 1-(2-pyrimidinyl)piperazine as a metabolite in the rat. 133 The mechanistic implications of these findings are as yet unclear. The analogue MJ 13805 (=) while equipotent with & in conflict testing, has much weaker effects than the latter upon DA neurotransmission, thus suggesting that DAergic effects may not be important to the antianxiety activity of these drugs.134 The SAR of a series of aryl and heteroarylpiperazine derivatives including & and b has been reported.135 A single-blind clinical study of the GABA agonist THIP (G) found it to have weak anxiolytic effects at doses at or near those which caused sedation and other side effects.136 Members of a series of (wpiperazinyla1koxy)indanes (16) exhibited BZ-like potency Various pyrimido[5,4-d]benzazepine in the fighting mouse test. 13' derivatives (11)showed potent antimetrazol activity and were more R'
1sp, X
= NH,Y = CHI
15b, X = CHI. Y -
i .
16 -
NH
- X = Y = CI, R' = R' 3711,
= H
17b, X = Y = CI, R' = H, R' -
*
OH
potent in displacing [3H]DZ binding than DZ, with lesser effects than DZ on motor coordination and ethanol interaction.13' A member of the series (G)has been selected for anxiolytic evaluation in man and 17b, its major metabolite (in dog and man), was found to be equipotenTwith the parent drug in pharmacological tests.
-
Sedative-Hypnotics The hypnotic and anticonvulsant profile of etomidate (Is) has been reviewed.139 Based on comparative clinical effects on the photopalpebral reflex, zopiclone (19) was slightly more potent than nitrazepam with more rapid onset, shorter duration of action, and fewer side effects.140 A study in insomniac patients showed that a 7.5 mg dose of zopiclone improved the quality of sleep with a reduction in both sleep onset latency and the number of nocturnal awakenings. Following their microiontophoretic application, the "sleep" peptides, delta sleep-inducing peptide and arginine-vasotocin caused predominantly excitatory actions on neurons in the brain stems of rats and rabbits.142 Following its microinjection into the brains of rabbits, the sites of action of the sleep-promoting muramyl peptide isolated from human urine were found to be in the forebrain region.143 While parenteral administration of an adenosine deaminase inhibitor, erythro-9-(2hydroxy-3-nonyl)adenine, to I>CO,CH.CH, gNN e N n Q mice and rats caused profound ot-N N-Cnr behavior sedation, the accom@CH, 0 panying EEG changes showed 19 18 greatly enhanced time awake.144
Chap. 2
Anti-Anxiety Agents
Yevich, New, Eison 1 7
-
Anticonvulsants The effects of several marketed antiepileptic drugs including carbamazepine, phenytoin, and sodium valproate, upon cognitive function and behavior have been clinically assessed.14' Adenosine receptor binding studies of carbamazepine indicate that its anticonvulsant action may be due in part to A1 receptor agonist and A2 receptor antagonist activities.146 A computer graphics-based patternrecognition analysis of several series of 5-ethyl-5-substituted barbiturates has revealed that the region of occupied space for the low energy conformation o f the lipophilic side-chain differs between anticonvulsant and convulsant members of the series.147 N-g-prppylnorapomorphine was the most potent of a series of apomorphine-related DA agonists in protecting genetically seizure-prone mice and baboons. 148 Potential anticonvulsant activity of a-adrenergic agonists was indicated by their in vitro inhibition of interictal discharge in rat hippocampal slices; p-adrenergic agonists showed proconvulsant actions.14y Compared with placebo, the GABAergic drug progabide (20) caused a significant decrease in seizures, with mild side effects, in a double-blind clinical trial in "therapyresistant'' epileptic patients. A single-blind evaluation of THIP in epileptic patients failed to show significant differences from placebo with maximal doses of the drug.lS1 THPO a glialselective GABA uptake inhibitor had anticonvulsant activity in chicks but not in adult mice."* Denzimol (21) was shown to have a general anticonvulsant profile similar to that of carbamazepine and phenytoin in animal models.153 The triazine, LY 81067 (22) protects mice against pentylenetetrazol- and bicuculline-induced convulsions and enhances both [3H]GABA and [3H]FLU binding.154'15s Other compounds reported to have anticonvulsant activity in various animal models include the p-carboline ZK 91296 (g) ,lS6 2-phthalimidoethanelS7 eugenol analogues (g), lS8 pyrido[3,4-b] [1,4] sulfonamides benzothiazines (25)lS9 and oxoquinazolines (26).160
'''
(e),
(c),
Q
cb
C = N(CHiJs-CONHi
D
O
H
& = ( 6" 0 +Hi
CHzCHi \ /
F
zo
21
HsC \ /
1 y ) - N D OH
N=N
Lz
X = CHorN
References 1. 2. 3. 4.
5. 6. 7. 8. 9.
R.I.Altesman and J.O.Cole, J.Clin.Psychiat., 44, 12 (1983) W.Janke and P.Netter, Neuropsychobiol., 9, 33 (1983) M.Williams, J.Med.Chem., 26, 619 (1983) J.Schopf, Pharmacopsychiat., 16, 1 (1983) D.J.Greenblatt, R.I.Shader, and D.R.Abernethy, The New England J.Med., 309, 410 (1983) T.Roehrs, F.J.Zorick, J.H.Sicklestee1, R.M.Wittig, K.M.Hartse, and T.Roth, J.Clin. Psychopharmacol., 3 , 310 (1983) A.Kales, C.R.Soldatos, E.O.Bixler, and J.D.Kales, Pharmacol., 26, 121 (1983) D.Ladewig, Pharmacopsychiat., 16, 103 (1983) R.Miller, The Mt.Sinai J.Med., 50, 289 (1983)
18 -
Sect. I
- CNS Agents
10, K.G.Lloyd, Therapie 1983, 3 8 , 355 (1983) 11. M.J.Croucher, B.S.Meldrum, and P.Krogsgaar-d-Larsen,Eur.J.Pharmacol.,
Hesp, Ed.
e,
217 (1983) 12. M.M.Airaksinen, Acta Neurol.Scand., 67,31 (1983) 13. R.G.Fariello and M.K.Ticku, Life Sci., 33, 1629 (1983) 14. A.Chapman, P.E.Keane, B.S.Meldrum, J.Simiand, and J.C.Vernieres, Prog.Neurobiol., 19, 315 (1982) 15. K G .Corda . W.D.Blaker . W.B.Mendelson. A.Guidotti. and E .Costa. Proc. Natl .Acad.Sci. USA, 80, 2072 (1983) ' 16. T.J.McCown. R.A.Voge1, and G.R.Breese, Pharmacol.Biochem.Behav.,- --18, 277 (1983) 17. J.D.Leander, Drug 6ev: Research, 2, I85 (1983) 18. J.B.Pate1, C.Martin, and J.B.Malick, Eur.J.Pharmacol., 86, 295 (1983) 19. M.Gerecke, Br.J.Clin.Pharmacol., 16, 11s (1983) 20. S.Banfi, W.Fonio, E.Allievi, and S.Raimond, Pharmacol.Res.Commun.,15, 553 (1983) 21. T.Haug, Eur.J.Pharmacol., 93, 221 (1983) 22. M.W.Emmett-Oglesby, D.G.Spender, M.Lewis,Jr., F.Elmesallamy, and H.Lal, Eur.J. Pharmacol., 9 2 , 127 (1983) 23. M.W.Emmett-Oglesby, D.G.Spender,Jr., F.Elmesallamy, and H.Lal, Life Sci., 3 3 , 161 (1983) 24. L.J.Herberg and S.F.Williams, Pharmacol.Biochem.Behav., 19, 625 (1983) 25. Y.Ichimaru, M.Moriyama, and Y.Gomita, Life Sci., 2_?, 43771983) 26. Y.Gomita, Y.Ichimaru, and M.Moriyama, Jap.J.Pharmacol., 2 , 498 (1983) 27. M.Davis, Psychopharmacol.Bull., 19, 457 (1983) 28. N.M.Blampied and R.C.Kirk, Life Sci., 33, 695 (1983) 29. S.E.File and R.G.Lister, Pharmacol.Biochem.Behav., 9, 185 (1983) 30. S.E.File and R.G.Lister, Neurosci.Letters, 3 9 , 91 (1983) 31. M.Mariotti and E.Ongini, Arch.Intl.Pharmacodyn., 264, 203 (1983) 32. Y.Mizuk, M.Hashimoto, T.Tanaka, K.Inanaga, and M.Tanaka, Psychopharmacol., 80, 311 (1983) 33. J.P.Laurent, M.Mangold, U.Humbe1, and W.Haefely, Neuropharmacol., 11. 501 (1983) 34. L.Pieri, Br.J.Clin.Pharmaco1., 16, 175 (1983) 35. M.C.Cassone, L.Molinengo, and M.Orsetti, Life Sci., 33, 1215 (1983) 36. R.Scherschlicht and J. Marias, Br.J.Clin.Pharmacol., l6, 29s (1983) 37. J.M.Goldstein, L.G.Knobloch, and J.B.Malick, Life Sci., 32, 613 (1983) 38. V.E.Grimm and A.Jancourt, Intl.J.Neurosci., 8 , 127 (198q 39. S.J.Cooper, Life Sci., 32, 1043 (1983) 40. S.J.Cooper, Life Sci., 32, 2453 (1983) 41. K.Yamaguchi, K.Suzuki, T.Niho, M.Shimora, C.Ito, and H.Ohnishi, Can.J.Physio1. Pharmacol., 9, 619 (1983) 42. H.C.Rosenberg, S.Smith, and T.H.Chiu, Life Sci., 32, 279 (1983) 43. E.H.Ellinwood,Jr., M.Linnoila, M.E.Easler, and D.W.Molter, Psychopharmacol., 79, 137 (1983) 44. G.P.Ryan and N.R.Boisse, J.Pharmacol.Exp.Ther., 226, 100 (1983) 45. L.F.McNicholas, W.R.Martin, and S.Cherian, J.Pharmacol.Exp.Ther., 226, 783 (1983) 46. S.T.Mernoff, H.M.Cherwinski, J.W.Becker, and A.L.deBlas, J.Neurochem., 41, 752 (1983) (1983) 47. E.Sigel , F.A. Stephenson, C.Mamalaki, and E.A.Barnard, J.Bio1.Chem., 258,6965 48. J.H.Skerritt and G.A.R.Johnston, Eur.J.Pharmacol., 89, 193 (1983) c 315 (1983) 49. J.H.Skerritt and G.A.R.Johnson, Neurosci.Letters, L 50. B.K.Koe, Drug Dev.Res. 2, 421 (1983) 51. C.Martini, T.Rigacci, and A.Lucacchini, J.Neurochem., 41, 1183 (1983) 52. P.F.Morgan and T.W.Stone, Br.J.Pharmacol., 2,973 (1983) 53. R.Thyagarajan, R.Ramanjaneyulu, and M.K.Ticku, J.Neurochem., 41, 578 (1983) 54. M.Gavish, Life Sci., 33, 1479 (1983) 55. D.L.Niehoff, R.D.Masha1, and H.J.Kuhar, Eur.J.Pharmacol., 92, 131 (1983) 56. M.M.S.Lo, D.L.Niehoff, M.J.Kuhar, and S.H.Snyder, Neuroscixetters, 39, 37 (1983) 57. R.Mitchel1 and L.E.Wilson, Neuropharmacol., 22, 935 (1983) 58. K.W.Gee, F.J.Ehlert, and H. I .Yamamura, J.Phazacol.Exp.Ther., 225, 132 (1983) 59. K.P.Lippke, W.G.Schunack, W.Wenning, and W.E.Miiller, J.Med.Chem., 26, 449 (1983) 60. G.Neef, U.Eden, A.Huth, D.Rahtz, R.Schmiechen, and D.Seidelmann, Heterocycles, 20, 1295 (1983) 61. C.Braestrup, M.Nielsen, and T.HonorC, J.Neurochem., 41, 454 (1983) 62. A.Concas, M.Salis, and G.Biggio, Life Sci., 32, 1175 (1983) 63. A.Concas, M.Salis, M.Serra, M.Giuseppa Corda, and G.Biggio, Eur.J.Phamacol., 9 , 179 (1983) 64. L.Prado de Carvalho, G.Grecksch, G.Chapouthier, and J.Rossier, Nature, 301, 64 (1983) 65. 1.L.Martin and A.Doble, J.Neurochem., 40, 1613 (1983) 66. R.Dorow, R.Horowski, G.Paschelke, and KAmin, Lancet, July 9, 98 (1983) 67. M.M.Schweri, J.V.Martin, W.B.Mendelson, J.E.Barrett, S.M.Pau1, and P. Skolnick, Life Sci., 3,1505 (1983) 68. L.M.F.Leeb-Lundberg and R.W.Olsen, Mol.Pharmacol., 23, 315 (1983) 69. A.Doble, J.Neurochem., 40, 1605 (1983) 70. T.H.Chiu and H.C.Rasenberg, Trends in Pharmacol. Sci., 4, 348 (1983) 71. F.J.Ehlert, W.R.Roeske, K.W.Gee, and H.I.Yamamura, Biochem.Pharmacol., 32, 2375 (1983)
Chap. 2
Anti-Anxiety Agents
Yevich, New, E i s o n
9
72.
P.Polc, E.P.Bonetti, R.Schaffner, and W.Haefely, Nauyn.Schiedebergs Arch.Pharmacol.,
13. 74. 75. 76. 77. 78. 79.
m . T i c k u , T.P.Burch, and W.C.Davis, Pharmacol.Biochem.Behav. ( S u p p l . l ) , 18, 15 (1983) W.B.Mendelson, T.Davis, S.M.Pau1, and P.Skolnick, Life Sci., 32, 2241 (1985) D.T.Wong and F.P.Bymaster, Drug Dev.Res., 3, 67 (1983) W.Sieghart, Neurosci.Letters, 38, 73 (1983) H.A.Robertson and M.L.Riives, E a i n Res., 270, 380 (1983) S.V.Vellucci and R.A.Webster, Eur.J.Pharmacol., 9 3 , 263 (1983) C.O'Boyle, R.Lambe, A.Darragh, W.Taffe, I.Brick, and M.Kenny, Br.J.Anaesth., 55, 349
80. 81.
A.Darragh, R.Lambe, C.O'Boyle, M.Kenny, and I.Brick, Psychopharmacol., 80, 192 (1983) J.Feldon, T.Lerner, D.Levin, and M.Myslobodsky, Pharmacol.Biochem.Behav., 19, 39
82. 83. 84. 85. 86. 87. 88.
S.E.File and S.Pellow, Psychopharmacol., 80, 166 (1983) I.L.Martin, C.L.Brown, and A.Doble, Life Sci., 32, 1925 (1983) W.E.Fann, J.Garcia, and B.W.Richman, J.Clin.Pharmacol., 23, 100 (1983) N.Desai, A.Taylor-Davies, and D.B.Barnett, Br.J.Clin.Pharmacol., 15, 197 (1983) Y.D.Lapierre, H.J.Butter, L.K.Oyewwni, Neuropsychobiology, 2, 88 n 9 8 3 ) R.L.Singha1, R.B.Rastogi, and Y.D.Lapierre, J.Neura1 Transmission, 56, 127 (1983) J.N.Nestoros, N.P.V.Nair, J.R.Pulman, G.Schwartz, and D.Bloom, Psychopharmacol., 81,
89.
M.M.Singh, R.E.Becker, R.K.Pitman, H.A.Nasrallah, and H.Lal, Brain Res.Bull.,
321, 260 (1982)
(1983)
(1983)
42 (1983)
11, 179
(1983)
K.Rickels, W.G.Case, R.W.Downing, and A.Winokur , J.Am.Med.Assoc. , 250, 767 (1983) P.Tyrer, R.Owen, and S.Dawling, Lancet, June 25, 1402 (1983) Y.Kawazu, S.Nakano, N.Ogawa, and K.Taeuber, Drug Dev.Res., 3 , 371 (1983) J.John, A.Roy, and A.Verghese, Curr.Ther.Res., 22, 990 (1987) H.Oblowitz and A.H.Robins, Br.J.Clin.Pharmacol., 16, 95 (1983) K.Aranko, M.J.Mattila, and T.SeppaLa, Br.J.Clin.Pharmacol., 5 , 545 (1983) J.K.Walsh, P.K.Schweitzer and S.Parwatikar, Clin.Pharm.Ther., 2 , 496 (1983) K.Davidson, R.G.Farquharson, M.C.Khan, and A.Majid, Psychopharmacol., 80, 308 (1983) K.Rickels, I.Csanalosi, P.Greisman, D.Cohen, J.Werblowsky, H.A.Ross, and H.Harris, Am.J.Psychiat., 140, 82 (1983) 99. T.M.Iti1, R.K.Shrivastava, D.M.Collins, S.T.Michae1, G.Dayican, and K.Z. Itil, Curr. Ther.Res., 2 , 441 (1983) 100. P.Hauri, T.Roth, M..Sateia, and F.Zorick, Br.J.Clin.Pharmacol., 16,109s (1983) 101. G.W.Voge1 and F.Voge1, Br.J.Clin.Pharmacol., 16, 103s (1983) 102. R.Lupolover, U.Ballmer, J.Helc1, J.Escher, and B.Pavletic, Br.J.Clin.Pharmacol., 16,
90. 91. 92. 93. 94. 95. 96. 97. 98.
1395 (1983)
A.C.Gudgeon and I.Hindmarch, Br.J.Clin.Pharmacol., 16, 121s (1983) Ch.Feldmeier and W.Kapp, Br.J.Clin.Pharmacol., 16, 151s (1983) K.Rickels, J.Clin.Psychopharmacol., 2, 133 (1983) 0.Dehlin and G.Bjornson, Acta Psychiat.Scand., 3, 290 (1983) O.Dehlin, G.Bjornson, L.Borjesson, L.Abrahamsson, and R.B.Smith, Eur.J.Clin.Pharmacol., 25, 91 (1983) 108. R.Jochemsen, C.J.van Boxtel, J.Hermans, and D.D.Breimer, Clin.Pharmacol.Ther., 34, 42
103. 104. 105. 106. 107.
(1983) 109. D.Bliwise, W.Seide1, I.Karacan, M.Mitler, T.Roth, F.Zorick, and W.Dement, Sleep, 5, 156 (1983) 110. C.Gorenstein and V.Genti1, Psychopharmacol., 80, 376 (1983) 111. P.A.Ellingsen, Acta Psychiat.Scand., 67, 154 n 9 8 3 ) 112. I.C.McManus, S.I.Ankier, J.Norfolk, M.Phillips, and R.G.Priest, Br.J.Clin.Pharmacol., 16, 291 (1983) 113. ZKrieger, M.Perianu, C.Bertagna, P.Mangin, and D.Kurtz, Drug Dev.Res., 3 , 143 (1983) 114. M.Matejcek, C.Neff, K.Abt, and W.Wehrli, Neuropsychobiology, 2, 52 (19837 115. M.Viukari, P.Jaatinen, and T.Kylmamaa, Curr.Ther.Res., 33, 828 (1983) 116. D.M.Barnes, W.F.White, and M.A.Dichter, J.Neurosci., 5 , 7 6 2 , (1983) 117. K.W.Gee, R.E.8rinton and H.L.Yamamura, Life Sci., 21, 1037 (1983) 118. K.W.Gee, R.E.Brinton and H.L.Yamamura, Brain Res., 264, 168 (1983) 119. D.G.Spencer and H.Lal, Drug Dev.Res., 3 , 365 (1983)120. K.Rickels, K.Weisman, N.Norstad, M.Singer, D.Stoltz, A.Brown and J.Danton, J.Clin. Psychiatry, 2 , 12 (sec. 21, 81 (1982) 12 (Sec. 2 1 , 92 (1982) 121. D.Wheatley, J.Clin.Psychiatry, 9, 12 (Sec. 2 ) , 122. J.P.Feighner, C.H.Merideth and G.A.Hendrickson, J.Clin.Psychiatry, 9, 103 (1982) 123. J.S.Hendry, R.L.Balster and J.A.Rosecrans, Pharmacol.Biochem.Behav., 1 9 , 97 (1983) 124. H.Y.Meltzer, R.Flemming and A.Robertson, Arch.Gen.Psychiat., 40, 109971983) 125. M.Cimino, F.Ponzio, G.Achilli, G.Vantini, C.Perego, S.Algeri, and S.Garattini, Biochem.Pharmacol., 2, 1069 (1983) 126. P.L.Wood, N.P.V.Nair, S.Lal, and P.Etienne, Life Sci., 2 , 269 (19831 127. B.A.McMillen, R.T.Matthews, M.K.Sanghera, P.D.Shepard, and D.C.German, J.Neurosci., 3 , 733 (1983)
20
Sect. I
-
CNS Agents
Hesp, Ed.
128. B.A.McMillen and C.C.McDonald, Neuropharmacol., 2 2 , 273 (1983) 129. M.K.Sanghera, B.A.McMillen and D.C.German, Eur.J.Pharmacol., 3, 107 (1983) 130. T.Glaser and J.Traber, Eur.J.Pharmacol., 88, 137 (1983) 131. N.R.Oakley and B.J.Jones, Eur.J.Pharmacol., 87, 499 (1983) 132. S.M.Pau1 and P.Skolnick, Pharmacol.Biochem.Behav., 17 (Suppl. l), 37 (1982) 133. S.Caccia, S.Garattini, A.Mancinelli and M.Muglia, JT-dhromatography, 252, 310 (1982) 134. B.A.McMillen and L.A.Mattiace, J.Neura1 Transmission, 57, 255 (1983) 135. J.P.Yevich, D.L.Temple,Jr., J.S.New, D.P.Taylor and L.A.Riblet, J.Med.Chem., 26, 194 (1983) 136. R.Hoehn-Saric, Psychopharmacol., @, 338 (1983) 137. R.Kikumoto, A.Tobe, H.Fukami and M.Egawa, J.Med.Chem., 26, 246 (1983) 138. E.J.Trybulski, L.E.Benjamin, J.V.Earley, R.I.Fryer, N.W.Gilman, E.Reeder, A.Walser, A.B.Davidson, W.D.Horst, J.Sepinwal1, R.A.O'Brien and W.Dairman, J.Med.Chem., 26, 1589 (1983) 139. A.Wauquier, Anaesthesia, 38 (Suppl) 26 (1983) 140. M.Tanaka, Y.Mizuki, H.IsoGki and K.Inanaga, Eur.J.Clin.Pharmacol., 24, 469 (1983) 141. P.J.Chaudoir, N.C. Jarvie and G. J.Wilcox, J.Int.Med.Res., 11, 333 (19B). 142. J.R.Normanton and J.P.Gent, Neuroscience, 8, 107 (1983) 143. J.E.Garcia-Arraras and J.R.Pappenheimer, J.Neurophysiol., 9, 528 (1983) 144. W.B.Mendelson, A.Kuruvilla, T.Watlington, K.Goeh1, S.M.Pau1 and P.Skolnick, Psychopharmacol., 2,126 (1983) 145. M.R.Trimble and P.J.Thompson, Epilepsia, 24 (Suppl. l), S55 (1983) 146. J.H.Skerritt, L.P.Davies, and G.A.R.Johnston, Epilepsia, 24, 634 (1983) 147. P.R.Andrews, L.C.Mark, D.A.Winkler and G.P.Jones, J.Med.Chem., 26, 1223 (1983) 148. A.M.Anlezark, D.H.R.Blackwood, B.S.Meldrum, V.J.Ram and J.L.Neumeyer, Psychopharmacol., 81, 135 (1983) 149, zL.Mueller and T.V.Dunwiddie, Epilepsia, 2, 57 (1983) 150. P.Loiseau, L.Bossi, M.Guyot, B.Orofiamma and P.L.Morselli, Epilepsia, 24, 703 (1983) 151. H.R.Petersen, 1.Jensen and M.Dam, Acta Neurol.Scand., 5, 114 (1983) 152. J.D.Wood, D.D.Johnson, P.Krogsgaard-Larsen and A.Schousboe, Neuropharmaco ., 22, 139 (1983) 153. G.Graziani, F.Tirone, E.Barbadoro and R.Testa, Arzneim-Forsch., 33 (II), 155 (1983) 154. D.T.Wong, R.C.Rathbun, F.P.Bymaster and W.B.Lacefield, Life Sci., 2,917 (1983) 155. D.T.Wong, F.P.Bymaster and W.B.Lacefield, Drug Dev.Res., 3 , 433 (1983) 156. B.S.Meldrum, H.C.Evans and C.Braestrup, Eur.J.Pharmacol., 9 l , 255 (1983) 157. I.B.Linden, G.Gothoni, P.Kontro and S.S.Oja, Neurochem.Internatioaa1, 5 , 319 (1983) 158. K.R.D.Zelger, J.L.Zelger and E.A.Carlini, Pharmacol., 27, 40 (1983) 159. R.J.Chorvat, B.N.Desai, S.E.Radak, J.Bloss, J.Hirsch and S.Tenen, J.Med.Chem., 26, 845 (1983) 160. N.A.Vaidya, C.H.Panos, A.Kite, W.B.Iturrian and C.D.Blanton, J.Med.Chem., 26, 1422 (1983)
Chapter 3.
Antipsychotic Agents
Tomas de Paulis and Sten Ramsby, Astra Lakemedal AB, Sweden Introduction - Schizophrenia continues to be one of the most fascinating and challenging research topics for medicinal chemists and neurochemists. Tools such as 3H-spiperone binding assays and an understanding of the biochemical abnormalities associated with schizophrenia may provide the path to future discoveries Haloperidol-induced dopamine (DA) receptor supersensitivity in schizophrenics appears to be attenuated by concurrent treatment with lithium.2 Noninvasive radioimaging techniques have brought new insight into the role of the regional distribution and receptor binding of antipsychotic agents .3 Studies of the blood flow in the brains of schizophrenic patients with positron-emitting Xenon-133 have revealed an over-activation in the left hemisphere during performance of a spatial line orientation test.4 PET scanning with oxygen-15 (half-life 123 s ) in some schizophrenic patients failed to support the hypothesis of reduced blood flow in frontal cortex. Enlarged ventricles and sulcal widening were correlated with type I1 schizophrenia, which is characterized by predominance of negative symptoms.6 The DA hypothesis of schizophrenia has been reviewed in the light of recent findings.’l Perioral dyskinesias can be induced acutely in rats by the DA antagonists spiroperidol and sulpiride, and by the selective D agonist SKF 38393, but not by the selective D2 agonist LY 141865.18 Coadministration of 1.Y 141865 with SKF 38393 did not induce dyskinesias, implying that the perioral movements are mediated by the D1 receptors and by an imbalance in D1_D2 responsivity.8 It has been hypothesized that the D-3 binding site is the high-affinity agonist state of the D-1 r e ~ e p t o r . ~Accumulated experience with depot neuroleptics, such as clopenthixol decanoatelO and pipotiazine palmitate, l1 has been reviewed. Phenothiazines and related riRid compounds - The antihallucinator effect of chlorpromazine correlates with serum levels of prolactin,18 consistent with the DA hypothesis of schizophrenia. No regional sitespecificity for limbic areas was found with thioridazine or with clozapine.13 An excellent correlation between daily clinical dose and the dose-dependent increase in cocaine self-administration in rats was found for seven typical and atypical neuroleptics. Clozapine, however, produced a dose-dependent decrease in cocaine intake. l4 HH2 calculations of the energies of the butaclamol structure have been utilized to suggest that a cisoid trans conformer (1) is responsible for the DA antagonist activity of this drug.15 The previously assumed active conformer was found to have 2.7 kcal/mol higher energy.
Unlike taclamine, the thiophene analog QM 7184 (2) blocks apomorphine or amphetamine induced stereotypy in the rat.36 It is equipotent with chlorpromazine but less potent than the structurally related compound butaclamol. Binding studies showed that QM 7184 is 30-50 times
ANNUAL REPORTS IN MEDICINAL CHEMISTRY-I9
Copyright 0 1984 by Academic Press. Inc. All nghts of reproduction in any form reserved. ISBN 0-12-0?10519-9
22
Sect. I
-
CNS Agents
Hesp, Ed.
less active than butaclamol or haloperidol in displacing 3H-spiperone from rat striatum. In contrast to the reference compounds, Ql4 1184 has a high affinity for a-noradrenergic receptors, as shown in binding studies with 3H-wB-4101.16.
I
Me 1 -
3
2
Attempts to separate the multitude of effects shown by cyproheptadine have included introduction of nuclear substituents and replacement of a benzene ring by a pyrrole ring.17 In an extension of this study to include 9-substituted pyrrolobenzapine analogs, compound 3 was found to be 2-3 times more potent than chlorpromazine versus G-spiperone and also showed high affinity for the serotonin S-2 binding The conformational flexibility was higher for these new pyrrolo-compounds than for the corresponding cyproheptadine derivatives as evidenced from the rates of racemization of the atropisomers.
:i:fta
The tetracyclic derivative GP 50302 (4)blocks DA receptors in the same dose range as chlorpromazine, and also shows strong 5-HT blocking properties. Thus in contrast with haloperidol, GP 50302 is much more potent h -viva in dis lacing 3H-spiperone from cortical, versus striatal, binding sites. lg However, in clinical trials GP 50302 had no therapeutic effects in acute schizophrenic patients, but was beneficial in withdrawn and apathetic schizophrenics. 2o The imidazole derivative CGS 10146 B (21, structurally related to clozapine, blocked Sidman avoidance at a dose of 10 mg/kg p.0. in squirrel monkeys.21 However, 1. did not produce the acute dyskinetic syndrome, characteristic of classical neuroleptic agents. In an open multicenter study in 104 schizophrenic patients, fluperlapine (NB 106-689, 6) showed significant improvement from the fifth day of treatment.n Fluperlapine has demonstrated little or no effect in a number of tests, such as catalepsy and inhibition of apomorphine- and amphetamine-induced behavior, which 3re considered specific for antipsychotic agents.23 It is a muscle relaxant and an uptake inhibitor of norepinephrine.
Me
4
5
6
Diphenvlpiperidines and butyrophenones - Haloperidol decanoate, lOOmg once per month, in chronic schizophrenic patients provoked few Parkinson-like side effects.24 DA receptor supersensitivity induced by chronic pimozide treatment was found to be dependent on the dose and not the duration, if measured as an increase in density of spiperone binding sites. When the induced supersensitivity was measured as increased inhibition of apomorphine-induced stereotypy, it was dependent on the duration and not on the dose. Thus, in the absence of pharmacologically-induced DA receptor stimulation, the functional consequences
3
Chap.
Antipsychotic Agents
de Paulis, Ramsby
3
of neuroleptic-induced supersensitivity at the receptor level remain unknown.25 X
2
X = CF3 R =CH20H
X=F
R=H
Structure-activity studies of 1-piperazino-3-phenylindanes led to the development of the potent and long-lasting neuroleptic, tefludazine (B). The %-isomer of tefludazine has 1/1000 the activity of 71 in blocking methylphenidate-induced stereotypy in mice. One member of the tefludazine series, the bisfluoro derivative (7&) was resolved: the antidopaminergic activities resided in the (+)-enantiomer. The (-)-enantiomer, however, proved to be an active uptake inhibitor of DA.Z~
(a)
is a highly potent neuroleptic agent. Positron Spiperone Emission Tomography (PET) imaging with lk-labelled N-methyl-spiperone (half-life 20 min) was used to study the distribution of DA receptors in the human brain. There was a high accumulation of activity in the basic ganglia in comparison to the rest of the brain.27 In another experiment, using 18F-spiperone (half-life 110 min) administered to a baboon 2h before the tomography imaging, it was clearly demonstrated that the ratio of binding in striaturn to cerebellum was ten times higher for 18F-spiperone than for 18F-haloperidol. 28
(m)
Cyclic oxime ethers of butyrophenones exhibit neuroleptic properties. Thus, the benzisoxazole analog of haloperidol, 9, has an ED50 of 1.6 lmol kg in blocking apomorphine-induced climbing in mice .29 The corresponding benzisoxazole analog of benperidol, HRP 913 (lo),seems to be a more selective DA antagonist than those presently in clinical use. HRP 913 is twice as potent as haloperidol in displacing spiperone from striatal binding sites and equipotent in the antiapomorphine stereotypy assay.30 It induces a biphasic atypical catalepsy at a dose 45 times higher than haloperidol, resembling thioridazine in this respect. A similar isosteric arrangement of the aromatic part of the molecule is found in FfJ 13859 (11) which in contrast to buspirone exhibits a clear neuroleptic p r 0 f i 1 T ~ ~ The molindone-butyrophenone hybrid Ro 22-6600 (12) is both a preand postsynaptic DA-antagonist.32 There are differences in the SAR of the Ro 22-6600 series and typical butyrophenones since hydrogenation of the chain carbonyl group in the former only halves activity in conditioned-avoidance response.33 Milenperone (R 34009, 12) displayed antiaggressive activity in a group of mentally retarded patients, with no greater incidence of side effects than with placebo.34 Double blind studies with timiperone (DD-3480, 14) versus ~ l o c a p r a m i n e , ~ ~
Sect. I
24
--
- CNS Agents
Hesp, Ed.
s ~ l p i r i d e ~or~ h a l o p e r i d 0 1 ~ ~ showed an equal or superior efficacy against schizophrenia. The separation between catalepsy and anti-a o morphine activity for timiperone in the monkey seems to be small. 87Another new butyrophenone, HR 375 ( s ) , shows weak and short-lasting muscle relaxing properties besides being active on neuroleptic parameters such as block of climbing and conditioned avoidance behavior. However, it neither blocks stereotypy nor does it induce catalepsy in the rat.38
13 -
Substituted benzamides - The unique behavioral profile in animals of substituted benzamide neuroleptics and their selective action on a subpopulation of D-2 receptors might explain their clinical usefulness in the treatment of s c h i ~ o p h r e n i a . ~ The ~ Ki-value for sulpiride displacement of spiperone binding was approximately 20 times greater than the KD value for sulpiride binding in the presence of 120 mM Na+, suggesting that sulpiride and spiperone label different receptor sites .40 In a comparative study with classical neuroleptics, benzamides were generally 1000 times more potent in stimulating rat prolactin secretion than would have been predicted from their potencies in displacing 3H-spiperone from bovine anterior pituitary membranes .41
16 -
17 -
18 -
In structural analogy with the retro-amide i s ~ s u l p r i d e ~(16). ~ the retro-amide of clebopride, BRL-20596 (u),retains the antiapomorphine activity but totally lacks effect on gastric stimulation,43 thereby showing that separation is possible between the central and peripheral activity. Introduction of a methoxy group in the piperidine ring of clebopride abolishes the central effects. In a series of 3-piperidine substituted benzamides, cisapride (R 51619, 18) is a potent peripheral 5-HT antagonist which shows high potency in increasing gastric p r ~ m o t i l i t y . ~Another ~ compound, BRL 20627 (E),with potent peripheral stimulatory action on the gastric motility of the rat, is only a weak central DA receptor antagonist.45 Conformational studies of clebopride and YH-08050 (m)imply that it is the six-membered pseudo-ring, formed by the hydrogen bond between the amide proton and the ether oxygen atom, rather than the benzene ring, that interacts with the aromatic binding site of the DA re~ e p t o r . ~YU~ 09151-2 was the most potent and selective D-2 receptor antagonist of a series tested: the Ki value for 20b versus 3H-spiperone binding in rat striatal membranes was 0.1 nUT" X-ray studies with Yn 09151-2 have revealed that the tertiary m i n e nitrogen is i n a c c e ~ s i b l e . ~Thus ~ the active conformer must be different from that in the crystalline state if the lone pair on the tertiary nitrogen interacts with the receptor.
(m)
Chap. 3
Antipsychotic Agents
de Paulis, Ramsby
2
In a double blind study, amisulpride (DAN 2163, displayed the same antipsychotic efficacy as haloperidol with favorable effects on certain symptoms.49 At low doses in man, amisulpride behaves like a DA agonist with stimulating properties, but at doses over 600 mg the
20a 20b
19 -
R =H R=CH3
neuroleptic properties predominate.50 Similar to amisulpride, but in contrast to haloperidol, the N-cyclopropylmethyl analog LUR 2366 (m) inhibits apomorphine-induced climbing at a 10 times lower dose than that which blocks stereotypy: in fact LUR 2366 potentiates the gnawing behavior in mice.51 In this series, the n-ally1 substituted sulfone derivative alpiropride ( R I V 2093, displays the largest separation between high-affinity apomorphine (D-4) receptor sites and domperidone (D-2) receptor sites, thereby indicating a lack of effect on the pituitary and no consequent release of p r ~ l a c t i n . ~ ~
a)
clgNHO[ f-+m "*A? a.
G
R
N
OMe
3
Me0
CI
OMe
Me NI - . y $ N ; e
Me
Me0
CBS 22a -
R
=
H
R=CH3
24
23
(z),
A tetrasubstituted benzamide, A 32799 was equipotent with chlorpromazine in'blocking apomorphine-induced stereotypies in the rat, showing that introduction of sterically bulky substituents in the aromatic ring does not abolish antidopaminergic activity.53 However, the pentasubstituted compound, was only 1/50th as active as its corresponding des-4-methyl substituted analog,54 indicating the requirement of a free La= position in this series. The ability of a substito increase the basal tritium outtuted nicotinamide, CGP 11109 flow from caudate slices of the rabbit preincubated with 3H-DA, was comparable to that of s ~ l p i r i d e . ~The ~ metabolic and pharmacokinetic properties of a bis-N-methyl derivative of veralipride, sulverapride (24) were investigated in man. No radioactivity was found in the brain, indicatin very poor penetration of sulverapride across the blood-brain barrier. 5%
(a),
(a)
A new substituted salicylamide, FLB 131 exhibited potent anti-DA properties in the rat.57 Selective labeling of the striatum was demonstrated with both FLB 13158 and the N-methyl analog (25b)59 in PET imaging experiments in cynomolgus monkeys. In a series of 3-substituted 6-methoxysalicylamides, compound FLA 965 (26) showed optimal activity in displacing 3H-spiperone from rat striatal preparations ,60 A remarkable increase in the antiapomorphine activity through introduction of an alpha-hydroxyethyl group was demonstrated in the substituted benzamide MD 781124 (21). Thus, MD 781124 was 540 times more potent in antagonizing apomorphine-induced stereotypy in the rat than the corresponding 5-sulfonamide analog, sulpiride.61
26 -
Sect. I
- CNS Agents
Hesp, Ed.
The tropylamine derivative tropapride (MD 790501, 28) shows a neurophacmacological profile equivalent to that of haloperidol but with substantially less sedative, cataleptogenic or dyskinetic properties.62 In the rat, i.p., tropapride was four times more potent than
26
27 -
haloperidol on antiapomorphine activity. Among a series of azabicyclo(3.3.lJnonylbenzamide derivatives with neuroleptic properties, compound 29 was one of the most potent agents. Its EDSO value in blocking apomorphine-induced climbing in the mouse was 63 times that of clebopride. 63
30 -
28 -
The weak blocking properties of tiapride (FLO 1347, 30) at receptors labelled by various neuroleptics could not be explained solely by its poor penetration into the brain.64 Instead it was suggested to be due to a specific action of tiapride on receptor sites selectively labelled by 3H-sulpiride. Further clinical experience with tiapride in the treatment of tardive dyskinesia has shown that it is an effective agent. In a double-blind comparison with placebo, tiapride significantly improved dyskinesia in 15 patients who had received neuroleptics for 15 years.65 Miscellaneous compounds - Similar to dihydro-oxypertine (CL 77328) ,66 the structurally related isochroman derivative U-54537 E, (2)displays an atypical neuroleptic profile.67 Both compounds are weak in displacing 3H-spiperone binding and in antagonizing the behavioral syndrome induced by apomorphine. Yet, U-54537E is three times more potent than thioridazine in decreasing conditioned avoidance response and is equipotent with chlorpromazine in blocking adenylate cyclase coupled D-1 receptors.67 A thiazoledione analog MJ 13980-1 (32) of buspirone (MJ
32 -
33 -
9022-1, 33) has shown promise as a. potential antipsychotic in that it possesses antidopaminergic activity but does not induce catalepsy. In fact, MJ 13980-1 is potent in reversing phenothiazine-induced catalepsy in the rat.68 The physicochemical parameters of the aromatic orthosubstituent do not correlate with the anti-DA activity in this series.69
Chap. 3
Antipsychotic Agents
de Paulis, Ramsby
7
A double-blind phase I study of zetidoline (DL-308, 34a) revealed a strong sedative effect as judged by self-reported performance scores on logical reasoning and coordination tests.70 In an open study in 40 schizophrenic patients, doses of 10 to 90 mg daily of zetidoline exerted a good antipsychotic efficacy with akathisia as the most notable side effect.71 Substitution in the aromatic nucleus with a p-hydroxy group (E) substantially increases both duration and antiapomorphine activity in rodents.IZ m
NHCONEt,
34a R = H -
35
R=OH
2-Bromolisuride (35) is the first ergot derivative with a definite antagonist effect at central DA receptors.73 In comparison with haloperidol, 21 shows ten times larger separation between drug-induced catalepsy and apomorphine-induced stereotypy in the rat.74 S(+)-N-propylnorapomorphine shows DA receptor blocking activity75 as was shown previously for S(+)-ap~morphine.~~ A new pyrazole derivative 36 also exhibits DA antagonist properties as evident from its prolactin elevating effect on the pituitary.77 Both molindone and its rigid derivative Ro 22-1319 (21) were confirmed to be more active as presynaptic DA-antagonists than postsynaptic ,32 thereby indicating an explanation for the relatively weak anti-amphetamine activity of molindone.78 Ro 22-1319 was equipotent with haloperidol in elevating serum prolactin levels in the rat.79 More receptor-specific agonists and antagonists of DA continue to appear. A new benzazepine, SCH 23390 is claimed to be the first selective D-1 antagonist and promises to be a useful neuropharmacological tool.80 SCH 23390 is equipotent with flupentixol in displacing 3H-piflutixol (D-1) binding, but 1200 times less active in displacing 3H-spiperone (D-2) binding.81 It is virtually free from blocking effects on apomorphine-induced hypothermia and emesis and does not cause hyperprolactinemia,82 which suggests that these effects are related to the D-2 receptor.
(s)
EEDQ (2)is a potent and irreversible D-2 anta onist which apparently binds covalently to DA receptors in the CNS.8el EEDQ produces catalepsy and inhibits both amphetamine-induced stereotypy and conditioned avoidance behavior. HO
A 37 -
38
A six week study with the GABA agonist progabide (SL 76002, g ) , in schizophrenic patients on neuroleptic maintenance therapy, revealed improvement on items such as vigilance and affective i n ~ o l v e m e n t . ~ ~ There is evidence that SL 76002 blocks striatal cholinergic neurons through a gabergic mechanism. Thus repeated treatment with SL 76002 in rats prevents tolerance to the cataleptogenic action of haloperidol.85
28
Sect. I
- CNS Agents
Hesp, Ed.
Unlike TL99 (41), neither (*)-3-PPP ( 4 3 8 6 9 8 7 nor its (-)-enantiomer UH 106(-) nappear to be presynaptic agonists in vitro: thus they do not inhibit evoked release of 3H-DA from rat striatal slices. HO
"omN"" no
H"
42 -
40 -
Instead, both the r a ~ e m a t e and ~ ~ ( - ) - e n a n t i 0 m e r 8 ~ * ~behave ~ as postsynaptic D-2 antagonists in vitro. For example, the latter prevents the blocking action of the D-2 agonist LY 141865 on potassium-induced However , the (-)-enanrelease of 3H-acetylcholine from striatum.88 tiomer does behave as a presynaptic DA agonist at low doses in V ~ V O . ~ References 1. R. Rodnight, J. Neurochem., 41, 12 (1983). 2. D. E. Sternberg, M. B. Bowers, Jr., G. 8. Heninger and D. S. Charney, Psychiat. Res., lo, 79 (1983). 3. N. D. Heindel and N. Foster, Ann. Rep. ned. Chem.. H, 293 (1983). 4. R. E. Cur, B. E. Skolnick, R. C. Gur, S. Caroff, W. Rieger, W. D. Obrist, D. Younkin and M. Reivich, Arch. Gen. Psychiat., 40, 1250 (1983). 5. G. Sheppard, J. Gruzelier, R. kanchanda, S. 8. Hirsch, R. Wise, R. Frackowiak and T. Jones, Lancet 21, 1448 (1983). 6. H. A . Nasrallah, S. Kuperman, C. G . Jacoby. M. McCalley-Whitters and B. Hamra. Psychiat. Res., lo, 237 (1983). 7. Y. Sayed and J. W. Garrison, Psychopharm. Bull., 19. 283 (1983). 8. H. Rosengarten, J. Y. Schweitzer and A . J. Friedhoff, Life Sci., 33. 2479 (1983). 9. S. E. Leff and I. Creese, Trends Pharmacol. Sci., 5 , 463 (1983). 170 (1982). 10. S. Sieberns and H. Spechtmeyer, Int. Phacmacopsychiat., 11. E. A. Burch, Jr. and 9. J. Ayd, Jr., J. Clin. Psychiat., 44, 242 (1983). 12. H. Y. Meltzer and D. Busch, Psychiat. Res., 2, 285 (1983). 13. P. Seeman and C. Ulpian, Eur. J. Pharmacol., 94, 145 (1983). 14. D. C. S. Roberts and G. Vickers, Psychopharmacol., 82 135 (1983). 15. M. Froimowitz and S. Mathysse, nol. Pharamcol., 24, 243 (1983). 16. E. Arribas, S. Vega, C. Benito, M. P. Pernandez-Tome and J. del Rio, Arzneim.Forsch, 33, 1417 (1983). 17. D. C. Remy, S. F. Britcher. P. S. Anderson, P. C. Belanger. Y . Girard and B. V. clineschmidt, J. Med. Chem. 25, 231 (1982). 18. D. ,.C Remy, S. F. Britcher, S. W. King, P. S. Anderson, C. A . Hunt, W. C. Randall, P. Belanger, J. G. Atkinson, Y. Girard, C. S. Rooney, J. J. Puentes, J. A . Totaro, J. L. Robinson, E. A. Risley and M. Williams, J. Wed. Chem., 3,974 (1983). 19. R. Ortman. S. Bischoff, E. Radeke, 0. Buech and A . Oelini-Stula, Arch. Pharmacol.. 321, 265 ii982). 20. A . Delini-Stula, P. Waldmeier, P. Baumann, L. Maitre, H. Blattner and P. Schmidlin, 11th C.I.N.P. Congress (Vienna, July 9-14, 1978) Abst. p . 373. 21. J. W . Liebman, G. P. Quinn, R. A . Lovell, I. Vlattas and T. W. Glenn, Fed. Proc., 42, 1152 (1983). Abst. 5037. 22 * K. A. Fisher-Cornelssen, Arzneim-Forsch., 34, 125 (1984). 23. H. R. Burki, 186th Meet. Am. Chem. SOC. (Washington, Aug. 22-26, 1983) Abst. 765. 24. Y. G. Gelders, A . J. M. Reynjiens, C. W. Ash and T. J. L. Aerts, Int. Pharmacopsychiat., l7, 247 (1982). 25. K. J. Dewey and H. C. Fibiger, Arch. Phacmacol., 322, 261 (1983). 26. K. P. Bogeso, J. Ned. Chem., 3,935 (1983). 27. H. N. Wagner, H. 0. Burns, R. F. Dannals, D. F. Wong, B. Langst&m. T. Duelfer. J. J. Frost, H. T. Ravert, J. W. Links, S. B. Rosenbloom, S. E. Lukas, A . V. Kramer and M. J. Kuhar, Science 221, 1264 (1983). 28. M. J. Welch, M. 8. Kilbourn, C. J. Hathias, M. A . Mintun and W . E. Raichle, Life Sci., 33, 1687 (1983). 29. L. Davis, 8. C. Effland and J. T. Klein, Eur. Pat. Appl. EP 63799 (1982). Chem. Abst. 98 179353 r (1983). 30. S. Fielding, W. J. Novick, Jr., H. 1. Gayer, W. W. Petko, J. C. Wilker, L. Davis, J. T. Klein and 1. Cornfeldt. Drug Dev. Res., 3, 233 (1983).
u,
-
~
Chap. 3 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58.
59. 60. 61. 62, 63, 64. 65. 66. 67. 68. 69,
A n t i p s y c h o t i c Agents
d e P a u l i s , Ramsby
J . P. Yevich. D. L. Temple, J. S. New, W. G. Lobeck, J . D. Catt, D. P. Taylor,
3
n. s.
Eison and L. A. Riblet, 186th Meet. Am. Chem. SOC., (Washington. Aug. 22-26, 1983) Abst. 69. H. H. Keller, Arch. Pharmacol., 324, Suppl. R 19 (1983) Abst. 74. G. L. Olson, H.-C. Cheung, E. Chiang and L. Berger in "Dopamine Receptors", ACS Symposium Series 224. C. Kaiser and J. W. Kebabian, Eds., Washington D. C., 1983, p. 251. H. De Cuyper, H. M. van Praag and D. Verstraeten. VII World Congr. Psychiat., (Vienna, July 11-16, 1983) Abst. P 714. T. Nakasawa, K. Ohara, Y. Sawa, VII World Congr. Psychiat., (Vienna, July 11-'16, 1983) P 722. K. Mori, M. Miyasaka and Y. shimazono, VII World Congr. Psychiat., (VIenna, July 11-16, 1983) P 72. T. Shibuya, T. Nishimori, H. Matsuda and P. C. Chen, Int. J. Clrn. Pnarmacol. Ther. Toxicol., 20. 251 (1982). F. J . Hock, H. J. Kruse. H. Gerhards and E. Konz, Pharmacologist. 25. 130 (1983). Abst. 103. P. Jenner and C. D. Marsden, Acta Psychiat. Scand. Suppl. 69. 109 (1984). A. E. Theodorou. P. Jenner and C. D. Marsden, Life Sci., 32. 1243 (1983). H. Y. Melzer, M. Simonovic and R. So, Life Sci.. 32, 2877 (1983). G. Le Fur, F. Guilloux and A. Uzan, Biochem. Pharmacol., 29, 267 (1980). F. E. Blaney, M. S. G. Clark, D. V. Gardner, M. S. Hadley, D. Middleton and T. J . White, J. Med. Chem., 26. 1747 (1983). H. J. Cooke and H. V. Carey, Eur. J. Pharmacol., 98, 147 (1984). M. S. Hadley, F. D. King, B. McRitchie, D. H. Turner and E. A. Watts, 2nd SCI-RSC Med. Chem. Symp. (Cambridge. Sept. 12-14, 1983) Abst. p 9. H. van de Waterbeemd and B. Testa, J. lied. Chem., 26. 203 (1983). M. Terai, S. usuda, I. Kuroiwa, 0. Noshiro and H. Maeno, Jap. J. Pharmacol., 33. 749 (1983). T. Furuya, S. Iwanami. A. Takenaka and Y. Sasada. Bull. Chem. SOC. Jap. 55. 2321 (1982). H. E. Klein, D. Dieterle. E. Ruther, E. Eben, N. Nedopil and H. Hippius. VII World Congr. Psychiat. (Vienna, July 11-16, 1983). Abst. S 1090. J. Grunberger, 8. Saletu, L. Linzmeyer and H. Stohr, VII World Congr. Psychiat. (Vienna, July 11-16, 1983). Abst. S 1089. M. P. Martres, P. Sokoloff, M. Delandre, J.-C. Schwartz, P. Protais and J. Costentin, Arch. Pharmacol., 325, 102 (1984). P. Sokoloff, M. Delandre, M. P. Martres, J.-C. Schwartz, P. Laibe and C. Wermuth, 5th Catecholamine Symp. (Gothenburg, June 12-16, 1983). Abst. 459. L. Florvall, M.-L. Persson and S.-0. Ogren, Acta Pharm. Suec., 20. 365 (1983). L. Florvall and S.-0. Ogren, J. Med. Chem., 2 5 , 1280 (1982). K. Starke, L. Spath, J. D. Lang and C. Adelung, Arch. Pharmacol.. 323, 298 (1983). A . Benakis, F. 8. Sugnaux, C. Plessas, C. Rey. C. Gallay, R. Happe and P. Allais, Pharmacologist, 25. 115 (1983) Abst. 28. L. Florvall. J. Lundstram, S. Ramsby and S.-0. &ran, Eur. Pat. Appl. EP 60235 (1982). Chem. Abst. 98. 53687 j (1983). G . Sedvall, G. Blomqvist, T. de Paulis, E. Ehrin, L. Eriksson, L. Farde, T. Greiz. C. ,G. Hedstrom, D. H. Ingvar, J.-E. Litton, J. L. G . Nilsson, S. Stone-Elander, L. Widen, F. A. Wiesel and G. Wit, Ann. Meet. Am. Coll. Neuropsychopharmacol. (San Juan, Dec. 12-16, 1983). G. Sedvall, G. Blomqvist, T. de Paulis et al., in "Proceedings of VII World Congress of Psychiatry", P. Berner, Ed., Plenum Press, N.Y 1984. T. de Paulis, U. H. Lindberg, L. Florvall, S.-0. Ogren and H. Hall, 2nd SCI-RSC Med. Chem. Symp. (Cambridge. Sept. 12-14, 1983). Abst. p. 14. M. Langlois, T. Imbert and B. Bucher, Fr. Pat. Appl. 2446274 (1980). Chem. Abst. 94. 208572 m (1981). M. Jalfre, B. Bucher, N. Donne, G. Mocquet and 8. D. Porsolt, Arch. Int. Pharmacodyn.. 264. 232 (1983). M. S. Hadley and F. E. Blaney, Eur. Pat. Appl. EP 76592 (1983). Chem. Abst. 99, 70583 k (1983). J. K. Chivers, W. Gommeren, P. Jenner. J. Leysen. C. D. Marsden, C. Reavill and A. Theodorou, Brit. J. Pharmacol., 78, 398 P (1983). VII World Congr. Psychiat. (Vienna, July 11-16, 1983). Abst. S 1085. E. N. Greenblatt, J. Coupet, E. Rauh and V. A. Szucs-Myers, Arch. Int. Phannacodyn., 248. 105 (1980). P. F. von Voigtlander, R. A. Lahti, A. H. Tang and V. H. Sethy. Arch. Int. Pharmacodyn., 266, 23 (1983). D. P. Taylor, M. S. Eison, D. L. Temple and J. P. Yevich, Fed. Proc., 42, 1153 (1983). Abst. 5045. J. P. Yevich, D. L. Temple, J. S. New, D. P. Taylor and L. A. Riblet. J. Mad. Chem., 26, 194 (1983).
...
30 -
Sect.
I
- CNS Agents
Hesp, Ed.
70. L. A . Riblet, M. Herbert, P. J. Standen, A. H. Short and A. T. Birmingham, Psychopharmacol., 8l, 335 (1983). 71. M. Zapletalek, J. Libiger, I. Tuma and K. Kubicek. VII World Congr. Psychiat. (Vienna, July 11-16, 1983). Abst. P 685. 72, L. Fontanella, E. Martinelli and M. A . Assandri, Ger. Pat. DE 3307172-A (1983). 73. H. Wachtel, Arch. Pharmacol. Suppl., 324. R 90 (1983). Abst. 360. 74. H. Wachtel, W. Kehr and G. Sauer, Life Sci.. 33, 2583 (1983). 75. J. L. Neumeyer, D. Reischig, C. W. Arana, A . Campbell, R. J . Baldessarini, N. S. Kula and K. J. Watling, J. Med. Chem., 26, 516 (1983). 76. R. V. Smith, R. E. Wilcox, K. Young, U. H. Riffee and Y. C. Clement-Cornier, Fed. PCOC., 4 l , 105 (1982) Abst. 71. 77. E. 8. Smalstig, E. C. Kornfeld and J. A . Clemens, Fed. Proc., 4 l , 162 (1982). Abst. 118. 78. R. W. Fuller and H. D. Snoddy, Life Sci., 21, 2357 (1983). 79 * S. J. Kolis, T. H. Williams, T. F. Mowles, B. Burghardt, V. Toome and H. A. Schwartz, J. Pharmacol. Exp. Ther., 227, 652 (1983). 80. J. Hyttel, Eur. J. Pharmacol., 91, 153 (1983). 81. L. C. Iorio, A . Barnett, P. H. Leitz, V. P. Houser and C. A . Korduba, J. Pharmacol. Exp. Ther., 226, 462 (1983). 82. A . Hilditch, G. M. Drew and 8. J. Naylor, Eur. J . Pharmacol., 9 7 , 333 (1984). 83. H. W. Hamblin and I. Creese, Life Sci., 32, 2247 (1983). 84. P. Sevestre, N. Seguier, J. Lagrange, V. Fournier, B. Musch and P. L. Morselli, VII World Congr. Psychiat. (Vienna, July 11-16, 1983) Abst. P 730. 85. G. Bartolini, B. Scatton and B. Zivkovic in "Adv. Biochem. Psychopharmacol.", Vol. 24, B. Cattabeni et al., Eds., Raven, New York, 1980, p. 207. 86. P. Siminia and A. H. Mulder, Euc. J. Pharmacol., 89, 183 (1983). 87. R. Markstein and D. Lahaye, J. Neural Transm., 5 8 , 43 (1983). 88. J. F. Plantje, A . H. Mulder and J. C. Stoof, Pharm. Weekblad Sci. Ed.. 5 , 265 (1983). 89. S. Hjort, A . Carlsson, D. Clark, K. Svensson, M. Wikstr'd.m, D. Sanchez, P. Lindberg, U. Hacksell, L.-E. Arvidsson, A. Johansson and J. L. G. Hilsson, Psychopharmacol. 81, 89 (1983).
CHAPTER 4.
COGNITIVE
DISORDERS
F r e d M. Hershenson and John G. M a r r i o t t
Warner-LambertIParke-Davis, Ann Arbor, M I
48105
I n t r o d u c t i o n - The treatment of c o g n i t i v e d i s o r d e r s remains one of t h e g r e a t c h a l l e n g e s f a c i n g medicine and science. I n s p i t e of impressive advances i n our understanding of t h e b r a i n , s a f e and e f f e c t i v e treatments f o r t h e major d i s o r d e r s of c o g n i t i o n , e.g., mental r e t a r d a t i o n , l e a r n i n g d i s a b i l i t i e s , amnes t i c syndromes, and t h e dementias, have y e t t o be demonstrated. To t h e s e major d i s o r d e r s of c o g n i t i o n can be added many d i s o r d e r s and d i s e a s e s of t h e c e n t r a l nervous system (CNS) which have c o g n i t i v e sequelae, although they are n o t p r i m a r i l y c o g n i t i v e d i s o r d e r s , e . g . , e p i l e p s y and schizophrenia. Research i n t o human d i s o r d e r s of c o g n i t i o n i n r e c e n t y e a r s has focused t o a l a r g e degree upon Alzheimer's d i s e a s e o r Primary DegenRecent c l i n i c a l evidence,1'l6 a l o n g w i t h e r a t i v e Dementia (PDD) earlier l a b o r a t o r y s t u d i e s , 17-21 i n d i c a t e s t h a t t h e c o g n i t i v e d e f e c t s i n Alzheimer's d i s e a s e , t h e primary cause of dementia i n t h e e l d e r 1 are due t o a l o s s of f u n c t i o n i n g of c h o l i n e r g i c neurons i n t h e S i n c e many a r t i c l e s have r e c e n t l y a p p e a r e d summarizing c h o l i n e r g i c approaches t o t h e treatment of dementia,22-26 w e w i l l only b r i e f l y review t h i s a c t i v e r e s e a r c h area and then d i s c u s s o t h e r chemotherapeutic approaches which show promise i n the treatment of c o g n i t i v e dysfunction.
.
The C h o l i n e r g i c System - Following t h e precedent of 2-dopa therapy f o r P a r k i n s o n ' s d i s e a s e , many s t u d i e s have attempted t o treat t h e c h o l i n e r g i c d e f i c i t presumed t o account f o r t h e c o g n i t i v e impairments i n Alzheimer's d i s e a s e , by t h e use of p r e c u r s o r s t o a c e t y l c h o l i n e (ACh), such a s c h o l i n e c h l o r i d e o r l e c i t h i n . R e s u l t s from t h e s e s t u d i e s have been almost unif ormly negative.27-33 One r e c e n t long-term, six-month study u s i n g high doses of l e c i t h i n showed b e n e f i c i a l e f f e c t s i n PDD p a t i e n t s on a mental t e s t and a p a i r e d - a s s o c i a t e l e a r n i n g task.34 A r e p o r t demonstrating g r e a t e r enhancement of memory i n aged r a t s w i t h a combination of c h o l i n e c h l o r i d e and piracetam than w i t h e i t h e r compound a l o n e has s timula t e d s e v e r a l c l i n i c a l s t u d i e s w i t h combinations of p r e c u r s o r therapy and o t h e r drugs.35 An i n i t i a l s t u d y w i t h piracetam and c h o l i n e c h l o r i d e , i n p a t i e n t s f o r whom t h e d i a g n o s i s was mild t o moderate PDD, found g r e a t e r improvement w i t h t h e combination therapy than w i t h piracetam alone.36 Recently, t h e s u g g e s t i o n has been made t h a t p r e c u r s o r therapy be combined w i t h c h o l i n e s terase i n h i b i t o r s i n a l l f u t u r e t r i a l s of t h e l a t t e r i n Alzheimer's d i s e a s e , and i n t r i a l s of o t h e r a g e n t s which a f f e c t c h o l i n e r g i c f u n c t i o n , e.g. n a l o ~ o n e . ~ T h~i s s u g g e s t i o n i s supported by r e c e n t animal s t u d i e s showing s t r i k i n g reduct i o n s i n t h e optimal doses of c h o l i n e r g i c a g o n i s t s r e q u i r e d t o produce improved r e t e n t i o n on a T-maze t a s k in'mice, when given as two o r threedrug combina ti on^.^^ However, c l i n i c a l trials w i t h combinations of a n t i c h o l i n e s terases and ACh p r e c u r s o r s have shown l i m i t e d success. I n i t i a l p o s i t i v e e f f e c t s were r e p o r t e d i n e l d e r l y dementia p a t i e n t s , 3 9 and two r e c e n t s t u d i e s using o r a l physos tigmine supplemented by l e c i t h i n
ANNUAL REPORTS IN MEDICINAL CHEMISTRY-I9
Copyright 0 1984 by Academic Preas. Inc All rights of reproduction in any form reserved. ISBN 0-12-040519-9
32 -
Sect. I
- CNS Agents
Hesp, Ed.
reported o s i t i v e e f f e c t s upon c o g n i t i v e performance i n Alzheimer patients.g0,41 Others f a i l e d t o f i n d p o s i t i v e e f f e c t s upon c o g n i t i o n i n normal aged s u b j e c d 2 o r i n p a t i e n t s w i t h Alzheimer's d i s e a s e t r e a t e d i n t h i s manner.43 Many s t u d i e s have reported b e n e f i c i a l e f f e c t s i n p a t i e n t s t r e a t e d w i t h a n t i c h o l i n e s t e r a s e s alone,22,25,44-47 though o t h e r s have f a i l e d t o f i n d improvement i n c o g n i t i v e performance i n similar patients.48949 4-aminopyridine (4-AP) and 3,4-diaminopyridine (3,4-DAP) have been s t u d i e d i n animal models f o r p o t e n t i a l e f f e c t s upon cognition. These drugs enhance release of ACh, presumably by blocking potassium channels i n nerve cells, thereby promoting calcium flux.50 3,4-DAP p a r t i a l l y r e v e r s e s t h e d e f i c i t s i n ACh metabolism and motor behavior ( t i g h t - r o p e t e s t ) produced by hypoxia i n mice.51 It a l s o improved performance on a n 8-arm radial maze i n aged rats.52
-
Studies of the biochemical and h i s t o p a t h o l o g i c a l changes Animal Models i n Alzheimer's p a t i e n t s , 4 - l 6 p a r t i c u l a r l y i n t h e c h o l i n e r g i c system, have opened new approaches t o developing animal models f o r t e s t i n g hypotheses and new chemical e n t i t i e s . Already s e v e r a l s t u d i e s have appeared d e f i n i n g t h e r o l e of v e n t r a l p a l l i d a l l e s i o n s i n animals. Acquisition of a c t i v e and passive avoidance was impaired i n r a t s with u n i l a t e r a l elect r o l y t i c a l l e s i o n s i n t h e ventromedial p o r t i o n of t h e pallidum, a n area which corresponds t o the nucleus b a s a l i s of Meynert i n primates.53 Responses learned before l e s i o n i n g were n o t impaired. Ventral p a l l i d a l l e s i o n s produced by i b o t e n i c a c i d d i d n o t a l t e r performance of rats on a b a t t e r y of psychomotor t a s k s o r a f f e c t s e n s i t i v i t y t o shock.54 Howe v e r , severe d e f i c i t s i n r e t e n t i o n of a passive avoidance response were found i n these lesioned animals. S i m i l a r d e f i c i t s i n passive avoidance r e t e n t i o n were found i n rats lesioned b i l a t e r a l l y i n t h e v e n t r a l pallidum using another e x c i t a t o r y .neurotoxin, k a i n i c acid.55 Ethylcholine mustard a z i r i d i n i u n i o n (AF64A, l-), a neurotoxic c h o l i n e analog, h a s been shown t o produce long-lasting hypofunction of c e n t r a l c h o l i n e r g i c systems i n mice56 and a reduction of presynaptic c h o l i n e r g i c markers i n r a t hippocampus57 without a f f e c t i n g post-synaptic muscarinic r e c e p t o r binding. It has been proposed t h a t AF64A-lesions may provide a n animal model of Alzheimer's d i s e a s e , although behavioral evidence t o support t h i s view i s q u i t e preliminary.58 A n t i c h o l i n e r g i c i n d u c e d c o g n i t i v e def i c i t s have a l s o been used as a model of age-related impairments, with a g e n t s being t e s t e d f o r t h e i r a b i l i t y t o antagonize o r r e v e r s e t h i s a c t i v i t y . Systemically administ e r e d a t r o p i n e has been shown t o produce i n c r e a s e s i n running time and working memory e r r o r s i n mice t r a i n e d on a six-arm r a d i a l maze.59 I n a s w i m maze, a t r o p i n e - t r e a t e d rats were impaired with r e s p e c t t o f i n d i n g a hidden escape platform.60 S i m i l a r d e f i c i t s were found i n rats with t o t a l hippocampalectomy.61 Atropine was found t o d i s r u p t a c q u i s i t i o n of a l i g h t l d a r k d i s c r i m i n a t i o n and a tonelno tone d i s c r i m i n a t i o n i n r a t s . b 2 Physos tigmine, conversely, f a c i l i t a t e d performance on t h i s task. Anticholinergics are a l s o e f f e c t i v e i n d i s r u p t i n g memory when i n j e c t e d d i r e c t l y i n t o the b r a i 1 1 . ~ ~ , 6 4 Conversely, c h o l i n e r g i c a g e n t s such as a r e c o l i n e , physostigmine, oxotremorine, and muscarine, a l l improved r e t e n t i o n on a n a c t i v e avoidance t a s k when administered ICV a f t e r t r a i n i n g and p r i o r t o r e t e n t i o n t e s t i n g one week l a t e r . 6 4 was 4-( o-Benzy1phenoxy)-Nme thylbutylamine hydrochloride (MCI-2016, found t o r e v e r s e scopolamine-induced impairments of spontaneous a l t e r a t i o n of responding i n r a t s similar t o t h e e f f e c t s of physostigmine, chol i n e and a m ~ h e t a r n i n e . ~ ~
z),
Chap. 4
Cognitive Disorders
Hershenson, M a r r i o t t
3
Old animals continue t o be used e x t e n s i v e l y as models of agerelated c o g n i t i v e d i s o r d e r s . Old mice, f o r example, were found t o be impaired on p a s s i v e avoidance compared t o young mice.66 I n c o n t r a s t w i t h c l i n i c a l d a t a , phosphatidylcholine i n t h e d i e t enhanced performance of o l d mice i n a shuttle-box avoidance test.67 Aged rats performed a t chance l e v e l s a f t e r 15 t r a i n i n g t r i a l s using a 12-arm r a d i a l maze, wherea s young rats had mastered t h e task.68 I n t h i s study, p o s i t i v e c o r r e l a t i o n s i n aged rats were found between maze performance and hippocampal c h o l i n e a c e t y l t r a n s f e r a s e a c t i v i t y . Aged primates, b o t h cebus and rhesus monkeys, have been employed i n s t u d i e s of age-related memory i m p a i r m e n t ~ and ~ ~ drug e f f e c t s upon memory.7a Drug t r i a l s i n monkeys have demonstrated e f f e c t s w i t h c h o l i n e r g i c a g e n t s and neuropeptides similar t o those r e p o r t e d i n human t r i a l s , adding t o t h e v a l i d i t y and u t i l i t y of t h e s e models. 71
-
While c h o l i n e r g i c approaches t o t h e treatment of cogniBiogenic Amines t i v e d i s o r d e r s have been t h e focus of much c l i n i c a l work, cumulative labo r a t o r y d a t a i m p l i e s a n i m o r t a n t r o l e i n l e a r n i n g and memory f o r t h e a d r e n e r g i c nervous ~ y s t e m . ~ I ~ n ,a d~d ~ i t i o n , t h e r e i s a dramatic l o s s of c e l l s i n t h e l o c u s c o e r u l e u s i n b r a i n s of Alzheimer p a t i e n t s , b u t n o t i n m u l t i i n f a r c t dementia, s u g g e s t i n that t h i s d i s e a s e i s n o t simply a d i s o r d e r of c h o l i n e r g i c There i s a l s o a s u g g e s t i o n t h a t c h o l i n e r g i c i n f l u e n c e s upon memory may involve dopaminergic mechanisms .76
rigi in.^^,^!
C l i n i c a l t r i a l s of amphetamine, methylphenidate, p e n t y l e n e t e t r a z o l , and p i p r a d o l have g e n e r a l l y f a i l e d t o f i n d s i g n i f i c a n t e f f e c t s upon cogn i t i o n i n impaired e l d e r l y s u b j e c t s , although mood improvement and reduct i o n i n f a t i g u e have been noted.74 These results c o n t r a s t w i t h t h e p o s i t i v e e f f e c t s upon performance induced by psychostimulant drugs i n h y p e r a c t i v e c h i l d r e n w i t h a t t e n t i o n a l d e f i c i t d i ~ o r d e r . ~ Only ~ , ~ ~ Hyderginem, which has both alpha-adrenergic and dopaminergic a c t i v i t y , h a s been shown t o have c o n s i s t e n t e f f e c t s i n improving mental performance i n dementia p a t i e n t s , although t h e o v e r a l l degree of improvement i s usually Medical and psychological improvements have a l s o been r e p o r t e d i n normal e l d e r l y v o l u n t e e r s t r e a t e d w i t h Hyderginem.80 Two r e c e n t c l i n i c a l s t u d i e s have found impairment of c o i t i v e f u n c t i o n i n s u b j e c t s t r e a t e d w i t h a n t i h y p e r tens i v e medica t i o n .
r8
I n animals, p r o p r a n o l o l a t t e n u a t e d b o t h t h e memory f a c i l i t a t i o n and amnesia produced by post- t r a i n i n g s t i m u l a t i o n of f r o n t a l c o r t e x i n r a t s t r a i n e d using two l e v e l s of footshock.83 Amphetamine attenuated C02induced amnesia f o r o n e - t r i a l i n h i b i t o r y avoidance i n young r a t s , b u t had no e f f e c t i n o l d animals suggesting a change i n t h e neuromodulatory i n f l u e n c e of catecholamines on memory processes i n s e n e ~ c e n c e . ~A s~ has been r e p o r t e d f o r c h o l i n e r g i c drugs, combinations of a d r e n e r g i c and dopaminergic drugs have produced more improvement i n performance than i n d i v i d u a l drugs alone. The a c t i o n s of t h e c e n t r a l stimulants, c a f f e i n e , s t r y c h n i n e , o r methylphenidate, on r e t e n t i o n of shuttle-box avoidance i n r a t s were much more e v i d e n t when combined w i t h o r o t i c acid.85 p-Chlorophenylalanine f a c i l i t a t e d l e a r n i n g and/or memory when admins t e r e d i n con-
34 -
Sect. I
-
CNS Agents
Hesp, Ed.
j u n c t i o n w i t h c a f f e i n e , s t r y c h n i n e , o r amphetamine.86 Apomorphine prot e c t e d a g a i n s t t h e d i s t u r b a n c e s i n conditioned avoidance responding produced by hypobaric h y p ~ x i a . T ~ h~i s a c t i v i t y of apomorphine was blocked by adrenalectomy b u t n o t by domperidone. Apomorphine i n j e c t e d i n t r a hippocampally immediately a f t e r a c q u i s i t i o n of a b r i g h t n e s s discrimi n a t i o n t a s k improved re t e n t i o n and increased incorpora t i o n of L-f ucose i n t h e hippocampus of rats.88
-
A number of s t u d i e s have been conducted aimed a t c o r r e Neuropeptides l a t i n g abnormal l e v e l s of a p a r t i c u l a r neuropeptide w i t h Alzheimer's d i s e a s e . The following neurope t i d e s have been s t u d i e d r e c e n t l y : s o m a t o s t a t i n 89990 substance-P,gl n e u r o t e n s i n g2 CCK,g3,g4 VIP,93 TRH,92 g l ~ c a g o n and , ~ ~b e t a - e n d ~ r p h i n . ~Only ~ somatostatin l e v e l s i n CSF and b r a i n appear t o be reduced i n r e l a t i o n t o t h e s e v e r i t y o f t h e d i s e a ~ e . ~ Angiotensin ~ , ~ ~ , ~ c~o n v e r t i n g enzyme a c t i v i t y has been r e p o r t e d t o be e l e v a t e d i n d i s c r e t e b r a i n r e g i o n s from Alzheimer p a t i e n t s when compared t o age-ma tched c o n t r o l s .97
The neurophysiological e f f e c t s g 8 of v a s o p r e s s i n and oxytocin and t h e e f f e c t s of v a s o p r e s s i n on memory99 have been r e c e n t l y reviewed. Behavioral s t u d i e s w i t h t h e s e p e p t i d e s i n d i c a t e t h a t v a s o p r e s s i n enhances, w h i l e oxytocin i m a i r s memory,100,101 and that t h e s e effects a r e c e n t r a l l y mediated. 105 Arginine v a s o p r e s s i n (3) improved p a s s i v e avoidance i n c h i c k s l o 3 and l y s i n e v a s o p r e s s i n (2) was found t o r e v e r s e anisomycin-induced amnesia i n mice. l o 4 Recently, i t h a s been suggested that p e r i p h e r a l l y administered v a s o p r e s s i n e l i c i t s i t s e f f e c t on memory through a n a v e r s i v e property, r e s u l t i n g i n a n a r o u s a l response. l o 5 C l i n i c a l s t u d i e s w i t h v a s o p r e s s i n i n head-injured106 and Alzheimer p a t i e n t s 1 0 7 have f a i l e d t o demonstrate d i f f e r e n c e s i n performance on l e a r n i n g and memory t a s k s between drug and placebo-control groups. A r e p o r t that oxytocin produces amnestic e f f e c t s i n normal human s u b j e c t s h a s been r e p l i c a t e d i n a r e c e n t study.108 A number of c l i n i c a l i n v e s t i g a t i o n s have been conducted w i t h t h e v a s o p r e s s i n analog, 1-desamino-8-D-arginine v a s o p r e s s i n (d esmopres s i n , DDAVP, 51, and have y i e l d e d c o n f l i c t i n g results. P o s i t i v e e f f e c t s on learnin- and memory were observed i n c o g n i t i v e l y unimpaired subj e c t s , l E g * l l o depressed i n d i v i d u a l s , l l O and p a t i e n t s w i t h d i a b e t e s i n s i p i d u s . l l l A 25 pg i n t r a n a s a l dose of DDAVP, however, f a i l e d t o r e v e r s e t h e amnesia i n p a t i e n t s r e c e i v i n g elec troconvulsive shock therapy.l12 T h i s may be d u e t o t h e s i n g l e , r e l a t i v e l y low dose t h a t was used. Other s t u d i e s of DDAVP i n i n d i v i d u a l s w i t h memory d i s o r d e r s f a i l e d t o show any s i g n i f i c a n t i m p r ~ v e r n e n t . l l ~ One , ~ ~ p~ a t i e n t developed a paranoid-like s c h o s i s a f t e r r e c e i v i n g 30 pg of DDAVP by i n t r a The v a s o p r e s s i n analog, desglycinarnide n a s a l administration. a r g i n i n e v a s o p r e s s i n (DGAVP, 5 ) improved l e a r n i n g i n rats on a foodmotivated task.116 However, DGAVP f a i l e d t o produce any b e n e f i c i a l e f f e c t s on memory i n p a t i e n t s s u f f e r i n g from Korsakoff's Syndrome.l17
I
H-Cis-Tyr-Phe-Gln-Asn-Cys-X X = Pro-Arg-Gly-NH2
Pro-Lys-Gly-NH2 Pro-Arg-OH
3 4
(Am) (LVP) 6 (DGAVP)
1 I Mpr-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH2
-5
(DDAVP) (Mpr = Mercapto p r o p i o n i c a c i d )
Chap. 4
Cognitive Disorders
Hershenson, M a r r i o t t
22
Vasopressin may s e r v e a s t h e p r e c u r s o r of s m a l l e r molecules with e f f e c t s on l e a r n i n g and memory. The c y c l i z e d d e r i v a t i v e of t h e C-termi n a l d i p e p t i d e of a r g i n i n e v a s o p r e s s i n ( c clo-(Arg-Gly)) was found t o block puromycin-induced amnesia i n mice. lf8 The C- terminal t r i p e p t i d e of oxy t o c i n (L-prolyl-L-leucyl-glycineamide o r PLG) has been r e p o r t e d t o c a u s e a n enhancement of memory i n c h i c k s . l l g I t has been suggested t h a t while v a s o p r e s s i n i s involved i n memory p r o c e s s e s , t h e neuropeptides ACTHIMSH a f f e c t m o t i v a t i o n a l and a t t e n t i o n a l processes.120 However, s t u d i e s comparing t h e e f f e c t s of a number of neuropep t i d e s on s h o r t - term memory i n young a d u l t primates i n d i c a t e d t h a t a-MSH produced some f a c i l i t a t i o n of memory.lZ1 Use of aged primates t o a s s e s s t h e e f f e c t s of neuropeptides on memory suggested t h a t a r g i n i n e and l y s i n e v a s o p r e s s i n produced t h e b e s t o v e r a l l e f f e c t s followed by ACTH4-10. l Z 2 Somatostatin was v i r t u a l l y i n a c t i v e and oxytocin caused a n impairment i n memory i n h a l f t h e aged animals tested. ACTH4-10 h a s a l s o been r e p o r t e d t o be involved i n r e t r i e v a l processes of memory. In r a t s t r e a t e d w i t h a n t i v a s o p r e s s i n serum, which d i s r u p t s s t o r a g e l r e t r i e v a l p r o c e s s e s , ACTH4-10 r e s t o r e d t h e r e t r i e v a l of memory, p o s s i b l y by i n c r e a s i n g t h e s t a t e of arousal.123
The ACTHq-g analog (ORG 2766) h a s been compared to methylpheni d a t e i n h y p e r k i n e t i c c h i l d r e n w i t h a t t e n t i o n a l d e f i c i t d i s o r d e r . 1*4 Although a n e c d o t a l r e p o r t s i n d i c a t e d a n improvement i n t h e s o c i a b i l i t y of t h e s e c h i l d r e n , t h e r e d i d n o t appear t o be a n improvement i n a t t e n t i o n . ACTHq-g h a s a l s o been administered t o p a t i e n t s w i t h severe senile dementia. No improvement was observed a f t e r f o u r weeks of drug t h e r apy.125 There appears t o be some r e l a t i o n s h i p between t h e b e h a v i o r a l e f f e c t s of both ACTH126 and t h e ACTHq-g analog127 and t h e o p i o i d s ys tem. The r o l e of enkephalins and endorphins i n l e a r n i n g and memory pres e n t s a somewhat confusing p i c t u r e . It has r e c e n t l y bee? suggested t h a t t h e a p p a r e n t c o n f l i c t s i n the l i t e r a t u r e may be due t o t h e d i f f e r e n t doses of o p i a t e s used i n p a r t i c u l a r s t u d i e s ; high doses appear t o f a c i l i t a t e l e a r n i n g w h i l e l o w doses cause a d e ~ r e m e n t . ~The ~ ~e,f f~e c~t s~ o f t h e endorphins on animal l e a r n i n g have been r e c e n t l y reviewed, and t h e p r o p o s a l made that d i s t u r b a n c e s i n the endor h i n system may l e a d t o a t t e n t i o n a l d e f i c i t d i s o r d e r s i n c h i l d r e n . 138 Actions of o p i a t e a n t a g o n i s t s , such as naloxone, on l e a r n i n g and memory have been s t u d i e d i n both l a b o r a t o r y animals and humans. Again, c o n f l i c t i n g results have been reported. Naloxone and diprenorphine have been r e p o r t e d t o enhance t h e s p a t i a l memory of rats t r a i n e d on a n 8-arm r a d i a l maze.131 Another i n v e s t i g a t i o n , however, found t h a t naloxone had a d i s r u p t i v e e f f e c t on a l e a r n e d behavior i n r a t ~ . 1 Cognitive ~ ~ impairments were e v i d e n t a f t e r i n f u s i o n s of 2 mg/kg naloxone i n normal i n d i v i d u a l s ; 33 no changes i n c o g n i t i v e performance were observed a t lower doses. R e s u l t s from a double-blind, placebo-controlled study of naloxone i n seven p a t i e n t s w i t h Alzheimer's Disease i n d i c a t e d a t l e a s t temporary p o s i t i v e e f f e c t s on cognition,134 however o p e n - t r i a l s conducted a t f o u r separate c e n t e r s d i d n o t show any e f f e c t 1 3 . l ~ ~ nootropic (noos = thought o r reason; t r e p o = t u r n drug which s e l e c t i v e l y a f f e c t s higher c e r e b r a l chemistry and pharmacology of n o o t r o p i c s have been r e c e n t l y reviewed.139 Most examples of t h i s c l a s s a r e comprised o f gamma lactams which a r e chemically related t o t h e folded conforma t i o n
36 -
Sect. I
- CNS Agents
Hesp, Ed.
of GABA. These include piracetam etiracetam (8), pramiracetam (CI-879, 9 ) , oxiracetam (ISF-2522, and aniracetam (Ro 13-5057, 11). ~ ~ ,neurochemicall42 1~~ e f f e c t s of praThe n e u r o ~ h a r m a ~ o l o g i c a l ~and miracetam s u g g e s t t h a t t h e compound i s a c o g n i t i o n a c t i v a t o r . A c l i n i c a l study involving computerized q u a n t i t a t i v e EEG a n a l y s i s i n d i c a t e d t h a t t h i s drug a c t s a s a v i g i l a n c e enhancer, 143 Preliminary f i n d i n g s from a n open-label study of pramiracetam i n Alzheimer p a t i e n t s w i t h mild t o moderate co n i t i v e d e c l i n e i n d i c a tea a n improvement i n goal-direc ted behavi o r 14& Oxiracetam has a l s o been s t u d i e d i n e l d e r l y p a t i e n t s w i t h o r g a n i c b r a i n syndrome, and p o s i t i v e e f f e c t s have been n 0 t e d . 1 ~ ~Aniracetam improved impaired l e a r n i n g and memory i n rodents,146 and produced some b e n e f i c i a l e f f e c t s i n aged p a t i e n t s i n a g e r i a t r i c n u r s i n g home s e t t i n g . 147 F i n a l l y , c o g n i t i o n a c t i v a t i n g p r o p e r t i e s have been 3-Phenoxypyridine (CI-844, d e s c r i b e d f o r a series of 3 - a r y l o q p y r i d i n e s . 1 2 ) was found t o be the most a c t i v e member of t h i s series i n enhancing l e a r n i n g and/or memory i n a s i n g l e t r i a l passive avoidance t a s k i n mice r e t e s t e d one week a f t e r training.148
(l), 10)
.
R
0
I
Q
I
0
R' -CHCNHR"
-7,
a
R = R' = R" = H
8, R = R" = H; R' = E t 9, -
Q3
no N
R = R' = H; R" = CH CH N(i-Pr)* 11 12 10, R OH;2R'2= R" = H Summary and Conclusions - The l a s t few y e a r s have seen s i g n i f i c a n t p r o g r e s s made i n e f f o r t s t o understand and t r e a t c o g n i t i v e d i s o r d e r s . With t h i s progress has come a n even g r e a t e r a p p r e c i a t i o n of t h e complexity and r i c h n e s s of t h e p h y s i o l o g i c a l e v e n t s underlying c o g n i t i v e f u n c t i o n and t h e d i f f i c u l t i e s f a c i n g t h e physician and s c i e n t i s t i n f i n d i n g e f f e c t i v e treatments f o r c o g n i t i v e d i s o r d e r s . 3
REFERENCES
1. 2.
3. 4. 5.
6. 7. 8. 9. 10. 11.
12.
D. A. Drachman in: "Aging of the Brain,'' D. Samuel, S. Algeri, S. G e r shon, V. E. G r i m m and G. Toffano, Eds., Raven Press, New York, N.Y., 1983, p. 19. D. M. Bowen, S. J. Allen, J. S. Benton, M . J. Goodhardt, E. A. Haan, A . M. Palmer, N. R. Sims, C. C. T. Smith, J. A. Spillane, M. M. Esiri, D . Neary, J. S. Snowdon, G. K. Wilcock and A. N. Davison, J. Neurochem., 41, 266 (1983). F. Tagliavini and G. P i l l e r i , Lancet, X, 469 (1983). N. R . Sims, D. M. Bowen, S. J. Allen, C. C. T. Smith, D. Neary, D. J. Thomas and A. N. Davison, J. Neurochem., 40, 503 (1983). J. H. Growdon, Med. Res. Rev., 3, 237 ( 1 9 m . K. L. Davis, J. Y. K. Hsieh, M. I. Levy, T. B . Horvath, B. M . Davis and R . C . Mohs, Psychopharmacol. B u l l . , Ifl, 193 (1982). B. Chipperfield, P. M. Newman and I. C. A. Moyes, Lancet, IX, 199 (1981). J. T. Coyle, D. L. Price and M. R. DeLong, Science, 219, 1184 (1983). P. J. Whitehouse, Science, 215, 1237 (1982). P. J. Whitehouse, D. L. Price, A. W. Clark, J. T. Coyle and M. R. DeLong, Ann. Neurol., lo, 122 (1981). D. L. Price, P. J. Whitehouse, R. G. Struble, A. W. Clark, J. T . Coyle, M. R. DeLong and J. C. Hedreen, Neurosci. Comment., 1,84 (1982). R. G. Struble, Science, 216, 413 (1982).
Chap. 4 13. 14. 15. 16.
17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29 30. 31.
32. 33. 34. 35. 36.
37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52.
Cognitive Disorders
H e r s h e n s o n , Marriott
G . K . Wilcock, M . M . Esiri, D. M . Bowen and C . C . T. Smith, J. Neurol. S c i . , 57, 407 (1982). E . K. P e r r y , B . E . Tomlinson, G . Blessed, R . H. P e r r y , A. Cross and T . T . Crow, Lancet, 11, 149 (1981). R . M . Marchbanks, J . Neurochem., 2, 9 (1982). M. N . Rossor, P. C . Emson, C. Q. Mountjoy, M . Roth and L. L. I v e r s e n , Exp. Brain Res., s u p p l . 5, 153 (1982). H. P. A l p e r n and J. G. M a r r i o t t , Physiol. Behav., 571 (1973). R . T. B a r t u s , R . L . Dean, B. Beer and A . S . Lippa, Science, 217, 408 (1982). J. A. Deutsch, Science, 3, 788 (1971). T . Cox and N . Tye, Neuropharmacol., 477 (1973). 0. Buresova, J. Bures, A . Bohdanechy and T . Weiss, Psychopharmacol., 2, 255 (1964). S. D. Brinkman and S . Gershon, Neurobiol. Aging, 4, 139 (1983). B. S. Greenwald, R. C . Mohs, and K. L. Davis, J. &I. G e r i a t r . SOC., 2, 310 (1983). B . S. Greenwald and K. L . Davis, Adv. Neurol, 2, 87 (1983). C. A. Johns, B. S . Greenwald, R. C. Mohs and K. L. Davis, Psycho185 (1983). pharmacol. B u l l . , P. S. Anderson and D. Haubrich, Ann. Rep. Med. Chem., 51 (1981). G. S. Rosenberg and K. L. Davis, Am. J. Clin. N u t r . , 2 , 709 (1982). P. E t i e n e e , D. Dastoor, S . G a u t h i e r , R. Ludwick and B . C o l l i e r , Neurology, 2, 1552 (1981). L. J. Thal, W. Rosen, S . S h a r p l e s s and H. C r y s t a l , Neurobiol. Aging, 2, 205 (1981). S. D. Brinkman, N. Pomara, P. J. Goodnick, N. B a r n e t t and E. F. Domino, J . Clin. Psychopharmacol., 2, 281 (1982). S. Weintraub, M . M . Mesulamy R . Auty, R . B a r a t z , B . N . Cholakos, L. Kapu s t , B. R a n s i l , J. G. T e l l e r s , M . S. A l b e r t , S. LoCastro and M. Moss, Arch. Neurol. , 40, 527 (1983). N . Pomara, E. F. Domino, H . Yoon, S . Brinkman, C . A . Tamminga and S . Gershon, J . Clin. P s y c h i a t r y , 293 (1983). M . Fisman, H . Mersky and E. Helmes, Am. J. P s y c h i a t r y , 970 (1981). R. Levy, A . L i t t l e , P. Chuaqui and M . R e i t h , Lancet, I , 987 (1983). R . T . B a r t u s , R . L. Dean, K . A . Sherman, E. F r i e d m n and B. Beer, Neurob i o l . Aging, 2, 105 (1981). B. Reisberg, S. H. Ferris, M. K. Schneck, J . C o w i n , P. Mir, E. F r i e d man, K. A. Sherman, M . McCarthy and R. T . Bartus, Drug Development Res., 2. 475 (1982). _. R. J. Wurtman, N. Eng. J. Med. , 555 (1983). J. F . Flood, G. E. Smith and A. Cherkin, Neurobiol. Aging, 5 , 37 (1983). W. H. Kaye, N . Sitaram, H. Weingarhler, M . H. Ebert, S . Smallberg and J. C . G i l l i n , Biol. P s y c h i a t r y , 275 (1982). L. J. "ha1 and P. A . Fuld, N. Engl. J . Med., 308, 720 (1983). L. J. Thal, P. A. Fuld, D. M . Masur and N. S . S h a r p l e s s , Ann. Neurol., 13, 491 (1983). D. A . Drachman, G. G l o s s e r , P. Fleming and G. Longenecker, Neurology, 2, 944 (1982). A. Wettstein, Ann. Neurol., 2, 210 (1983). E. Goldberg, L. J. Gerstman, S. Mattis, J. E. Hughes, C. A. S i r i o and R . M . B i l d e r , J r . , J . Clin. Neuropsychol., 5 , 219 (1982). E. Goldberg, L. J. Gerstman, S . Mattis, J. E. Hughes, C . A . Sirio and R . M. B i l d e r , J r . , Arch. Neurol., 2, 581 (1982). K. L. Davis, R. C . Mohs, W . G . Rosen, B. S . Greenwald, M. I. Levy and T . B . Horvath, N. Engl. J. Med., 721 (1983). A . Agnoli, N. Martucci, V. Manna, L. Conti and M. F i o r a v a n t i , C l i n . Neuropharm., 311 (1983). M. Franceschi, 0. Trancredi, G. Savio and S . S m i r e , E u r . Neurol., 2, 399 (1982). C . C a l t a g i r o n e , G. G a i n o t t i and C . Masullo, I n t . J . Neurosci., 2, 247 (1982). B. Katz and R . Meledi, Proc. R . SOC. (Lond.), 2,369 (1979). C. Peterson and G. E . Gibson, J. Pharmacol. Exp. Therap. 222, 576 (1982). H. P. Davis, A . Idowu and G. E. Gibson, Exper. Aging R e s . , 9, 211 (1983).
11,
11,
19,
a,
44,
138,
309,
17,
308,
a,
37
38 53. 54. 55.
Sect. I
- CNS Agents
Hesp, Ed.
G. LoConte, L. B a r t o l i n i , F. Casamenti, I . Marconcini-Pepeu
and G. Pepeu, Pharm. Biochem. Behav., 933 (1982). C. F l i c k e r , R. L. Dean, D. L. Watkins, S. K. F i s h e r and R . T . B a r t u s , Pharm. Biochem. Behav., 973 (1983). E. Friedman, B . Lerer and J. K u s t e r , Pharmacol. Biochem. Behav., 309
17,
Is,
19,
(1983). 56. A. F i s h e r , C . R . Mantione, D. J. Abraham and I. Hanin, J. Pharmacol. Exp. T h e r . , 222, 140 (1982). 57. C. R . Mantione, M. J. Zigmono, A . F i s h e r and I . Hanin, J. Neurochem., g, 251 (1983). 58. I. Hanin, W. C . DeGroat, C. R . Mantione, J . T . Coyle and A. F i s h e r in: "Conference on B i o l o g i c a l Aspects of Alzheimers Disease," R. Katzman Ed., Cold S p r i n g Harbor L a b o r a t o r y , Cold S p r i n g Harbor, N.Y., 1983, p . 243. 59. A. Levy, P..G. Kluge and T. F. Elsmore, Behav. Neural. B i o l . , 2, 229 (1983). 60. R . J. S u t h e r l a n d , I. Q . Whishaw and J. C. Regehr, J. Comp. P h y s i o l . P s y c h o l . , 96, 563 (1982). 297, 61. R. G. M. Morris, P. Garrud, J. N. P. Rawlins and J. O'Keefe, Nature, 681 (1982). 62. R. T. Rick, K. L. W h i t t l e and S . H . Cross, Neuropharmacol., 2, 747 (1981). 351 (1982). 63. D. Blozovski and N . Hannocq, Psychopharmacology, 5, 64. J. F. Flood, D. W. Landry and M . E. J a r v i k , B r a i n Res., 215, 117 (1981). 65. A. Tobe, M. Egawa and R . Nagai, Jpn. J. Pharmacol., 2, 775 (1983). 66. P. Kubanis, S. F . Z o r n e t z e r and G . Freund, Pharmacol. Biochem. Behav., 17, 313 (1982). 1065 (1982). 67. P. D. Leathwood, E. Heck and J. Mauron, L i f e S c i . , 2, 68. D. K. Ingram, E. 0. London and C. L. Goodrick, Neurobiol. Aging, 2, 41 (1981). 69. J. G. M a r r i o t t . a n d J. S . Abelson, Age, 2, 7 (1980). 70. R. T. B a r t u s , R . L. Dean and B. Beer, Neurobiol. Aging, 1,145 (1980). 71. R. T. B a r t u s , R . L. Dean and B. Beer, Psychopharmacol. B u l l . , 19,168 (1983). 72. P. Kubanis and S . F. Z o r n e t z e r , Behav. Neural. B i o l . , 31, 115 (1981). 73. P. E. Gold and S. F. Z o r n e t z e r , Behav. Neural. B i o l . , 2, 151 (1983). 74. B. R e i s b e r g , E . London, S . H. F e r r i s , R . Anand and M. J. de Leon, Psychopharmacol. B u l l . , 19 220 (1983). 75. D. M . A. Mann, P. 0. Yates and J. Hawkes, J . Neurol. Neurosurg. P s y c h i a t r y , 65, 113 (1982). 76. C. M . B a r a t t i , I. B. I n t r o i n i , P. Huygens and F. Gusovsky, Psychopharmacology, 161 (1983). 77. B. E. Golinko, P. M . Rennick and R. F. Lewis, Prog. Neuropsychopharmacol., 2, 65 (1981). 78. P. T. Ackerman, R . A . Dykman, P. J. Holcomb and D. S. McCray, P s y c h i a t r y Res., 1, 199 (1982). 79. P. Cook and I . James, N. Engl. J. Med., 305, 1560 (1981). 80. R . S p i e g e l , F. Huber and S. Koeberle, J. Am. G e r i a t . SOC., 2, 549 (1983). 81. L. R. H a r t l e y , S. Ungapen, I . Davie and D. J. Spencer, B r . J. P s y c h i a t r y , 142, 512 (1983). 82 S. Solomon, E. Hotchkiss, S . M . Saravay, C. Bayer, P. Ramsey and R . S . Blum, Arch. Gen. P s y c h i a t r y , do, 1109 (1983). 83. D. B. S t e r n b e r g , P. E. Gold and J. L. McGaugh, Behav. Neural. B i o l . , 2, 261 (1983). 84. R. B . Messing, H. R i g t e r and V. J. Nickolson, Neurobiol. Aging, 3, 133 (1982). 85. D. Yonkov, W . Wetzel, H. M a t t h i e s and K. Roussinov, Psychopharmacology, 73, 399 (1981). 86. D. Ionkov, K. Rusinov and Iu Vuglenova, Acta. P h y s i o l . P h a r m c o l . Bul. 8, 57 (1982). 87. C. S a l i g a u t , N. Moore, P. C h r e t i e n , M. Daousf, 0. Richard and F. Boismare, S t r o k e , 2, 859 (1982). 88. R. J o r k , G . Grecksch and H. M a t t i e s , Pharmacol. Biochem. Behav., 17, 11 (1982)
-
so,
-
-
)
.
Chap. 4 89. 90. 91. 92. 93. 94. 95. 96.
97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111.
Hershenson, Marriott
Cognitive Disorders
P. L. Wood, P. Etienne, S. Lal, S . Gauthier, S . Cajal and N. P . V. Nair, L i f e S c i . , 2, 2073 (1982). P. Davies and R . D. T e r r y , Neurobiol. Aging, 2, 9 (1981). H. A . C r y s t a l and P. Davies, J. Neurochem., 1 7 8 1 (1982). J. A . Biggins, E . K. P e r r y , J. R . McDermott, A . I . Smith, R . H. Perry and J. A . Edwardson, J . Neurol. S c i . , = , 117 (1983). R . H . P e r r y , G . J . Dockray, R . Dimaline, E. K. P e r r y , G. Blessed and B . E . Tomlinson, J . Neurol. S c i . , 465 (1981). D. J. Sanders, S . Zahedi-As1 and A . P. Marr, Prog. Brain Res., 55, 465 (1982). H . Kaiya, T . Tanaka, K. Takeuchi, K. Morita, S . Adachi, H. Shirakawa, H . Ueki and M . Namba, L i f e S c i . , 33, 1039 (1983). E. K. P e r r y , G . Blessed, B . E . Tomlinson, R . H. P e r r y , T . J. C r o w , A . J. Cross, G . J . Dockray, R . Dimaline and A. Arrequi, Neurobiol. Aging, 2, 2 5 1 ( 1 9 8 1 ) . A. Arrequi, E. K. P e r r y , M. Rossor and B. E. Tomlinson, J . Neurochem., 38, 1490 (1982). R. E. J. Dyball and A. T. Paterson, P h a m c . Ther., 20, 419 (1983). D. M . Gash and G. J. Thorns, Trends Neurosci., 197 (1983). T . B . van Wimersma Greidanus, J. M. van Ree and D. de Wied, Pharmac. T h e r . , 20, 437 (1983). G. L. Kovacs and G. Telegdy, Pharmac. T h e r . , 375 (1982). G. Meisenberg and W. H . Simmons, Neurosci. Biobehav. Rev., 7, 263 (1983). J. L. Davis, R. M . Pic0 and A. Cherkin, Behav. Neur. B i o l . , 242 (1982). M . E. Judge and D. Quartermain, Pharmacol. Biochem. Behav., 463 (1982). '' A . E t t e n b e r g , D. van der'Kooy, M. Le Moal, G. F . Koob and F . E. Bloom, Behav. Brain Res., 3 3 1 (1983). W. D. Fewtrell, A . 0. House, P. F. Jamie, M. R. Oates and J. E. Cooper, Psychol. Med., 2, 423 (1982). R. Durso, P. Fedio, P. Brouwers, C. Cox, A. J. Martin, S. A . Ruggieri, C . A. Tamminga and T. N. Chase, Neurology, 32, 6 7 4 (1982). D. J. Kennett, M . C. Devlin and B. M. F e r r i e r , L i f e S c i . , z , 273 (1982). B. E. Beckwith, T . P e t r o s , S. Kanaan-Beckwith, D. I. a u k , R. J. b u g , and C . Ryan, P e p t i d e s , 2, 627 (1982). H. Weingartner, P. Gold, J. C. Ballenger, S. A . Smallberg, R. Summers, D. R. Rubinow, R . M . P o s t and F. K. Goodwin, Science, 211, 6 0 1 (1981). F. L a c z i , J. M . van Ree, A. Wagner, 2s. Valkusz, T . Jardanhazy, G. L. Kovacs, G. Telegdy, J. S z i l a r d , F. A. Laszlo and D. d e Wied, Acta. Endo205 (1983). crinol., B. L e r e r , T. Zabow, N . Egnal and R. H . Belmaker, Biol. P s y c h i a t . , Is, 8 2 1 (1983). J . S . J e n k i n s , H . M . Mather and A . K. Coughlan, J . Neurol. Neurosurg. P s y c h . , '5, 8 3 0 (1982). J . R . Tinklenberg, A . Pfefferbaum and P. A. Berger, Psychopharmacol. Bull., 206 (1981). G . B . C o l l i n s , D. J. Marzewski and M . B . R o l l i n s , Lancet, 11, (8250) 808 (1981). R. B . Messing and S . B . Sparber, E u r . J. Pharmacol., E, 43 (1983). F. L a c z i , J. M . van Ree, L. Balogh, A . Szasz, T . Jardanhazy, A . Wagner, L . Gaspar, Z . Valkusz, I . Dobranovics, J . S z i l a r d , F. A , Laszlo and D . de Wied, Acta. Endocrinol., 177 (1983). R . Walter, P. L. Hoffman, A . C . Church, J. B . Flexner and L. B . Flexner, Horm. Behav., 3, 234 (1982). J . L. Davis, R . M . Pic0 and A. Cherkin, Pharmacol. Biochem. Behav., 893 (1982). D. de Wied and J. M . van Ree, L i f e S c i . , s , G O 9 (1982). G. A . Olson, R . Roip-Smith, M. D. Mauk, G . J . La Hoste, D. H . Coy, C . W . Hill and R . D. Olson, P e p t i d e s , 2, 1 3 1 (1981). R. T. Bartus, R : L. Dean and B . Beer, Neurobiol. Aging, 6 1 (1982). T . B . van Wimersma Greidanus, P e p t i d e s , 2, 7 (1982). H . J . B u t t e r , Y. L a p i e r r e , P . F i r e s t o n e and A. Blank, J . Clin. Psychopharmacol., 3, 226 (1983).
s,
11,
a,
18,
35,
9,
L,
102,
112. 113. 114. 115. 116. 117.
17,
104,
118. 119. 120. 121. 122. 123. 124.
17,
2,
2
40
Sect. I
- CNS Agents
Hesp, Ed.
J. C. Martin, B. R . B a l l i n g e r , L. L. Cockram, F. M. McPherson, R. M. Pigache and D. Tregaskis, Acta. P s y c h i a t r . Scand., 7 ,205 (1983). 126. I . Izquierdo and R . D. Dias, Psychoneuroendocrinol., 8, 81 (1983). 127. M . Fekete, F. Drago, J. M . van Ree, B. Bohus, V. M . Wiegant and D. d e Wied, L i f e S c i . , 32, 2193 (1983). 128. J. D. B e l l u z z i and L. S t e i n , Ann. N.Y. Acad. S c i . , 398, 221 (1982). 129. C. C a s t e l l a n o , Behav. Neur. B i o l . , 36, 189 (1982). 130. S. R . Rose and J. Orlowski, J. Dev. Behav. P e d i a t r . , 6 , 131 (1983). 131. M. Gallagher, R . A . King and N. B. Young, Science, 221, 975 (1983). 132. W. C. Lynch and S . Clark, L i f e S c i . , 32, 2801 ( 1 9 8 3 r 133. M . R. Cohen, R. M . Cohen, D. P i c k a r , H . Weingartner and D. L. Murphy, Arch. Gen. P s y c h i a t . , 0, 613 (1983). 134. B. Reisberg, S. H. F e r r i s , R. Anand, P. Mir, V. Geibel and M . J. De Leon, N. Engl. J. Med., 308, 721 (1983). 135. J. P. Blass, M. J. Reding, D. Drachman, A. M i t c h e l l , G. Glosaer, R. Katzman, L. J. Thal, S . G r e n e l l , J. E. Spar, A . Larue and E. L i s t o n , N. Eng. J. Med., 309, 556 (1983). 136. T. M. I t i l , Biol. P s y c h i a t r . , 521 (1983). 137. S. Kancwski, Drug Dev. Res., 2, 433 (1982). 138. C. E. Giurgea, Drug Dev. Res., 2, 441 (1982). 139. B. J. R . Nicolaus, Drug Dev. Res., 2, 463 (1982). 140. T. A . Pugsley, B. P. H. Poschel, D. A. Downs, Y. H. S h i h and M. I. Gluckman, Psychopharmacol. B u l l . , 2, 721 (1983). 141. B. P. H. Poschel, J. G . M a r r i o t t , and M. I. Gluckman, Psychopharmacol. Bull., 720 (1983). 142. T. A . Pugsley, Y. H . Shih, L. Coughenour and S . F. S t e w a r t , Drug Dev. Res., 2, 407 (1983). 143. T. M. I t i l , S. Mukherjee, G. Dayican, D. M. Shapiro, A. M. Freedman and L. A. Borgen, Psychopharmacol. B u l l . , 19, 708 (1983). 144. R. J. Branconnier, J. 0. Cole, E. C. Dessain, K. F. Spera, S. Ghazvinian and D. D e V i t t , Psychopharmacol. B u l l . , 726 (1983). 145. T. M. I t i l , G. N. Menon, M. Bozak and A. Songar, Drug. Dev. Res., 2, 447
125.
la,
19,
19,
(1982). 146. R. Cumin, E. F. Bandle, E. Gamzu and W. E. Haefely, Psychopharmacol., 78, 104 (1982). 147. P. Foltyn, P. W. Lucker and J. S c h n i t k e r , Arzneim-Forsch., 2, 865 (1983). 148. D. E. B u t l e r , B. P. H. Poschel and J. G. M a r r i o t t , J . Med. Chem., 2, 346 (1981).
-
Chapter 5 . Adaptive Changes in Central Nervous System Receptor Systems B. Kenneth Koe and Fredric J. Vinick Pfizer Central Research, Groton, CT 06340
Introduction -The phenomenon that repeated (subacute, chronic) administration of drugs can induce pharmacological effects that become progressively a t t e n u a t e d or accentuated compared t o the original effects of a single (acute) dose is well known. In the past decade, the molecular events involved in the rapid loss o f the ability o f the norepinephrine (NE) receptorcoupled adenylate cyclase system of intact cells to generate cyclic AMP (CAMP) f o l l o w i n g stimulation o f P-adrenoceptors by P-agonists have been w e l l studied.l.2 In such cells, isoproterenol stimulates the formation of CAMP, but continual exposure t o this agonist induces a refractoriness, characterized by a rapid desensitization of agonist-stimulated adenylate cyclase and a slower loss o f P-adrenoceptors. The reduction in sensitivity is measured as a change in maximal.response of the adenylate cyclase, while t h e loss in padrenoceptors (down-regulation) is ascertained as a decrease in receptor density (determined by Scatchard analysis of saturation binding o f antagonists). The K0.5 values for adenylate cyclase activity and the KD values (affinity-1) for antagonist binding are unchanged i n desensitization and down-regulation, respectively. Prior t o the irreversible disappearance of 0-adrenoceptors, an uncoupling process occurs; although the number of receptors remains essentially the same, the sensitivity of these receptors t o isoproterenol is less than t h a t o f untreated cells. A rapid and reversible desensitization and down-regulation of the p-receptors of rat cerebral cortex is observed on incubation of tissue slices with isoproterenol3 or desipramine (DMI), an NE uptake blocker.4 Similar adaptive changes in the receptors o f the NE system also occur in wiwo in the brain when NE levels are altered. Prolonged NE depletion can be effected by drugs (reserpine) or selective lesions (6-hydroxydopamine [6-HDA] or electrolytic), whereas prolonged elevation can be achieved by preventing metabolism ( M A 0 inhibitors) or increasing synaptic concentrations through inhibition o f reuptake.fi.6 This chapter examines the recent literature on adaptive changes in central NE, serotonin (5-HT) and dopamine (DA) receptor systems and concentrates on drug-induced effects which could relate to therapeutic modes o f action in human diseases. Reviews o f related topics have appeared .7-10
-
Norepinephrine Receptors Depression is a CNS disease believed to be associated with a perturbation of central NE transmission. The first effective drugs in depression were M A 0 inhibitors and tricyclic uptake blockers which increase the concentration o f neuronal or synaptic NE, respectively. With the recognition that the onset of action of antidepressants was several weeks, attention turned t o studying the effects o f subacute and chronic administration of antidepressant drugs. In rats, multiple treatments w i t h antidepressant drugs1 1-14 and electroconvulsive shock (ECS)11.15-17 desensitized the NE receptor-coupled adenylate cyclase system in limbic forebrain slices and decreased the number of ji-adrenoceptors measured by antagonist binding. In contrast t o the subsensitivity observed after these chronic treatments, acute administration showed n o effects. In general, antidepressants,6.l1.12.18-34 M A 0 inhibitors,5.9,21,23.37.38 lithium3536 and REM sleep deprivation39 have all been shown t o induce desensitization andlor down-regulation of NE receptors. Administration of multiple daily doses of drug produces down-regulation faster than single daily dosing and allows a lower dose per injection.6.29 In a time course study in rats, D M I (10 mglkg b.i.d.) elicited maximal desensitization of CAMP accumulation by isoproterenol in cortical slices in 5 t o 7 days and down-regulation o f P-adrenoceptors in cortical membranes after 7 days. After D M I withdrawal, the subsensitive NE receptors returned to normal within a week.6 After multiple ECS treatments, 0-adrenoceptors remain down-regulated for at least a
ANNUAL REPORTS IN MEDICINAL CHEMISTRY-19
Copyright 0 1984 by Academic Press, Ino. All rights of reproduction in any form reserved. ISBN 0-12-040519-9
42
Sect. I
- CNS Agents
Hesp, Ed.
week.15 These studies indicate that faster onset of therapeutic effects might be achieved by rapidly increasing the dose of antidepressants. Since side effects may preclude such a strategy, other ways t o facilitate the desensitization/down-regulationhave been investigated. The coadministration o f a2-adrenergic antagonists (yohimbine, d i h y d r o e r g o t a m i n e or phenoxybenzamine) w i t h D M I and other antidepressants increased t h e rate o f downregulation.a-42 In contrast, the al-antagonist, prazosin, was ineffective in accelerating downregulation.42 Rapid desensitizationldown-regulation of Padrenoceptors by co-administration of iprindole and amphetamine occurred at doses of each which were ineffective alone.43.44 On the other hand, co-administration o f chlorpromazine with imipramine failed t o enhance the down-regulation of 6-receptors observed w i t h imipramine alone, even though this combination is reportedly more effective in treating delusional depression.45 Unlike most studies, some recent reports claim down-regulation of 6-adrenoceptors following a single ECS treatment or single doses of DMI on days 1 and 17.46 One explanation for the facilitation of down-regulation o f 6-adrenoceptors by a2adrenergic antagonists i s as follows: the expected synaptic build-up of NE after DMI is attenuated by concurrent stimulation of a2-autoreceptors, which inhibits NE release. Only when these a2-autoreceptors become down-regulated will synaptic levels of NE increase, thus accounting in part for the slow onset of therapeutic defects.47 The notion that repeated administration of antidepressants or ECS can induce subsensitivity of a2-autoreceptors is based on the tolerance t o various actions of low doses of clonidine in mice or rats induced by such regimens.48.49 Chronic administration of clorgyline desensitized a2-autoreceptors and downregulated &adrenoceptors before a decrease in the CAMPresponse t o NE could be observed.38 The a2-adrenoceptor adaptation elicited by clorgyline reverted t o normal very gradually.50 One potential disadvantage of using a2-antagonists i s that autoreceptors may quickly become supersensitive. Reduced antagonism of responses t o clonidine after long-term administration of mianserin, an a2-antagonist, may be the result of the development o f supersensitive autoreceptors.s1,52 Some authors propose that depression may be caused in part by supersensitivity of a2-adrenoceptors and report evidence t h a t chronic antidepressant treatments elicit down-regulation of these receptors.53.54 In other studies, however, an upregulation of a2-adrenoceptors has been observed.55.56 In contrast, al-adrenoceptor binding is not affected by chronic administration of antidepressants.21 The subsensitive P-adrenergic system resulting from chronic administration o f antidepressants implies that postsynaptic responsiveness t o NE is diminished, e.g., long-term administration of DMI, clomipramine, maprotiline or tranylcypromine reduced the sensitivity of cingulate cortical neurons t o iontophoretically applied NE.57 Similarly, chronic DMI markedly decreased the responsiveness of Purkinje cells in cerebellum t o applied NE.58 In contrast, other studies have shown that chronic antidepressant treatments enhanced postsynaptic NE and 5-HT responses in the facial motor neurons.59 Possibly related t o the enhanced NE responses is the finding that chronic antidepressant treatment can apparently facilitate the interaction o f the guanine nucleotide binding protein w i t h the catalytic protein.60 The subgroup of antidepressants comprising the selective 5-HT uptake blockers, zimelidine,24.31 fluvoxamine33 and sertraline34 also down-regulate j3-adrenoreceptors. Such agents may induce this subsensitivity by the removal of an inhibitory 5-HT constraint on NE neurons through inhibition of firing of raphe 5-HT neurons34 or enhancement o f 5-HT reuptake.6’ The notable exception is fluoxetine.21.25,26,30 In rats deprived of a 5-HT input, via lesions with 5,7-dihydroxytryptamine (5.7-DHT) or by p-chlorophenylalanine (PCPA), chronic administration of DMI failed t o down-regulate 6adrenoceptors, although the usual desensitization of NE sensitive adenylate cyclase was still observed.62.63 When NE receptors were desensitized and reduced in number by the DMI treatment, PCPA reversed the decrease o f preceptors without affecting the cyclase.14 These persistent &receptors may be “uncoupled”, since their affinity for isoproterenol is reduced.64 Possibly, the step from uncoupled receptors t o actual disappearance o f NE receptors is interrupted by the loss o f 5-HT input. An interesting corollary is the observation that depressed patients benefiting from either imipramine or tranylcypromine showed
Chap. 5
A d a p t i v e Changes i n CNS Receptor Systems Koe, V i n i c k
2
reemergence of their depressive symptoms when PCPA was administered along w i t h the antidepressant.65.66 Since drugs for the treatment of depression appear t o increase NE activity, P-agonists may be therapeutically effective in this disorder. Antidepressant activity has been reported following administration o f the P-agonist, salbutamol, w i t h a suggestion of more rapid onset of acti0n.67~68 The time course of clinical improvement w i t h oral salbutamol paralleled the induction of subsensitivity of a plasma NE-sensitive adenylate cyclase.68 Subacute infusion of the P-agonist, clenbuterol, was found t o desensitize isoproterenol-stimulated adenylate cyclase and down-regulate P-adrenoceptors i n the rat cerebellum.69 In contrast, the pantagonist, propranolol, not only blocked the effects o f chronic DMI but also elicited upregulation of P-receptors and enhanced sensitivity o f isoproterenol-sensitive adenylate cyclase.6 Subacute administration of phenoxybenzamine or propranolol also increased the cAMP response t o NE in mouse limbic forebrain.70 Interestingly, major depressive episodes have been reported for several patients on propranolol therapy.71 Unlike the rat experiment described above,6 propranolol did not attenuate the therapeutic effects of an antidepressant in a human study.72 Pharmacological treatments which deplete neurons of NE,70.73 and 6-HDA74 or DSP-4 induced lesions,75 increased the cAMP response t o NE or isoproterenol, and j3-adrenoceptor density. Unilateral electrolytic lesions o f the locus ceruleus prevented the desensitizing effects of D M I or iprindole on the lesioned side only.76 The P-adrenoceptors involved in down-regulation or up-regulation in rat cortex belong mainly t o t h e p1 subtype.77 A subpopulation of receptors w i t h neither a nor P characteristics is also coupled t o the adenylate cyclase of rat limbic forebrain78 Desensitization o f the P-receptor system by repeated administration of antidepressants also occurs in the pineal gland, which i s innervated by postganglionic sympathetic fibers. The stimulation of the P-receptor/adenylate cyclase system increases the synthesis of serotonin-Nacetyl transferase, a critical enzyme for melatonin production. Thus, the subsensitivity o f pineal P-adrenoceptors found after chronic D M I or nialamide was accompanied by a fall in melatonin formation stimulated by isoproterenol or darkness.79 Chronic administration o f amitriptyline, maprotiline and clenbuterol also attenuated the increase of pineal melatonin stimulated by isoproterenol, but iprindole, mianserin, fluoxetine and repeated ECS had n o effect80 Attempts t o detect subsensitivity of the P-receptors in patients treated w i t h D M I by monitoring night-time plasma melatonin levels failed.81 The exclusive P-adrenergic regulation of melatonin synthesis seen in rats may not extend t o man.82 Stress applied t o rats (electric foot shock) induced desensitization o f NE receptorcoupled adenylate cyclase in cortical slices.83 This f i n d i n g suggests t h a t a similar desensitization could be a natural response t o prolonged emotional stress. Thus, the NE receptors i n depressed patients may be unable t o down-regulate i n response t o stress, necessitating antidepressant therapy.84 In another study, however, t h e number o f padrenoceptors in rats was not altered by chronic foot shock stress.15 Most studies on adaptive changes in the P-adrenergic system focus on cerebral cortex, frontal cortex, limbic forebrain and hippocampus. Although ECS did n o t down-regulate P-adrenoceptors i n striatum, hypothalamus or cerebellum,15 chronic drug treatments d o cause a decrease in the density of P-receptors in these brain regions.85.86.69 Adaptation of NE receptors is also observed after long-term administration of other types of drugs. For example, chronic chlorpromazine desensitized cortical NE-sensitive adenylate cyclase in rats18 but caused supersensitivity in mouse limbic forebrain.70 Chronic haloperidol did not desensitize cortical NE-stimulated adenylate cyclase73 b u t apparently induced up-regulation of a2-adrenoceptors (enhanced locomotor response t o clonidine) in mice.87 The methylxanthines (caffeine,88 pentoxyfylline89), which increase turnover of brain NE, caused rapid down-regulation of p-adrenoceptors. Serotonin Receptors - The relationships between 5-HT receptors and the actions of drugs are much less clear than those for NE or DA receptors. Numerous conflicting findings result from the inherent difficulties of relating behavioral and electrophysiological effects. Also, the aforementioned effects d o not correlate well with drug-induced changes in binding sites that
44 -
Sect. I
- CNS Agents
Hesp, Ed.
are poorly defined functionally. Serotonin receptors are termed 5-HT1 (based on 3[H]5-HT bindingso) or 5-HT2 (based on 3[H]spiperone binding in frontal cortical membranes).21.91 The latter sites are also labeled by 3[Hlketanserin92 or 3[Hlmianserin.93,94 Serotonin agonists exhibit nanomolar affinities for 5-HT1 receptors but only micromolar affinities for 5-HTz binding sites. A 5-HT sensitive adenylate cyclase has been characterized, but i t s connection with 5-HT1 or 5-HT2 receptors is not clear.91.95.96 Increases in hippocampalso and cortical21 5-HT1 receptors are found i n rats lesioned w i t h 5,7-DHT. Similar lesions increased 3[H]mianserin binding sites61 but not 3[Hlspiperone97 or 3IHlketanserin binding.98 Chronic PCPA treatment effected increases in 5-HT199 and 5-HT2 receptors (3[H]spiperone binding)loo and 3[H]mianserin binding sites.61 The binding of 3[H]imipramine t o brain membranes i s supposedly associated with 5-HT uptake sites, but there is a question whether 3[H]imipramine labels a physiologically relevant site.101 3[Hllmipramine binding sites are decreased in rats with 5,7-DHT lesions but remain unchanged in rats following chronic treatment with chronic PCPA.61 The role of serotonergic changes in depression and antidepressant therapy has been a subject of intense study. For example, brains of suicide victims exhibited an increase in cortical 5-HT2 binding sites102.103 and either an increase103 or a decrease104 in ,[H]imipramine binding. Furthermore, cortisol secretion stimulated by 5-hydroxytryptophan was found t o be greater for depressed and manic patients than normal controls, suggesting the involvement of supersensitive 5-HT receptors.105 Thus, an increased risk t o suicide and depression may be characterized by a decrease in serotonergic function.106 If up-regulation of 5-HT receptors is associated with suicide and depression, then the question arises as t o whether antidepressant therapy normalizes 5-HT receptor density. Several investigators have, reported that chronic administration of M A 0 inhibitors results in a decrease in the number of 5-HT1 receptors (KO unchanged) in rat cortex or brain stem,99.107 inhibits the "5-HT syndrome" induced by 5-HT agonistslos and attenuates the response of cortical neurons t o microiontophoretically applied 5-HT.109 However, variable results have been obtained with tricyclic antidepressants. Many studies have indicated that chronic administration of these drugs does not down-regulate 5-HT1 receptors,21-23.lo7.111.112 but there are a few e x c e p t i o n s . ~ ~ ~ ~ One ~ ~ group . ~ 1 3 reported a decrease in t h e number o f 3[H]5-HT binding sites after long-ter DMI, imipramine, amitriptyline or dimetacrine treatments.113 Another group found that chronic treatment with imipramine or DMI produced high and low affinity 5-HT1 receptors in rat dorsal cortex.112 Even 5-HT specific uptake blockers have led t o conflicting findings: chronic clomipramine had no effect on 3[H]5-HT binding,llo whereas D-fenfluramine led t o a decrease in 3[H]5-HT binding (lowered KD and Bmax).114.115 Fluoxetine was found by several groups not t o alter 5-HT1 receptors;l9,2l.lll.l16 however, others have reported either a reduction in the number of high affinity 5-HT1 receptors in frontal cortex117 or a decrease in the affinity of 5-HT1 receptors in dorsal cortex.112 Similarly, one chronic study with zimelidine failed t o show downregulation of 5-HT1 receptors in rat cortex,llE while a different group observed an induction of high and low affinity 3[H]5-HT binding sites, amounting t o a "selective down-regulation" of 5-HT1 receptors.112 Chronic lithium treatment can also alter S-HTI receptors as evidenced by the fact that receptor density decreased in the rat hippocampus; no change was observed in the cortex.119 The 5-HT autoreceptor blocker, methiothepin, facilitated the down-regulation of 5-HT1 receptors induced by imipramine or mianserin, presumably by increasing 5-HT release.120 Chronic administration, of imipramine, DMI, amitriptyline, iprindole or pargyline down-regulated 3[H]spiperone-labeled5-HT2 receptors in rat brain.21.97.121 Pretreatment with the serotonergic neurotoxin, p-chloroamphetamine (PCA), did not lessen the effectiveness of amitriptyline, which suggests that the drug itself may be interacting with postsynaptic receptors. Interestingly, the PCA treatment, while reducing 5-HT uptake drastically, had no effect on 5-HT2 receptors.97 Chronic administration of mianserin decreased the number of 5-HT2 sites (3[H]spiperone binding) in rat cortex.122 Even a single dose of this drug lowered 5-HT2 binding.100.122 Similarly, amoxapine and loxapine were able t o reduce the density of 5-HT2 receptors after both acute and chronic treatment.100 Clozapine blocked the binding of 3[H]spiperone t o frontal cortex in intact mice as effectively as amitriptyline;123 long-term administration of clozapine decreased the number of 5-HT2 sites labeled by 3[H]ketanserin.124 Rats with lesioned 5-HT neurons did not show alterations in 5-HT2 receptor density as
Chap. 5
A d a p t i v e Changes i n CNS Receptor Systems
Koe, V i n i c k
5
measured by 3[H]spiperone,97 3[H]LSDl25 or 3[H]ketanserin binding.98 In contrast, chronic PCPA treatment increased 5-HT2 receptor binding.100 Chronic administration of imipramine decreased 3[H]ketanserin binding and 3[H]spiperone binding21 without affecting the binding of 3[H]mianserin,98 which also labels 5-HT2 receptors.94 Repeated administration of mianserin itself did n o t down-regulate 3[Hlmianserin binding61 nor did lesions of presynaptic 5-HT neurons.93 In fact, up-regulation of these binding sites has been reported after either lesions or PCPA treatment61 Electroconvulsive shock, unlike antidepressant drugs, caused an increase in the number of 5-HT2 binding sites labeled by 3[H]spiperone in rat cortex.126.127 Receptor affinity was unchanged as was 5-HT1 binding.128 Amitriptyline administered together w i t h the a2-antagonist, yohimbine, decreased 5-HT2 receptor binding after 4 days compared to 10 days for amitriptyline alone.129 Phenoxybenzamine and dihydroergotamine were also effective, whereas the specific al-antagonist, prazosin, was not. Very recently, it has been shown that subacute co-administration of imipramine and chlorpromazine produced a greater reduction of 5-HT2 binding in rat cortex than either drug alone;130 in contrast, this same drug combination had no effect on a2- and 0-receptor densities.45 Repeated administration of imipramine diminished 3[H]imipramine binding in rat hippocampus but not in cereb.ellum or cortex; in the same animals, down-regulation o f preceptors was induced in the latter regions but n o t in the hippocampus.131 The downregulation of 3[H]imipramine binding sites by chronic imipramine was accompanied by an increase in 5-HT reuptake in hippocampal slices.61 It was proposed that chronic administration of imipramine and DMI may effect the desensitization/down-regulation of 0-adrenoceptors by eventually facilitating 5-HT reuptake, thereby attenuating the inhibitory effects of 5-HT on NE neurons.61 This diminished 5-HT function could also lead t o the enhanced responses t o 5-HT observed after chronic tricyclics.132 The down-regulation of 3[H]imipramine binding sites I S supposedly a reduction in the effector sites for an "endogenous modulator'' (inhibitory) of 5-HT reuptake.61 It is notable that either deprivation of REM sleep or chronic ECS treatment can down-regulate 3[H]imipramine sites as well as P-receptors.39 However, iprindole and mianserin, w h i c h produce subsensitivity o f NE receptors, d o n o t d o w n - r e g u l a t e 3[H]imipramine sites.61.131 Chronic tricyclic antidepressants, but not fluoxetine, femoxetine, or chlorpromazine, increased sensitivity of postsynaptic forebrain neurons t o microionotophoretically-applied 5-HT.132 Similar treatments did not affect the sensitivity of raphe 5-HT autoreceptors, as assessed by the effect o f LSD on neuronal firing rates.133 Electrophysiological studies following chronic zimelidine treatment revealed enhanced 5-HT neurotransmission o n electrical stimulation o f rat hippocampus but not an enhanced responsivity of hippocampal neurons t o applied 5-HT.134 These results are at variance w i t h the notion t h a t long-term zimelidine may attenuate 5-HT transmission112 and w i t h the observation t h a t chronic antidepressants increase postsynaptic functional sensitivity.59.132 Acute zimelidine inhibited the firing of raphe 5-HT neurons, but the effect became progressively less w i t h continued drug administration. After 14 days of zimelidine, the firing rate returned t o normal, but the response o f raphe 5-HT autoreceptors t o intravenous LSD was much less.134 These findings suggest that the autoreceptors mediating the firing rate of 5-HT neurons become desensitized by continuat exposure t o this 5-HT uptake blocker. The postsynaptic 5-HT f u n c t i o n a l supersensitivity elicited by chronic clomipramine was n o t blocked by chronic l i t h i u m administration.135 Acute administration of amitriptyline, imipramine, trazodone, mianserin or viloxazine (but not D M I or iprindole) antagonized the "head-twitch" response t o 5-methoxy-N,Ndimethyltryptarnine (5-MeODMT) in mice. Chronic administration o f the same agents, including D M I and iprindole but excluding mianserin or viloxazine, e l i c i t e d enhanced responsiveness t o this 5-HT agonist.136 Recently, the head twitch response has been ascribed t o 5-HT2 receptor stimulation, whereas the 5-HT syndrome may involve activation of 5-HT1 receptors.137 Antagonism of the head twitch response by acute tricyclic drugs but enhanced responses after chronic treatments suggest that "receptors" blocked after one dose should be up-regulated by multiple doses. Instead, the effects of chronic tricyclic antidepressants o n 5-HT2 receptors (down-regulation) and the behavior presumably mediated by these receptors are opposite. As noted earlier, mianserin can down-regulate 5-HT2 receptors after acute or
46
Sect. I
- CNS Agents
Hesp, Ed.
chronic administration; both treatments also antagonized the head twitch response in mice.122.136 The up-regulation o f 5-HT2 receptors by multiple ECS treatments i s accompanied by enhanced behavioral responses t o 5-HT agonists.126 Thus, the effects on 5-HT2 receptors seem t o parallel a behavioral response for mianserin and ECS but not other antidepressant drugs. However, a recent investigation showed parallel increases in the 5-HT head twitch response and 5-HT2 receptor density following chronic DMI treatment.138 Finally, another study reported that 5-HT1 receptor binding was unaltered, whereas 5-HT2 binding was decreased after chronic administration of clomipramine or fluoxetine. The 5-HT syndrome in the clomipramine and fluoxetine-treated rats from 5-MeODMT was also diminished.111 This result supports other findings that postsynaptic activity appears t o be attenuated following long-term administration of 5-HT uptake blockers,ll2 but the behavioral subsensitivity t o 5-HT agonists is in contrast t o the supersensitivity t o microiontophoretically-applied 5-HT in chronic clomipramine treated rats.135 Amitriptyline, trazodone and other agents, in fact, may function as antagonists of 5-HT at the postsynaptic receptor.139-141 Chronic treatment with zimelidine induces a lower affinity 5-HT1 site in both rat cortex and hypothalamus, in concert with the persistent reduction o f 5-HT synthesis. These effects might result in reduced presynaptic and postsynaptic activity.112.142 A similar decrease in 5-HT transmission after chronic 5-HT uptake blockers could be responsible for their ability t o desensitize and downregulate P-adrenoceptors.34 Other investigators have proposed that antidepressant drugs alter the structure of the postsynaptic 5-HT receptor t o give a higher affinity 5-HT binding form which is inactive, i.e., no longer coupled t o a 5-HT sensitive adenylate cyclase.143 The relevance of these findings to the action o f antidepressant drugs is obscure, since M A 0 inhibitors were ineffective. Dopamine Receptors - All antipsychotic drugs (neuroleptics) are known to block DA receptors. The number of receptor subtypes claimed for DA, based on binding studies, include "D-1, D-2, D-3 and D-4".144.145 However, only t h e postsynaptic D-2 receptors (labeled by 3[H]butyrophenones) are most consistently relatable t o the effects of drugs. The D-1 subtype, a DA-stimulated adenylate cyclase site, has no clearcut function in brain.146 Recent studies on agonist binding disclosed that 3[H]DA binds t o t w o sites, both postsynaptic; one is related t o D-2 sites and the other t o D-1 sites.147 Changes in DA receptors are of particular relevance t o three major types o f CNS disorders, schizophrenia, tardive dyskinesia and Parkinson's disease. Strong evidence points t o the involvement of the DA system in many of the clinical manifestations of schizophrenia. Several studies have been conducted t o determine whether this disease ultimately causes alterations in DA receptors. In one investigation, 3[H]spiperone binding in 19 postmortem brains from schizophrenic patients showed an increase in the density of postsynaptic DA receptors (D-2) versus a control group.148 A concurrent increase in KD of 3(H]spiperone binding was attributed t o residual neuroleptics. Two patients had never received antipsychotic drugs, and five others had been drug-free for at least a year prior t o death (this latter group had normal K,I values). Thus, up-regulation of postsynaptic receptors in the caudate nucleus, putamen and nucleus accumbens may be an aspect of the disease process. Another study gave similar values, but it was difficult t o rule out supersensitivity induced by prior neuroleptic treatment.149 In Parkinson's disease, DA receptor supersensitivity i s postulated as a compensatory response t o the degeneration of nigrostriatal DA neurons. Examination of postmortem brains of Parkinson patients revealed an increase in 3[H]haloperidol binding in the putamen and a similar trend in the caudate.150 In the brains o f such patients on long term L-dopa therapy, 3[H]haloperidol binding was normal. L-Dopa thus normalizes the DA system. It was proposed that deliberate up-regulation by decreasing or withdrawing L-dopa treatment may be beneficial t o patients who become refractory t o this drug due t o the development of subsensitivity.lso.l51 The more disabled Parkinson patients showed a decreased number o f striatal D-2 receptors and loss o f therapeutic response t o L-dopa.152 In Huntington's disease, postmortem brain tissue from patients showed a significant decrease in the number o f 3[H]spiperone 0-2 sites (unchanged KD) in the putamen, caudate nucleus, and frontal cortex.153 This diminished dopaminergic function in the basal ganglia and frontal cortex may be a cause of the motor and mental disorders, respectively, in Huntington's disease.
Chap. 5
A d a p t i v e Changes in CNS R e c e p t o r S y s t e m s Koe, V i n i c k
2
Many animal studies have been carried out t o determine the effects of antipsychotic drugs on DA receptors.7.144.145 Rats treated chronically with haloperidol exhibited increases in 3[H]haloperidol binding in the striatum and mesolimbic region.154 Also, 3[H]apomorphine binding was increased in the aforementioned brain areas. Enhanced 3[H]haloperidol binding after chronic haloperidol, fluphenazine and reserpine was reflected by an increase in receptor density, not in affinity.155 In accord with the greater number of D-2 receptors, an augmented behavioral response t o apomorphine,l56.157 amphetamine157 or tranylcypromine + L-dopalss was observed. In general, chronic administration of neuroleptics alters the number of D-2 receptors; except for thioxanthenes, the number of D-1 sites, i.e., DA sensitive adenylate cyclase activity, is unchanged.156-158 The thioxanthene, cis-flupenthixol, which exhibits similar a f f i n i t i e s f o r D-1 a n d 0 - 2 receptors, u p - r e g u l a t e d D-1 receptors a f t e r c h r o n i c administration.l56,159 Longer treatment (18 months) increased the number o f D-2 sites without affecting that of D-1 sites (labeled by 3[H]piflutixol) despite increased DA-sensitive adenylate cyclase activity.160.161 Receptor plasticity was demonstrated by the fact that withdrawal after 18 months of cis-flupenthixol treatment resulted in the return of enhanced apomorphine-induced stereotypy t o normal and elevated Bmax for 3[H]spiperone binding t o control values after 1 month and 3 months, respectively. However, DA-stimulated adenylate cyclase activity remained elevated for 6 months, returning t o normal activity 1 year following drug withdrawal.161 Similar e f f e c t s were f o u n d upon continual administration o f trifluoperazine (1 year). This drug initially acted as a DA antagonist, but behavioral supersensitivity t o high dose apomorphine, increased density of D-2 receptors and enhanced DA-stimulated adenylate cyclase activity was observed at 6 and 12 months and persisted for 3 months after drug withdrawal.160 These receptor sensitivity changes appeared t o parallel the development o f drug-induced human tardive dyskinesia. Administration of haloperidol, trifluoperazine, fluphenazine or pifluthixol for 6-9 months resulted in an enduring functional blockade of DA receptors, as measured by low dose apomorphine elicited responses; D-2 binding was elevated.162 Other investigators have reported that neuroleptic-induced DA receptor supersensitivity can be reversed by chronic L-dopa administration, presumably by increasing the concentration o f DA, which in turn down-regulates the receptors.151.163 Concurrent chronic treatment of rats w i t h haloperidol and lithium did not lead t o the development of DA receptor supersensitivity.164 This prophylactic effect .of lithium i n preventing up-regulation o f t h e DA receptors may be involved in i t s antimanic properties. Studies of receptor regulation have also been useful in attempts t o understand the mechanism of action of antipsychotic drugs. In monkeys, it was found that after chronic haloperidol treatment, DA receptor sensitivity t o a challenge dose of haloperidol is maintained in the frontal and cingulate cortex, whereas tolerance is seen i n t h e putamen and caudate.165.166 Thus, these cortical regions may represent the site of therapeutic action of antipsychotic drugs. Furthermore, the unique effects of neuroleptics on the mesocortical DA neurons may be caused by the lack o f autoreceptors i n this brain region.167.168 In electrophysiological studies, DA autoreceptors (substantia nigra) were found t o be 6 t o 10 times more sensitive t o DA agonists than postsynaptic receptors (caudate nucleus); therefore, low doses of agonists may act preferentially at autoreceptors t o inhibit DA release.169 Thus, selective autoreceptor agonists could be effective antipsychotic agents; the development of tolerance may be a limiting factor.170.171 Conflicting results have been reported regarding the effects of chronic antidepressant administration on DA receptors: imipramine and iprindole induced subsensitivity o f autoreceptors,l72 b u t efforts t o repeat these findings have failed.173-175 Also, some investigators have observed a decrease in D-2 binding following tricyclic antidepressant treatment,lO whereas others have claimed no change.21 Conclusion - Recent years have witnessed an increased interest in the study of receptor plasticity i n the CNS following drug administration or i n relation t o disease processes. Generally, stimulation of receptors with agonists causes desensitization/down-regulation; antagonists produce the opposite effects. The NE system seems t o exhibit the best correlation between therapeutic drug response and receptor alteration. Many contradictions in the literature remain t o be explained. A better understanding of the functional significance of receptor subtypes would help answer many questions regarding adaptive mechanisms.
4a -
Sect . I
- CNS Agents
Hesp, Ed.
References 1. 2. 3.
4. 5.
6. 7. 8. 9. 10. 11.
12. 13.
14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33.
34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58.
V.-F. Su, T. K. Harden and 1. P. Perkins, 1. Biol. Chem., 255,7410(1980). V. Homburger, M . Lucas, B. Cantu, J. Barabe, J. Perrit and J. Bockaert, 1. Biol. Chem., 255,10436(1980). M. D. Dibner and P. B. Molinoff. I. Pharmacol. Exp. Ther., 210,433 (1979). D. C. U'Prichard and 5.1. Enna, Eur. 1. Pharmacol.. 59,297(1979). J. Vetulani, R. 1. Stawarz and F. Sulser, I. Neurochem., 27,661(1976). B. 8. Wolfe. T. K. Harden, 1. R. Sporn and P. B. Molinoff, 1.Pharmacol. Exp. Ther., 207,446(1978). I. Creese and D. R. Sibley, Ann. Rev. Pharmacol. Toxicol., 21,357(1981). M. F. Sugrue. Pharmacol. Ther.. 21,l (1983). G. N. Pandley and J. M. Davis, Drug Dev. Res., 3,393(1983). J. L. Anderson, Life Sci., 32,1791 (1983). J. Vetulani, R. 1. Stawarz. J. V. Dingell and F. Sulser. Naunyn-Schmiedeberg's Arch. Pharmacol.. 293.109 (1976) 5. P. Banerjee, L. S. Kung, 5 . J. Riggi and S. K. Chandra. Nature, 268,455(1977). F. Sulser, A. J. Janowsky. F. Okada. D. H. Manier and P. L. Mobley, Neuropharmacology, 22,425(1983). F. Sulser, Psychopharmacol. Bull.. 19.300 (1983). K. 1. Kellar, C. 5 . Cascio, D. A. Bergstrom. J. A. Butler and P. ladarola, 1. Neurochem., 37,830(1981). G. N. Pandley, W. 1. Heinze, B. D. Brown and J. M. Davis, Nature, 280,234(1979). D. D. Gillespie, D. H. Manier and F. Sulser, Commun. Psychopharmacol.. 3, 191 (1979). 1. Schultz. Nature, 261,417(1976). A. Maggi, D. C. U'Prichard and 5.1. Enna, Eur. 1. Pharrnacol., 61,91(1980). T. Koide and H. Matsushita, Neuropharmacology, 20,285(1981). S. Peroutka and S. H. Snyder, Science. 210,88(1980). D. A. Bergstrom and K. J. Kellar, 1. Pharmacol. Exp. Ther.. 209,256(1979). M. M . Sellinger-Barnette, J. Mendels and A. Frazer. Neuropharmaco/ogy.19,447(1980). V. H. Sethy and D. W. Harris, Eur. 1. Pharmacol., 75,53(1 981). R. Mishra, N. J. Leith, L. Steranka and F. Sulser, Naunyn-Schmiedeberg's Arch. Pharmacol., 316,218(1981). R. Mishra and F. Sulser. Commun. Psychopharmacol.,2.365 (1978). C. Kopanski. M. Turck and 1. E. Schultz, Neurochem. lnt., 5,649(1983). 5 . Clements-Jewery, Neuropharmacology, 17,779(1 978). R. Mishra, D. D. Gillespie, R. A. Lovell. R. D. Robson and F. Sulser, Life Sci., 30,1747 (1982). R. Mishra, A. Janowsky and F. Sulser, Eur. I. Pharmacol.. 60,279(1979). R. Mishra, A. Janowsky and F. Sulser, Neuropharmacology, 19,983(1980). 0. Gandolfi, M. L. Barbaccia, D. M. Chuang and E. Costa, Neuropharmacology, 22,927(1983). V. Claasen, Brit. 1. Clin. Pharmacol., 15.3495 (1983). B. K. Koe, A. Weissman, W. M. Welch and R. G. Browne, 1. Pharmacol. Exp. Ther., 226,686(1983). 1. E. Rosenblatt. C. 8.Pert, 1. F. Tallman, A. Pert and W. E. Bunney, Brain Res., 160,186(1979). 5 . Treiser and K. J. Kellar. Eur. 1. Pharmacol.,58.85(1979). R. Mishra, D. D. Gillespie, M. Voudim and F. Sulser, Fed. Proc., 41,1066(1982). R. M. Cohen, R. P. Ebstein, 1. W. Daly and D. L. Murphy, 1. Neurosci.. 2,1588 (1982). E. Mogilnicka, 5. Arbilla, H. Depoortere and 5 . 2 . Langer. Eur. 1. Pharmacol., 65,289(1980). N. L. Wiech and R. C. Ursillo. Commun. Psychopharmacol., 4,95(1980). F.T. Crews, 5 . M. Paul and F. K. Goodwin, Nature, 290,787(1981). 1. A. Scott and F. T. Crews, 1. Pharmacol. Exp. Ther., 224,640(1983). D. H. Manier, D. D. Gillespie and F. Sulser. Naunyn-Schmiedeberg's Arch. Pharmacol., 313,113 (1980). T. D. Reisine, D. C. U'Prichard, N. L. Wiech, R.C. Ursillo and H. I. Vamamura, BrainRes., 188,587(1980). M. Mikuni, D. M. Stoff and H. V. Meltzer, Eur. 1. Pharmacol.. 89,313 (1983). 1. W. Lace and 5 . M. Antelman. Brain Res.278.359 (1983). B. A. McMillen, W. Warnack, D.C. German and P. A. Shore, Eur. 1. Pharmacol., 61,239(1980). P.F. Von Voightlander, ti.1. Triezenberg and E. G. Losey. Neuropharmacology, 17,375(1978). D. J. Heal, H. Akagi, J.M.Bowdler and A. R. Green, Eur. 1. PharmacoL.75.231(1981). C.5 . Aulakh, R. M. Cohen, C. McLellan and D. L. Murphy, Brit. 1. Pharmacol., 80, 10 (1983). F. Cerrito and M . Raiteri. Eur. 1. Pharmacol.. 70,425(1981). M. F. Sugrue. Eur. 1. Pharmacol.. 68,377(1980). L. J. Siever, R. M. Cohen and D. L. Murphy, Am. 1. Psychiatry. 138,681(1981). C.B. Smith, 1. A. Garcia-Sevilla and P. J. Hollingsworth. Brain Res.. 210,413(1981). R. W. Johnson, T. Reisine, 5. Spotnitz, N. Wiech, R. Ursillo and H. I. Vamamura, Eur. 1. Pharmacol., 67,123(1980). M. Asakura, T. Tsukamoto and K. Hasegawa. Brain Res.. 235,192(1982). H.-R. Olpe and A. Schellenberg, Eur. 1. Pharmacol., 63,7(1980). 1. E. Schultz, G. R. Siggins, F. W. Schocker, M . Turek and F. E. Bloom, 1. Pharmacol. Exp. Ther.. 216.28 (1981).
Chap. 5 59. 60. 61. 62 63. 64. 65. 66. 67.
A d a p t i v e Changes i n CNS R e c e p t o r Systems Koe, V i n i c k
D. B. Menkes. G. K. Aghajanian and R. B. McCall, Life Sci.. 27, 45 (1980). D. B. Menkes. M. M. Rasenick, M . A. Wheeler and M . W Bitensky. Science, 219,65 (1983). M. L. Barbaccia, N Brunello, D. M. Chuang and E. Costa, Neurophdrmacology. 22,373 (1983). A. Janowsky, F. Okada. D. H. Manier, C. D. Applegate and F. Sulser. Science. 218.900 (1982). N. Brunello. M. L. Barbaccia. D. M . Chuang and E. Costa, Neuropharmacology. 21, 1145 (1982). D. H. Manier, F.Okada, A. J. Janowsky. L. R. Steranka and F. Sulser, Eur. 1. Pharmacol.. 86,137 (1983).
B. Shoprin, S. Gershon, M. Goldstein, E. Friedman and 5 . Wilk. fsychopharmacol. Common.. 1. 239 (1975).
B. Shopsin, E. Friedman and 5 . Gershon. Arch. Gen. Psychiatry, 33,811 (1976). Y . Lecrubier, A. 1. Puech, R. Jouvent, P. Simon and 0.Widlocher, Br. 1. Psychiatry, 136,354 (1980).
68.
B. Lehrer, R. P. Ebstein and R. H. Belmaker, fsychopharmacology, 75.16911981).
69. 70. 71.
0.1. Dooley and K. L. Hauser, Neurosci. Lett.. 36,93 (1983).
72. 73. 74. 75. 76. 77. 78.
C B. Nemeroff and D. L. Evans, Biol. Psychiatry, 18,237 (1983).
79. 80. 81. 82. 83. a4. 85.
86. 87. 88.
A. Dolphin, M. C. B. Sawaya. P. Jenner and C. D. Marsden, Naunyn-Schmiedeberg’s Arch. Pharmacol., 299, 167 (1977) W. M. Petrie, R. J. Maffucci and R. L. Woosley, Am. 1. Psychiatry, 139.92 (1982).
G. C. Palmer and H. R. Wagner, Res. Commun. Psychol. Psychiat. Behav., 1,567 (1976). 1. R. Sporn. 8.5. Wolfe. T. K. Harden and P. B. Molinoff, Mol. Pharmacol.. 13. 1170 (1977). D. J Dooley, H. Bittigec, K. L. Hauser, S F. Bischoff and P. C. Waldmeier, Neuroscience, 9, 889 (1983). A. 1. Janowsky. L. R. Steranka. D. 0 . Gillespie and F. Sulser. 1. Neurochem.. 39,290 (1982) K. P. Minneman. M. D. Dibner, B. B. Wolfe and P. B. Molinoff. Science. 204, 866 (1979). P L. Mobley and F. Sulser, Eur. 1. Pharmacol., 60,221 (1979). W. E. Heydorn, D. 1. Brunswick and A. Frazer. I Pharmacol. €xp. Ther., 222,534 (1982). P 1. Cowen, 5. Fraser. D. G. Grahame-Smith, A. R. Greene and C. Stanford. Br. 1. Pharmacol, 78.89 (1983). C. Thompson, 5 . A. Checkley,T. Corn, C. Franey and I. Arendt, Jhe Lancet, 1101 (1983).
G. M . Vaughan, R. W. Pelham. S. F. Pang, L. L. Loughlin, K. M . Wilson, K. L. Sandrock, M. K. Vaughan, S. H. Koslow and R. 1. Heiter. 1. Clin. Endocrinol. Metab.. 42,752 (1976). E. A. Stone, 1. Neurochem., 32,1335 (1979). E. A. Stone, Res. Commun. Psychol. Psychiat. Behav.. 4,241 (1979). K. P.Minneman, B. B. Wolfe and P. B Molinoff, Brain Res., 252,309 (1982). C. Stanford, 0.J. Nutt and P J. Cowen. Neuroscience,8, 1161 (1983). R. Dunstan and D. M. Jackson, Rychopharrnacology. 48, 105 (1976). M. R. Goldberg. P. W. Curatolo. C.-S. Tung and D. Robertson, Neurosci. Lett., 31,47 (1982).
89, P.R. Lowenstein, M. 1. Vacas and D. P. Cardinali, Neuropharmacobgy, 21,243 (1982). 90. D.L. Nelson, A. Herbet, 5 . Bourgoin, 1. Glowinski and M.Hamon. Mo/. Pharmacol., 14,983 (1978). 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101.
J. E. Leysen and 1. P. Tollenaere. Ann. Rep. Med. Chem.. 17, 1 (1982). J. E. Leysen, C. 1. E. Niemegeers, J. M. Van Neuten and P. Laduron, Mol. Pharrnacol.. 21,301 (1982).
A. Dumbrille-Ross, 5. W. Tang and D. V. Coscina, Life Sci., 29,2049 (1981). S. 1. Peroutka and S. H. Snyder, 1. Pharmacol. Exp. Ther.. 216,142 (1981). D. L. Nelson, A. Herbet. A. Enjalbert, 1. Bockaert and M. Hamon, Biochem. Pharmacol., 29,2445 (1980). M. L. Barbaccia, N. Brunello, D.-M. Chuang and E. Costa, 1. Neurochem.. 40,1671 (1983).
5. Clements-Jewery and P. A. Robson, Neuropharmacology. 21,725 (1982). M. L. Barbaccia, 0. Gandolfi. D.-M. Chuang and E. Costa, Neuropharmacology. 22,123 (1983) D. D. Savage, 1. Mendels and A. Frazer, Neuropharmacology, 19.1063 (1980) D. M. Helmeste and S W. Tang, Life Sci..33. 2527 (1983). S. 2. Langer and P. M. Laduron. Trends Pharmacol Sci., 5.51 (1984).
102.
Stanley and 1.1. Mann, The Lancet, 214 (1983)
103.
L. R. Meyerson, L. P. Wennogle, M. 5 . Abel. 1. Coupet. A. S . Lippa. C. E. Rauh and 8 Beer, Pharrnacol. Biochem Behav.. 17,159 (1982).
104. 105. 106.
M. Stanley, V. 1. Virgiloand 5. Gershon. Science. 216, 1337 (1982). H. Y. Meltzer, B. Uberkoman-Wiita, A. Robertson, B. 1. Tricou and M. Lowy, Lffe SCI., 33,2541 (1983). F. K. Goodwin and R. M. Post, Br. 1. Clin. Pharmacol., 15, 3935 (1983). D. D. Savage, J. Mendels and A. Frazer, J. Pharmacol. Exp. Ther., 212.259 (1980). I. Lucki and A. Frazer. fsychopharmacology, 77,205 (1982). H.-R.Olpe. Eur. 1. Pharmacol.,69.375 (1981). A. Wirz-Justice, K. Krauchi. M. Lichtsteiner and H. Feer, Life Sci.. 23, 1249 (1978). J. F. Stolz, C. A. Marsden and D. N. Middlemiss. fsychopharmacology, 80. 150 (1983). K. h u e . 5-0. Ogren, L. F. Agnati. F. Benfenati. B. Fredholm, K. Anderson, I. Zini and P. Eneroth,
107. 108. 109. 110. 111.
112. 113. 114. 115.
3
Neuropharmacology. 22.389 (1983). T. Segawa, T Mizuta and Y. Nomura, Eur. J. Pharmacol., 58,75 (1979). R. Samanin, T. Mennini, A. Ferraris, C. Bendotti and F. Borsini, Brain Res., 189,449 (1980).
R. Samanin, T. Mennini. A. Ferrarir, C. Bendotti and R. Borsini, Eur. 1. Pharmacol.. 61. 203 (1980).
50 116. 117. 118. 119. 120. 121.
122. 123. 124. 125. 126. 137. 128. 129. 130. 131. 132. 133. 134. 135. 136.
137 138. 139 140. 141. 142. 143. 144. 145. 146 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175.
Sect.
I
- CNS Agents
Hesp, Ed.
E. C. Hwang. J. Magnussen and M. H. Van Woert. Res. Comm. Chem. Pathol. Pharmacol.. 29,79 (1980). 0. T. Wong and F P. Bymaster. Rer. Commun. Chem. Pathol. Pharmacol., 32.41 (1981). 5.8. ROSS. H. Hall, A. L. Renyi and D.Werterlund. Psychopharmacology,72,219 (1981). 5. Treiser and K . 1. Kellar. Eur. 1. Pharmacol.,64,183 (1980). T. Segawa and M. Uehara. Life kr..30,809 (1982) S. J. Peroutka and S. H Snyder, 1. Pharmacol. Exp. Ther.. 215,582 (1980). M. A. Blackshear and E. Sanders-Bush.1. Pharmacol. Exp. Ther.. 221.303 (1982). S Clernents-Jewery and P A. Robron. Neuropharmacology.19.657 (1980). G. P Reynolds. N. J. Garrett. N. Rupnlak. P. Jenner and C. D Marsden. Eur. 1 Pharmacol.. 89.325 (1983). M. A. Blackshear. L. R. Steranka and E. Sanders-Bush. Eur. 1.Pharmacol.. 76,325 (1981). K. J Kellar. C. S. Cascio, J. A. Butler and R. N. Kurtzke. Eur. f Pharmacol..69,515 (1981). 1. Vetulani. U. Lebrecht and A. Pilc, Eur. 1.Pharmacol., 76,81 (1981). K. J Kellar and D A. Bergstrom, Neuropharmacology,22.401 (1983) F. T. Crews, J. A. Scott and N. H. Shorrtein, Neuropharmacology,22, 1203 (1983). M. Mikuni and H. V Meltzer, Life SCI. 34,87 (1984). W. 1. Kinnier, 0.-M. Chuang and E. Costa, Eur. 1. Pharmarol,67,289(1980). C. De Montigny and G. K. Aghajanian, Science, 202, 1303 (1978). P. Blier and C. De Montigny. Naunyn-Schmiedeberg’sArch. Pharmacol ,314.123 (1980) P Blier and C. De Montigny. 1. Neurosci.,3,1270 (1983). D W Gallager and W. E. Bunney. Jr . Naunyn-Schmied~~erg’s Arch Phdrmacol , 307,129 (1979). E Friedman. T B Cooper and A. Dallob. Eur. 1. Pharmacol., 89.69 (1983) I Lucki.M S Nobler and A. Frazer, 1. Pharmacol Exp. Ther..228,133(1984). A. R Greene, D 1. Heal, P Johnson.8. E. Lawrence and V L. Nirngaonkar, 8r 1 Pharmacol.. 80.377 (1983) K. Fuxe. S -0 Ogren. L. Agnati. 1. A. Gustafsson and G. Jonsson. Neurosci. Len.. 6,339 (1977). H . Nagayama. 1. N. Hingtgen and M H. Apriron. Pharmacol. Biochem. Behav.. 13,575 (1980). 1 N. Hingtgen. H C Hendric and M. H. Aprison. ibid., in press (1984). K. Fuxe, S.-0 Ogren and L. F . Agnati. Neurosci. Lett., 13,307 (1979) G. Fillion and M. P. Fillion. Nature. 292,349 (1981). P. Seeman. Pharrnacol. Rev., 32,229 (1980). I. Creese. M. W. Harnblin. S. E Leff and D. R. Sibley, in “Handbook of Psychopharmacology”,VoI 17, L. L. Iversen, 5 . D. lverren and S. H . Snyder, Ed..Plenum Press, New York. NV. 1983, p. 81. B Costall and R. 1. Naylor. Life Sci..28.215 (1981) N. G Bacopoulos. Life ScJ ,34,307 (1984). F Owen, T. J. Crow, M. Poulter, A. J. Cross, A Longden and G. J. Riley, The Lancet. 223 (1978). T Lee, P. Seeman, W. W Tourtello. I 1. Farley and 0 Hornykeiwicz. Nature. 274.897 (1978) T. Lee, P. Seeman. A. Rajput, 1.1. Farley and 0.Hornykeiwicz. Nature, 273.59 (1978). A. 1. Friedhof and J. C. Miller. Ann. Rev. Neurosci.. 6. 121 (1983) u. K. Rinne, 1.0.Rinne. 1. K Rinne, K. Laakso, A. Laihinen and P Lonnberg. 1. Neural Jransm. (Suppl.), 18,279 (1983). T. 0.Reisme. J. 2 . Fields. L 2 . Stern, P. C. Johnson, E. D. Bird and H. I. Yamamura, Life Sct., 21.1123 (1977). P. Muller and P. Seeman, Life Sci., 21, 1751 (1977). D. R. Burt, I.Creere and 5 . H. Snyder. krence. 196.326 (1977). S. Fleminger, N. M.l. Rupniak, M. D.Hall, P. lenner and C. D.Marsden. Biochem. Pharmacol.. 32.2921 (1983). P. von Voigtlander, E . C. Lorey and H. Triezenberg, J. Pharrnacol. Exp. Jher., 193,88 (1975). D J. Heal, A. R. Green, D. 1. Boullin and 0. G. Grahame-Smith. Psychopharmacology,49,287 (1976). J. Hyttel and A.V. Christenren. 1. Neural Transm. (Suppl.). 18. 157 (1983). N M. J. Rupniak, P. Jenner and C. D.Marrden, Life Sci.. 32,2289 (1983). K Murugaiah. S. Fleminger. A. Theodorou, P. Jenner and C. D. Marsden, Biochem. Pharmacol., 32.2495 (1983) 1. L. Waddington. A. 1. Cross, S. 1. Gamble and R. C. Bourne. Adv. Btochem. Psychopharmacol.,37,299 (1983) A. 1. Friedhoff. K . Bonnet and H. Rorengarten. Res. Commun. Chem. Pathol. Pharmacol.. 16,411 (1977). A. Pert, J. E Rosenblatt.C. Sivit, C. B Pert and W. E. Bunney. Jr.. Science, 201, 171 (1978). N. G. Bacopoulos. G. Burtos. D. E. Redmond. J. Baulu and A. H . Roth. Brain Res.. 157,396 (1978). N. G. Bacopoulos. 0. E. Redmond. 1. 8aulu and R. H. Roth, 1. Pharmacol. Exp. Tber.,212, 1 (1980) M.J. Bannon, 1. F. Reinhard. Jr., E. 8. Bunney and R. H. Roth. Nature. 296,44 (1982). M. 1. Bannon. R. L. Michaud and R. H . Roth, Mol. Pharmacol.. 19,270 (1980). L. R. Skirboll. A. A. Grace and 8.5. Bunney. Science. 206.80 (1979). H. V . Meltzer. Pharmacol. Biochem. Behaw., 17, Suppl. 1. 1 (1982). H. V . Meltzer. T. Kolakowrka, A. Robertson and 8.1. Tricou. Rychopharmacolopy, 81.37 (1983). L. A. Chiodo and S. M. Antelman, Nature, 287.451 (1980). 1. welch. H. Kim, 5. Fallon. 1. Liebman. D.A. McNeill and M. Cower, Nature. 298.301 (1982). H. H. Holcomb, M. 1. Bannon and R . H. Roth, Eur. 1. Pharmacol.. 82. 173 (1982). I. Creese, R. Kuczenrki and D. Segal, Pharmacol. Biochcm. Behav.. 17.375 (1982).
Chapter 6. CNS Autoreceptors as Targets for Drug Design Pieter B. U. W. U. T i m e r m a n s , Department of Pharmacy, Division of Pharmacotherapy, University of Amsterdam, Plantage Huidergracht 24, 1018 TV Amsterdam, The Netherlands Introduction - Several lines of evidence strongly suggest that presynaptic receptors are of physiological importance. I n contrast to somadendritic receptors, which primarily modulate impulse generation, presynaptic receptors primarily modulate synthesis and release of transmitter. Presynaptic receptors are located on, in or near the axon terminals of many neurons. Activation results in facilitation or inhibition of transmitter release/synthesis, whereas blockade generally induces the opposite of a ~ t i v a t i o n . l - ~ In view of the ubiquity of presynaptic receptors at central and peripheral sites,3 this Chapter focusses on the subset of presynaptic receptors termed autoreceptors, i.e. presynaptic receptors on a particular neuron which are activated by its own neurotransmitter. CNS autoreceptors have been postulated for, inter alia, norepinephrine (NE)/ epinephrine, dopamine (DA), serotonin (5HT), acetylcholine (ACh), histamine (H) and y-aminobutyric acid (GABA). Autoreceptors for Norepinephrine (NE) - Though the concept of autoinhibition of N E release is not universally a ~ c e p t e d , ~the , ~ consensus is that release of N E from sympathetic nerves is modulated through inhibitory a2-autoreceptors. By contrast, somadendritic a2-adrenoceptors of central noradrenergic neurons inhibit f i ~ i n g . ~ Release , ~ ~ ~ of 3H-amezinium from rat cortical noradrenergic axons has been advanced as a model for the study of the a2-autoreceptor h y p o t h e ~ i s . ~ There are a number of mechanisms possible for the link between presynaptic a2-adrenoceptor activation and transmitter release, in which a pivotal role for Ca2+ has been established.3~8 Uore recent data implicates inhibition of adenylate cyclase with receptor activation and subsequent attenuation of transmitter release. 9*10
CNS
(z),ll*lz
The a-adrenoceptor agonists 8-HT 9 2 0 (1) and 933 UK-14,304 (3),11,13 U-7 (9). l4 TL-99 DP-6.7-ADTN of Z-amin0-6,7-dihydroxybenzonorASL-7022 (9)17 and some =-isomers bornene preferentially stimulate this type of a-adrenoceptor. The antagonists yohimbine and rauwolscine,8 RS 21361 (11),19 idazoxan (RX 781094 g ) 2 0 and derivatives,21 BDF 6143 (u),22 Wy 26392 (14)
(z),l)
H
2
R = CHa-CH2-i X=O
3 -
and Wy 26703 (11)23 as well as S K W 86466 (13)24 block a2-adrenoceptors selectively. The stereochemical requirements of a2-adrenoceptors have been described in detail.25.
ANNUAL REPORTS IN MEDICINAL CHEMISTRY-19
Copynght 0 1984 by Academic Press, Inc. All rights of reproduction in any form reserved. ISBN 0- 12-0405 19-9
52 -
Sect. I
- CNS Agents
Hesp, Ed.
Presynaptic a2-adreqoceptors possibly represent only a minor fraction of the total a2-adrenoceptor population in the CNS 26 Although the general characteristics of presynaptic (auto) and postsynaptic a2-adrenoceptors with respect to drug selectivity are very similar,8 some findings suggest that in rat cerebral cortex the a2adrenoceptors for NE differ from the a2-adrenoceptors located on serotonergic terminals .27 Surprisingly, in rat frontal cortex a1adrenoceptors seem to modulate 5HT release.28 The suggestion that different recognition sites on the presynaptic a2-autoreceptor exist in
.
\
OH
9
-
4 X = 5,Mi-OH; R = CH3 X = 6,7-di-OH; R CH3 & X = 6,7-di-OH; R = n-CsH7 L X = 7-OH; R = n-C3H7 X = 8-OH; R = n-C3H7
7'
HozwN-R2 HO
10
4 ? + -02 ? N j
11
R1R2-H orCH3
q - 1
N
H
12
C2H5
..
I CI
H
13
14 R = n-propyl R = i-butyl N-S02-R CH3
the CNS for imidazoli(di)nes and cat echo la mine^,^^ has not found support. 30 Direct labeling of central a2-autoreceptors has been uns u c c e ~ s f u l . ~ ~The * ~ ~autoreceptors regulating NE release undergo sensitivity changes after long-term drug-induced activation or blockade: activation typically leads to a decrease in receptor number, whereas blockade produces the converse. 33 CNS Autoreceptors for Dopamine (DA)
-
DA autoreceptors, probably located on dopaminergic nerve terminals, modulate calcium-dependent stimulation evoked release of DA a negative feed-back 1 n e c h a n i s m , ~ ~ 3 as ~ ~ ~has 5 been reported for the field-stimulated release of 3H-DA from slices of the striatum/caudate nucleus of rats ,36 rabbits37 and cats.36,38 Presynaptic DA autoreceptors have also been implicated in the regulation of the synthesis of DA,39 whereas somadendritic DA receptors inhibit the firing of the dopaminergic neurons.40 In the rat, autoreceptor regulation of DA synthesis appears more significant in the mesolimbic as compared with the nigrostriatal DA pathway, while autoreceptors may be absent in the median eminence.41
Chap.
CNS A u t o r e c e p t o r s
6
Timmermans
53
The controversies in the classification of DA receptors have been reviewed.4 2 The majority of current receptor binding data supports two major DA receptor classes for the CNS, D-1 and D-2, with the DA autoreceptor probably belonging to the latter.42 However, the data is not sufficiently quantitative to assess conclusively whether more than one distinct DA autoreceptor is present on DA neurons.42 Furthermore, in studies with behavioral models of postsynaptic and neurochemical models of presynaptic dopaminergic activity have demonstrated that DA autoreceptors and postsynaptic DA receptors are diff ierent . 3 8 * 4 3 9 4 4 The suggestion that the so-called D-3 binding site corresponds to presynaptic DA auto receptor^^^*^^ has been refuted both on the basis of pharmacological and neurochemical evidence .47 ,48 Some agents have been proposed as selective presynaptic DA agonists, ,51 N.N-dipropyl-2-amino-7-hydroxye.g. 3-PPP (17)49,5O, RSD-127 (18) tetralin (1)and the selective a2-adrenoceptor stimulants TL-9953 and B-HT 920.54 TL-99 and 1 inhibit the release of 3H-DA from brain slices, but 3-PPP is inactive in this in vitro model for presynaptic DA a ~ t i v i t y . ~ ~The , ~ ~apparent DA autoreceptor selectivity of TL-99 as assessed in viva may be due at least partially to its a2agonist a ~ t i v i t y . 5 ~ ~ has I t been hypothesized that the presynaptic DA receptors mediating biochemical effects and those mediating effects on release are different.48*52 Both isomers of 3-PPP are selective agonists for the autoreceptor at low doses. At higher doses postsynaptic activity is also observed, with the ( + ) - and (-)-enantiomem behaving as an agonist and antagonist, r e s p e ~ t i v e l y . ~ ~ -For ~ ~ the more rigid the prelpost selectivity analogs of 3-PPP, c7-OBQ (19)and t7-OBQ (B), is lost for the trans compound whereas the compound (19)is inactive.61 Inhibition by d-amphetamine of the electrically-evoked release of 3H-DA does not involve the activation of presynaptic inhibitory DA autoreceptors .62*63
(a),
OH
I OCHq
?H
Effects of chronic neuroleptic administration on cerebral DA receptor function have been reviewed.64 Following chronic haloperidol treatment, the DA autoreceptors modulating 3H-DA release in the rabbit caudate develop supersensitivity to a p ~ m o r p h i n eor ~ ~ to DA itself .66 for Serotonin (5-HT) - Various experimental findings imply that presynaptic autoreceptors modulate the release of 5HT from the corresponding neurons in rat brain.67 In rat brain slices, or synaptosomes preincubated with 3H-5HT, the CaZ+-dependent stimulation-evoked release of the amine is inhibited by 5HT,68*69 5HT analog^,^^^^^ and numerous 5HT receptor agonists. 72 Hekitepine, metergoline and quipazine are competitive antagonists at the 5HT a u t o ~ e c e p t o r . ~ ~The - ~ ~ 5HT autoreceptors in rat cortical tissue may be different from the presynaptic excitator 5HT U - r e c e p t o r ~ ~on ~ sympathetic nerve endings of the rabbit heart,!O and from the somadendritic 5HT receptors in rat raphe nuclei75176 which mediate an inhibition of neuronal-activity. 70 Rank orders of 5HT agonists indicate that 5HT autoreceptors, inhibitory presynaptic 5HT receptors on sympathetic nerve endings of canine saphenous vein, and the binding sites of 3H-5HT in rat brain, designated as CNS Autoreceptors
54 -
Sect. I
- CNS Agents
Hesp, Ed.
5HT1 sites, are similar,70,71,77 but relative blocking potencies of antagonists show that they are not i d e n t i ~ a 1 . 6 9 , 7 ~ , 7 2 , ~In ~ fact, 5HT1 binding sites in rat brain cortex are not homogenous, since various compounds produce biphasic or shallow displacement curves.71,79*80 This may be one of the reasons why correlations between binding affinity for 5HT1 sites and functional activit frequently difficult to interpret .81 Two subtypes of the JH-TE; recognition site, designated ~ H T ~ (high A affinity site) and 5HT18 (low affinity site), have been recognized from displacement studies with spiperone, which exhibits a 3000-fold difference in affinity between the two sites.80 Both sites are differentially distributed in rat brain.82 A subset of the 3H-5HT binding sites (low affinity, rather than high affinity sites, for antagonists) may be localized on the serotonergic neurons and may correspond to the 5HT autoreceptors. 71 The 5HT agonist PAT ( 8 ) potently and selectively displaces 3H-5HT from the rrported ~ H T ~ binding A site in rat frontal cortex.83 However. H-PAT has been reported to bind to pre and postsynaptic 5HT sites in rat b ~ a i n . ~ 4 In the hippocampus, 3H-PAT binding sites have been associated with (postsynaptic) 5HT1 sites, whereas in the striatum they exhibit some properties of 5HT auto receptor^.^^ The agonist activity of PAT on the 5HT autoreceptor h vitro appears rather limited,85*86 and so the potent central effects of PAT on 5HT turnover are unH likely to be mediated by 5HT auto receptor^.^^ Additional selective 5HT1 (A or B) agonists/ antagonists may provide further clarification of several discrepancies. The selective 5HT1 agonist RU 24969 (21) may be a possible candidate.S8
*’
Citalopram, a selective inhibitor of 5HT uptake, does not affect per the stimulation-evoked overflow of 3H-5HT from rat hypothalamic slices , but antagonizes the inhibitory effect of LSDg9 and 5-methoxyt ~ y p t a m i n e on ~ ~ 3H-5HT release , indicating an interaction between the neuronal uptake mechanism and 5HT autoreceptors. On the other hand, stimulation or blockade of 5HT autoreceptors does not modulate the 5HT uptake process .91 The autoreceptor regulating 5HT release undergoes sensitivity changes after chronic pharmacological activation or blockade.33 However, long-term treatment with metitepine does not induce changes in the sensitivity or function of 5HT autoreceptors in rat hypothalamus. 92
se
CNS Autoreceptors for Acetylcholine (ACh) - Proposals have been made for the existence of an inhibitory muscarinic feedback regulation of ACh in the CNS, and at certain locations in the p e r i p h e ~ y . l * ~ ~Evidence *~~ for a negative feedback mechanism involving ACh autoreceptors has been obtained in both brain slices and s y n a p t o s o m e ~ . ~ ~Cyclic -~~ GWP has been found to act as a second messenger for the muscarinic autoreceptor regulating ACh release. 97*98 Rat hippocampal muscarinic autoreceptors become super or subsensitive following chronic in treatment with the muscarinic antagonist, scopolamine, or the cholinesterase inhibitor, paraoxon, r e s p e c t i ~ e l y . ~The ~ inhibitory muscarinic autoreceptors in synaptosomes of rat striatal nerve terminals have a markedly lower release modulating capacity than autoreceptors in cortical or h i p pocampal nerve endings. loo Since autoregulat ion of ACh release through muscarinic receptors occurs as effectively in the striatum as in the cottex or hippocampus, it has been suggested that in the former area the autoregulation of ACh release may not necessarily require the activation
-
Chap. 6
CNS Autoreceptors
Timmermans
55
of autoreceptors on cholinergic nerve terminals .loo Unlike the periphery,lol the autoreceptors for ACh in the CNS seem to be different from postsynaptic muscarinic receptors .94 CNS Autoreceptors for Histamine (H) - The first experimental evidence for histamine autoreceptors in rat brain has been presented tecently.lo2 3H-Histamine can be released in a calcium-dependent manner with K+ or veratridine from pre-labeled pools in slices or synaptosomes from rat cerebral cortex. Histamine, as well as its N-methyl and N,N'-dimethyl congeners, produces up to 60% inhibition. Other HI- or H2-agonists, like 2-methyl and 4-methylhistamine and dimaprit, were ineffective. The partial H2-receptor agonist imptomidine also lacked effect, but competitively antagonized the action of histamine. The HI-receptor antagonists mepyramine, cyclizine and chlorpheniramine were found inactive. The H2-receptor blocker burimamide was active, but tiotidine was without effect. The relative potencies of agonists and antagonists led the authors to suggest that autoinhibition of histamine release in rat brain is mediated by an as yet unidentified class of histamine receptor, for which they propose the designation H3.1°2 CNS Autoreceptors for GABA - Studies in vitro have demonstrated that the release of GABA is subject to negative feedback control through GABA autoreceptors on GABAergic terminals. In rat cortical synaptosomes, GABA and muscimol each inhibit evoked release of 3H-GABA, and are blocked by b i c u ~ u l l i n e . ~ ~The ~ K+-evoked release of GABA from rat frontal cortex is reduced by GABA, muscimol and 3-amino-propane sulphonic acid; the effect of muscimol being antagonized by bicuculline and picrotoxin.lo4 The GABA agonist 6-aminolaevulinic acid inhibits K+induced release of GABA from preloaded synaptosomes from rat cerebral cortex, and again this effect may be blocked by bicuculline and picrotoxin.lo5 Inhibition of the K+-evoked, Ca*+-dependent release of 3H-GABA from rat substantia nigra has been demonstrated with exogenous GABA and muscimol, and antagonism quantified for picrotoxin.lo6 Bicuculline-sensitive postsynaptic GABA receptors are called GABAA receptors, whereas baclofen-sensitive GABA receptors present on eripheral sympathetic nerve terminals are termed GABAB receptors,10~-108 The GABAB site has also been detected in the CNS, but its relationship to the presynaptic receptor which modulates transmitter release remains uncertain. 109 Physiological Role of Autorecevtors in the CIS; Targets for Drugs Though autoreceptors play a key role in modulating transmitter release, it should be emphasized that many other types of prejunctional receptors can influence transmitter synthesis, release, or neuron f i r i n ~ . l - ~ For example, NE release can be inhibited by stimulation of muscarinic, dopamine, serotonin, histamine, GABA, opiate, prostaglandin and adenosine receptors located at noradrenergic nerve endings. Furthermore, in many cases the net effect of an agonist or antagonist will be the sum of presynaptic and postsynaptic actions, since the majority of drugs cannot discriminate between both receptor populations. Thus it is frequently extremely difficult to interpret the (patho)physiological role of CNS autoreceptors or their interactions with drugs. Functional and biochemical studies suggest that endogenous depression may be related to impaired central noradrenergic transmission.llo*lll Drug-induced desensitization of central a2-autore-
56 -
Sect. I
- CNS
Agents
Hesp, Ed.
ceptors, stemming from chronic inhibition of neuronal NE uptake, and hence elevated synaptic NE levels, has been postulated to play a key role in the mechanism of action of many antidepressants.111 This would lead to yet further enhanced neurotransmission, with subsequent down regulation of central B-adrenoceptors111 - possibly a ivotal event in the induction of the desired therapeutic effect.llf However, the situation is far from clear with, on the one hand, conflictin reports as to whether chronic desipramine and imipramine do, lf3 or do not ,114 9 down regulate presynaptic a2-adrenoceptors in rat brain; and on the other, the finding that mianserin treatment results in supersensitive a2-adrenoceptors. It has been suggested recently that the induction of subsensitive central presynaptic a2-adrenoceptors cannot represent the fundamental mode of action of antidepressants .'-I1 Irrespective of the mechanism of action of tricyclic antidepressants, antagonists of a2-autoreceptors per gg might have a beneficial effect in depressive illness, since they facilitate noradrenergic neurotransmission. Phenoxybenzamine, dihydroergotamine and yohimbine, but not the selective al-adrenoceptor antagonist prazosin, have been shown to be synergistic with several antidepressants in decreasing 0-adrenoceptor density in rat cerebral cortex. Thus combined administration of an a2-adrenoceptor blocker with other antidepressants may provide a rapid onset t h e r a ~ y . 1 1 ~ RS 21361 produces a more rapid onset of 0-adrenoceptor desensitization by itself than desipramine.120 Chronically administered antidepressants also down-regulate the number of 5HT2 recognition sites in rat b~ain.1~1-123 Inasmuch as 5HT2 receptors are also implicated in the therapeutic action of antidepressants, blockade of central presynaptic a2-(auto)receptors accelerates the down regulation of 5HT2 receptors by antidepressants. 224 Desensitization of presynaptic DA receptors followin chronic administration of antidepressants has been observed in s0me,185*126 but not in other s t ~ d i e s . 1 ~ ~ -However, ~~8 central DA turnover is unaltered by such regimenslll and it is too soon to assess the relevance of these findings to the mechanisms underlying the clinical efficacy of these drugs. Clonidine and some related dru s suppress narcotic withdrawal signs in the rat, monkey and in man1299630 possibly via stimulation of presynaptic a2-adrenoceptors, thereby inhibitin the firing of the locus ceruleus through reduction of NE ~ e 1 e a s e . l ~ Clonidine ~ has also been found effective in the treatment of alcohol withdrawal states.lS2 Elevated central NE activity (e.g. in the locus ceruleus) is an important correlate of human anxiety, though not the sole one.133~134 The beneficial effects of clonidine as an antianxiety agent in humans could result from its inhibitory action on NE activity by stimulation of a2-autoreceptors . , The observation that ohimbine is anxiogenic in humans is in accord with this hypothesis. 1 3 7 The ideal agent €or facilitating central cholinergic transmisson would act simultaneously as an antagonist at ACh autoreceptors and as an agonist at postsynapttc ACh-receptors .138 It has been suggested13* that compounds, with this profile would be of therapeutic value in the
Chap. 6
CNS Autoreceptors
Timmermans
57
treatment of e.g. Huntington's chorea139 and Alzheimer-type demenan oxotremorine analog, is a presynaptic antagonist tia.140 BU-5 and a postsynaptic agonist at peripheral and central muscarinic synapses -in vitro.138
(a),
CH3-C
11
y 3 -N-CH-C=C-CHz-N
0
CHQ
3
22 -
The question of a physiological role for GABA autoreceptors remains open.3 GABA is involved in many CNS functions. Impaired GABA-mediated inhibition may contribute to the pathophysiology and phenomenology of epileptic seizures .Irr1 Consonant with this hypothesis, the purported GABA autoreceptor agonist 6-aminolaevulinic acid is a convulsant .Io5 "GABA replenishment" treatment has been advocated for seizures, psychosis, movement disorders, pain, hypertension and sleep disturbances Presynaptic autoreceptors for GABA have yet to be investigated as targets for potential drugs (e.g. GABA autoreceptor antagonists). The clinical significance of DA autoreceptor stimulation has been discussed. 14* Selective DA autoreceptor agonists, which reduce DA synthesis and release, represent a novel pharmacological approach to the treatment of various neurological disorders, including schizophrenia and Huntington's chorea, where an overactivity of central dopaminergic neurons is believed to be etiologic. Such drugs might lack some of the side-effects, e.g. tardive dyskinesia, associated with the currently prescribed neuroleptic agents, which are postsynaptic DA antagonists Apomorphine, N-pro ylnorapomorphine, and bromocryptine have been studied in the clinic.141-148 There is evidence for an antipsychotic effect following acute administration, particularly €or the two former agents. However, preliminary evidence suggests that the effect tolerates rapidly on repeated administration.149 References
12, 181 (1979). s . 2 . Langer, Pharmacol. Rev., 32, 337 (1981). 3. K. Starke, Ann. Rev. Pharmacol. Toxicol., 7 (1981). 4. M. J. Rand, U. W. McCulloch and D. F. Story, Trends Pharmacol. Sci., 2, 8 (1982). 5 . S. Kalsner. Trends Pharmacol. Sci., 2, 11 (1982). 6 . G . K. Aghajanian and M. A . Rogawski, Trends Pharmacol. Sci., 3, 315 (1983). 7. L. Hedler, K. Starke and A. Steppeler, Brit. J. Pharmacol., E , 645 (1983). 8. P. B. M. W. M. Timermans and P. A. van Zwieten, J. Ued. Chem., 21. 1389 (1982). 9. A . N. M. Schoffelmeer and A. H . Mulder, Naunyn-Schmiedeb. Arch. Pharmacol., 323, 188 (1983). 10. A. N. M. Schoffelmeer and A . H . Mulder, Eur. J. Pharmacol.. 81. 449 (1983). 11. 3. C. A. van Meel, A. de Jonge, P. B. M. W. M. Timermans and P. A. van Zwieten. J. Pharmacol. Exp. Ther., 291, 760 (1981). 12. W. Kobinger and L. Pichler, Eur. J. Pharmacol., 73, 313 (1981). 13. 0. Cambridge, Eur. J. Pharmacol., 72, 413 (1981). 14. P. 8. If. W. M. Timermans, B. Wilffert, D. Davidesko, M. J. Mathy, 0. Dijkstra, A . S. Horn and P. A . van Zwieten, J. Pharmacol. Exp. Ther., 225. 407 (1983). 15. P. E. Hicks and C. Waldron, Brit. J. Pharmacol., 74. 254P (1980). 16. P. B. M. W. M. Timecmans, M. J. Mathy, 8. Wilffert, H . 0 . Kalkman, G. Smit, 0. Dijkstra, A . S . Horn and P. A. van Zwieten, Eur. J. Pharmacol., 5 5 (1984). 17. R. R. Ruffolo, Jr. and E. L. Yaden, Eur. J. Pharmacol., 93, 117 (1983). 18. P. E. Hicks, C. Waldron, P. Burn and P. A . Crooks, J. Pharm. Pharmacol., 21. 94 (1983). 19. J. M. Caroon, R. D. Clark, A . F. Kluge, R. Olah, D. B. Repke. S. H . Unger, A . D. Michel and R. L. Whiting, J. Fled. Chem., 21, 6 6 6 (1982). 20. J. C. Doxey, A. G . Roach and C. F. C. Smith, Brit. J. Pharmacol., 78, 489 (1983). 1. E. s . Vizi, Progr. Neurobiol., 2.
z,
z,
58 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41: 42. 43. '44. 45. 46. 47. 48. e49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61.
62. 63. 64. 65. 66. 67.
Sect. I
- CNS Agents
Hesp, Ed.
J. C. Doxey. A. G. Roach, D. A. Strachan and N. Virdee, Brit. J. Pharmacol.. 7 9 . 311P (1983). I. B. A m a h , D. R. Ferry and H. Glossmann, Brit. J. Pharmacol., 78, 151P (1983). V. Pierce and J. F. Waterfall, Brit. J. Pharmacol., 2 263P (1982). J. M. Roesler, L. J. Kopaciewicz and J. P. Hieble, The Pharmacologist, 250, 242 (1983). R. R. Ruffolo, Jr., in "Stereochemistry and Biological Activity of Drugs", E. J. Ariens, W. Soudijn and P. B. M. W. M. Timermans, Eds., Blackwell. Oxford, 1983, p . 103. J. P. Dausse, K. H. Le Quan-Bui and P. Meyer, Eur. J. Pharmacol., 78, 15 (1982). M. Raiteri, G. Maura and P. Versache. J. Pharmacol. Exp. Ther., 224, 679 (1983). C. Ennis, J. Pharm. Pharmacol. 35, 750 (1983). F. Pelayo, M. L. Dubocovich and S. 2 . Langer. Eur. J. Pharmacol., 64, 143 (1980). E. Schlicker, M. Gothert, F. Kostermann and R. Clawing, Naunyn-Schmiedeb. Arch. Pharmacol., 323, 106 (1983). D. C. U'Prichard, T. D. Reisine, S. T. Mason, H. C. Fibiger and H. T. Yamamura, Brain Res., 187, 143 (1980). B. B . Hoffmann and R. J. Lefkowitz, Ann. Rev. Pharmacol.. 20. 581 (1980). M. Raiteri, M. Marchi, G. naura, P. Paudice and P. Versache, in "Basic and Clinical Aspects of Molecular Neurobiology", A. M. Giuffrida Stella, G. Gombos, G. Benzi and H. S. Bachelard, Eds., Fondazione Internationale Menarini, Milan, 1982. p . 207. S. Hjorth, A. Carlsson, D. Clark, K. Svensson. H. Wikstrijm, D. Sanchez, P . Lindberg, U. Hacksell. L.-E. Arvidsson, A. Johansson and J. L. G. Nilsson. Acta Pharm. Suec. ( S u p p l ) 1. 130 (1983). S. 2. Langer, S. Arbilla, L. Kamal and 8. Cantrill, Acta Pharm. Suec. ( S u p p l ) 1, 108 (1983). J. Lehmann, S. Arbilla and S. 2 . Langer, Naunyn-Schmiedeb. Arch. Pharmacol., 317, 31 (1981). L. X. Cubeddu and I. S. Hoffmann, J. Neurochem., 4 l . 91 (1983). J. Lehmann, R. V. Smith and S. 2 . Langer, Eur. J. Pharmacol., 3.81 (1983). A. H. Tissari, L. Atzori and M. T. Galdieri, Naunyn-Schmiedeb. Arch. Pharmacol., 322, 89 (1983). G. K. Aghajanian and 8 . S. Bunney, Naunyn-Schmiedeb. Arch. Pharmacol., 297, 1 (1977). T. C. Westfall, L. Naes and C. Paul, J. Pharmacol. Exp. Ther., 224, 199 (1983). s. E. Leff and I. Crease, Trends Pharmacol. Sci., 4, 463 ( 1 9 8 3 c E. Eriksson, K. Uodigh, A. Carlsson and H. Wikstrb, Bur. J. Pharmacol., 96, 29 (1983). K. Starke, L. Spith, J. D. Lang and C. Adelung, Naunyn-Schmiedeb. Arch. Pharmacol., 323 298 (1983). C S e e m a n , Pharmacol. Rev., 22, 229 (1980). P. Sokoloff, n.-P-Mattres and J.-C. Schwartz, Naunyn-Schmiedeb. Arch. Pharmacol., 315, 89 (1980). J. Lehmann, M. Briley and S. 2 . Langer, Bur. J. Pharmacol., 88, 11 (1983). S. E. Leff and I. Creese, Nature, 306, 586 (1983). J. L. G. Nilsson and A. Carlsson, Trends Pharmacol. Sci., 3, 322 (1982). J. F. Plantje', A. H. nulder and J. C. Stoof, Eur. J. Pharmacol., 91, 317 (1983). J. P. Arneric, J. P. Long, M. Williams, D. B. Goodale, G. M. Lakoski and G. F. Gebhart, J. Pharmacol. Exp. Ther., 224, 161 (1983). M. G. P. Feenstra, C. S u m e r s , J. H. Goedemoed, J. B. de Vries, H. Rollema and A. S. Horn, Naunyn-Schmiedeb. Arch. Pharmacol., 324, 108 (1983). D. B. Goodale, D. B . Rusterholz. J. P. Long, J. R. Plynn, B. Ualsh, J. G. Cannon and T. Lee. Science, 210, 1141 (19gO). N. E. And&, H. Nilsson and U. Thornstrom, Acta Pharmacol. Toxicol., 12. 51 (1983). P. Sminia and A. H. Mulder, Eur. J. Pharmacol., 89, 183 (1983). M. Williams, G. E. Martin, D. E. McClure, J. J. Baldwin and K. J. Watling. Naunyn-Schmiedeb. Arch. Pharmacol., 324, 275 (1983). S . Hjorth, A. Carlsson, D. Clark, K. Svensson, H. Wikstrom, D. Sanchez, P. Lindberg, U. Hacksell, L.-E. Arvidsson, A. Johansson and J. L. G. Nilsson, Acta Pharm. Suec. (Suppl) 1, 130 (1983). S. W. Koch, 8 . K. Koe and N. Bacopoulos, Eur. J. Pharmacol., 92. 279 (1983). K. J. Watling, Brit. J. Pharmacol., 646P (1983). S. Arbilla and S. 2 . Linger, Brit. J. Pharmacol., 2, 193P (1983). J. C. van Oene, H. A. Houwing, D. Dijkstra and A. S. Horn, Eur. J. Pharmacol., u, 491 (1983). L. Kamal, S. Arbilla, A . 4 . Galzin and S. 2 . Langer, J. Pharmacol. Exp. Ther., 227, 446 (1983). S. Arbilla, P. Baud and S. 2 . Langer, Brit. J. Pharmacol., 80 472P (1983). N. M. J. Rupniak. P. Jenner and C. D. Marsden. Life Sci., 32, 2289 (1983). J. Z. Novak, S. Arbilla, A.-W. Galzin and S. 2 . Langer, J. Pharmacol. Exp. Ther., 226, 558 (1983). S. Arbilla, S. 2 . Langer and J. 2 . Novak, Brit. J. Pharmacol., 78. 16P (1983). W . Gothert, Trends Pharmacol. Sci., 2, 437 (1982).
-
so,
-
Chap. 6 68. 69. 70. 71.
72. 73. 74. 75. 76.
77. 78. 79 80 * 81. 1
82. 83. 84. 85. 86. 87. 88.
89. 90. 91. 92. 93.
94. 95. 96.
97. 98. 99. 100.
101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123.
CNS Autoreceptors
Timmermans
59
M. Gothert, Naunyn-Schmiedeb. Arch. Pharmacol., 314, 223 (1980). I. Mounsey, K. A. Brady, J. Carroll, R. Fischer and D. N. Middlemiss. Biochem. Pharmacol., 31, 49 (1982). M. Gothert and E. Schlicker, Life Sci., 32, 1183 (1983). G. Engel, M. Gothert, E. Huller-Schweinitzer, E. Schlicker, L. Sistonen and P. A. Stadler. Naunyn-Schmiedeb. Arch. Pharmacol., 324. 119 (1983). C. Ennis and B. Cox, Neuropharmacol.. 21, 41 (1982). L. L. Martin and E. Sanders-Bush, Neuropharmacol., 21. 445 (1982). J. R. Fozard and G. M. P. Mwaluko, Brit. J. Pharmacol.. 57, 115 (1976). M. A. Rogawski and G. K. Aghajanian. J. Neurosci., 1, 1148 (1981). P. Blier and C. de Montigny, Neuropharmacol., 22, 495 (1983). L. L. Martin and E. Sanders-Bush, Naunyn-Schmiedeb. Arch. Pharmacol., 321, 165 (1982). B. cox and C. Ennis, J. Pharm. Pharmacol., 34, 438 (1982). D. L. Nelson, N. W. Pedigo and H. I. Yamamura, J. Physiol. (Paris), 77, 369 (1980). N. W. Pedigo. H. I. Yamamura and D. L. Nelson, J. Neurochem., 36, 220 (1981). J. R. Fozard, Trends Phannacol. Sci.. 4, 288 (1983). P. P. Deshmukh, D. L. Nelson and H. I. Yarnamura, Fed. Proc., 4 l , 6238 (1982). D. N. Middlemiss and J. 8. Fozard. Eur. J. Pharmacol., 90, 151 (1983). H. Gozlan, S. El Mestikawy, L. Pichat, J. Glowinski and M. Hamon, Nature, 305, 140 (1983). H. Gozlan, S. El Mestikawy, S. Bourgoin, M. Hall, L. Pichat, J. Glowinski and t4. Hamon, Naunyn-Schmiedeb, Arch. Pharmacol., 324 (Suppl), R19 (1983). D. N. Middlemiss, Naunyn-Schmiedeb. Arch. Pharmacol., 324 (Suppl), R19 (1983). : Hjorth, A. Carlsson. P. Lindberg, S. Sanchez, H. Wikstrom, L.-E. Arvidsson, U. S Hacksell and J. L. G. Nilson, J. Nueral Transm.. 55, 169 (1982). J. 8. Fozard and M. D. Tricklebank, Naunyn-Schmiedeb. Arch. Pharmacol., 324 ( S u p p l ) , 820 (1983). S. Z. Langer and C. Moret, J. Pharmacol. Exp. Ther., 222, 220 (1982). A . 4 . Galzin, S. 2 . Langer and B. Verzier, Brit. J. Pharmacol., 80, 718P (1983). M. Briley and C. Moret, Brit. J. Pharmacol., 80, 673P (1983). R. M. Hagan and I. E. Hughes, Brit. J. Pharmacol., 80, 513P (1983). J. C. Szerb. in "Presynaptic Receptors", S. Z. Langer, K. Starke and M. L. Dubocovich, Eds., Pergamon, Oxford, 1979, p. 293. P. C. Molenaar and R. L. Polak. Progr. Pharmacol., 3(4), 39 (1980). 0. Nordstrom and T. Bartfai, Acta Physiol. Scand., 108, 347 (1980). M. Marchi, P. Paudice and M. Raiteri, Eur. J. Pharmacol., 73, 75 (1981). 6. Nordstrom and T. Bartfai, Brain Res., 213, 467 (1981). P. Alberts and L. Stjarne, Acta Physiol. Scand., lJ.5, 269 (1982). M. Raiteri, 1. Marchi and P. Paudice, Eur. J. Pharmacol., 74, 109 (1981). M. Marchi, A. Caviglia, P. Paudice and N. Raiteri, Eur. J. Pharmacol., 9 l , 63 (1983). S. Halim, H. Kilbinger and I. Wessler, Scand. J. Gastroenterol. ( S u p p l ) , l7, 87 (1982). J. 1. Arrang, M. Garbarg and J.-C. Schwartz, Nature, 302, 832 (1983). S. R. Snodgrass, Nature, 273, 392 (1978). P. R. Mitchell and I. L. Martin. Nature, 274, 905 (1978). M. J. W. Brennan and R. C. Cantrill, Nature, 280, 514 (1979). S. Arbilla. L. Kamal and S. 2 . Langer, Eur. J. Pharmacol., 5 7 , 211 (1979). N. G. Bowery, A. Doble, D. R. Hill, A. L. Hudson, J . S. Shaw, M. J . Turnbull and R. Warrington, Eur. J. Pharmacol., 7 l . 53 (1981). M. S. Muhyaddin, P. J. Roberts and G. N. Woodruff, Eur. J. Pharmacol.. 9 2 . 9 (1983). N. G. Bowery, D. R. Hill and A. L. Hudson, Brit. J. Pharmacol., 7 8 , 191 (1983). C. B. Smith and J. A. Garcia-Sevilla, in "New Vistas in Depression", S. 2. Langer. 8 . Takanaski, T. Segawa and 1. Briley, Eds., Pergamon, Oxford, 1982. p. 99. M. F. Sugrue, Biochem. Pharmacol., 3 2 . 1811 (1983). F. Sulser. Trends Pharmacol. Sci., 1. 92 (1979). M. F. Sugrue, Life Sci., 28. 377 (1981). A. N. M. Schoffelmeer and A. H. Hulder, Naunyn-Schmiedeb. Arch. Pharmacol., 318. 173 (1982). E. Schlicker. M. Gothert and 8. Clausing, Naunyn-Schmiedeb. Arch. Pharmacol., 320, 38 (1982). F. Cerrito and M. Raiteri, Eur. J. Pharmacol.. 7 0 , 425 (1981). F. T. Crews, S. M. Paul and F. K. Goodwin, Nature, 290, 787 (1981). T. Reisine, R. Johnson, N. Wiech, R. Ursillo and H. I. Yamamura, Adv. Biochem. Psychopharmacol., 3l, 63 (1982). J. A. Scott, and F. T. Crews, J. Pharmacol. Exp. Ther., 224, 640 (1983). A. Dye, C. M. Page and R. L. Whiting, Brit. J. Pharmacol., 8 0 , 665P (1983). S. J. Peroutka and S. H. Snyder, Science, 210. 88 (1980). K. J. Kellar, C. S. Cascio, D. A. Bergstrom. J. A. Butler and P. Iadarola, J. Neurochem.. 21. 830 (1981). D. A. KendalK R. Duman, J. Slopis and S. J. Enna, J. Pharmacol. Exp. Ther., 222, 566 (1982).
60 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149.
Sect. I
- CNS Agents
Hesp, Ed.
F. T. Crews, J. A . Scott and N. H. Shorstein, Neuropharmacology, 22, 1203 (1983). G. Serra, A . Argiolas, V. Klimek, F. Padda and G. L. Gesna, Life Sci., 3,415 (1979). G. Serra, A . Argiolas, F. Padda, M. 61. Helis and G. L. Gessa, Psychopharmacology, 73, 194 (1981). C. Spyraki and H. C. Pibiger, Eur. J. Pharmacol.. 74, 195 (1981). H. H. Holcomb, M. J. Bannon and 8. H. Both, Eur. J. Pharmacol.. 82. 173 (1982). M. S. Gold, D. E. Redmond and H. D. Kleber. Lancet, 2, 599 (1978). n. La1 and G. T. Shearman, Progr. Clin. Biol. Rea., 3, 99 (1981). H. La1 and S. Fielding. Trends Pharmacol. Sci., 4. 70 (1983). J. A . Steiner, A. J. Wilkins and W. Jenkins, Brit. J. Clin. Pharmacol., l5, 583P (1983) . D. E. Redmond and Y. H. Huang, Life Sci., 25, 2149 (1979). It. Hoehnsacic, A . P. Merchant. M. L. Keyser and V. K. Smith, Arch. Gen. Psychiatry, 38, 1278 (1981). D. E. Redmond, Trends Pharmacol. Sci., 2, 477 (1982). D. S. Charnsy, G. 8. Heninger, D. E. Sternberg, K. H. Hafrtad, S. Giddings and D. H. Landis. Arch. Gen. Paychiatry, 39. 290 (1982). D. S. Charney, G. 8. Heninger and D. E. Redmond, Life Sci., 33, 19 (1983). 0. Nordstrk, P. Alberts. A. Westlind, A. Unde'n and T. Bartfai, Mol. Pharmacol., 24. 1 (1983). E. G. S. Spokes, Trends Neurochem. Sci.. 4, 115 (1981). S. Corkin. Trends Neurochem. Sci., 4, 287 (1981). R. G. Fariello and H. It. Ticku, Life Sci., 33, 1629 (1983). H. Y . Meltzer, Dopamine Receptors and Their Behavioral Correlates Pharmacology Biochemistry 6 Behavior, Vol. 17 (Suppl 1 ) . 1 (1982). H. Meltzer, Schizophrenia Bull., 6, 456 (1980). R. W. Fuller, Trends Pharmacol. Sci., 4, 394 (1983). I(. J. Uatling, Trends Pharmacol. Sci., 3, 232 (1982). H. Y. neltzor, Schizophr. Bull., 6, 456 (1980). C. A. Tllma~inga, 1. D. Gotts and M. R. Miller, Acta Pharm. Suec. (Suppl) 2, 153 (1983). H. Y. Meltzer, T . Kolakowska, A. Robertson and B. J. Trfcou, Psychophormocology, 81. 37 (1983). C. A. Tamminga, 22nd Ann. Meeting Am. College Phormacol.. San Juan, Puerto Rico, December 12-16, 1983.
-
-
-
-
S e c t i o n I1 Editor:
-
Pharmacodynamic Agents
W i l l i a m T. Comer, Bristol-Myers Research and Development 345 Park Avenue, N e w York, New York 10154
Chapter 7.
A n t i h y p e r t e n s i v e Agents
P e t e r Sprague and James R. Powell, The Squibb I n s t i t u t e f o r Medical Research, P r i n c e t o n , New J e r s e y 08540 I n t r o d u c t i o n - A r t e r i a l h y p e r t e n s i o n c o n t i n u e s as a major r i s k f a c t o r i n t h e development of c a r d i o v a s c u l a r d i s e a s e . C u r r e n t l y i t i s n o t p o s s i b l e t o prevent e s s e n t i a l h y p e r t e n s i o n and t h i s p r e s e n t s a c h a l l e n g e t o t h e c l i n i c i a n , pharmacologist, and m e d i c i n a l chemist t o d i s c o v e r adequate t h e r a p i e s . The b e n e f i c i a l e f f e c t s of drug t h e r a p y i n t h e management of h y p e r t e n s i o n have been r e c e n t l y reviewed. A number of r e c e n t reviews d e s c r i b e t o p i c s r e l a t e d t o h y p e r t e n s i o n . The s i g n i f i c a n c e of catecholamine l e v e l s i n h y p e r t e n s i o n h a s been discussed and a c a u t i o n a r y n o t e o f f e r e d t h a t l e v e l s i n mixed venous blood a r e unreThe l i a b l e i n d i c a t o r s of sympathetic n e u r a l a c t i v i t y i n h y p e r t e n s i o n . , r o l e of t h e sympathoadrenal a x i s i n h y p e r t e n s i o n h a s been r e ~ i e w e d . ~The need f o r i n t a c t v a s c u l a r endothelium f o r v a s c u l a r responses t o a number of a g e n t s h a s been d e s c r i b e d . 5 A r e c e n t review examines t h e r o l e of r e n i n subs t r a t e i n h y p e r t e n s i o n . L a s t l y , based on t h e unimodal d i s t r i b u t i o n of blood p r e s s u r e s , t h e e x i s t e n c e of h y p e r t e n s i o n as an e n t i t y h a s been questioned. Renin I n h i b i t o r s - A review of p r o g r e s s made i n d e f i n i n g t h e s t r u c t u r e of mouse submaxillary gland r e n i n h a s appeared. The presence of two a s p a r t y l , two t y r o s y l and one a r g i n y l r e s i d u e s a t t h e a c t i v e s i t e h a s been demonstrated. Current approaches t o r e n i n i n h i b i t i o n have been reviewed. Monoclona l a n t i b o d i e s w i t h h i g h a f f i n i t y and s p e c i f i c i t y f o r human r e n i n have been developed and s e v e r a l new p e p t i d e s modeled a f t e r t h e minimal s u b s t r a t e ochave been prepared. tapeptide 1 His-Pro-Phe-His-Leu-Leu-Val-Tyr 2 His-Pro-Phe-His-Leuseu-Val-Tyr
(1)
3 Iva-His-Pro-Phe-His-Sta-Ile-Phe-NH2
4 BOC-Phe-His-Sta-Leu-(4-amido-l-benzylpiperidine) H-77 ( 2 ) , i; which t h e Leu-Leu amide i s reduced t o an amine, suppresses t h e p r e s s o r e f f e c t i n dogs of i n j e c t e d dog r e n i n (ID50=0.06 mglkgjhr) . l o * 1 1 Heptapeptide 2, i n which Leulo-Leu11 i n 1 i s r e p l a c e d by s t a t i n e ( S t a ) , i s one of t h e most p o t e n t human r e n i n i n h i b i t o r s i n v i t r o y e t d i s c o v e r e d ( I ~ o = 2 nM).12 F u r t h e r refinement of t h i s c l a s s gave 4, a p r o t e c t e d t e t r a p e p t i d e amide w i t h a 60 picomolar K i a g a i n s t human r e n i n . 1 3 Angiotensin Converting Enzyme I n h i b i t o r s - An e x c e l l e n t review on t h e mechanisms by which i n h i b i t o r s of a n g i o t e n s i n c o n v e r t i n g enzyme (CEI) reduce blood p r e s s u r e h a s appeared. l 4 Current evidence sup o r t s t h e h y p o t h e s i s t h a t CEI e x e r t t h e i r hypotensive e f f e c t s p r i m a r i l y gy i n h i b i t i o n of circu-'
ANNUAL REPORTS IN MEDICINAL CHEMISTRY-I9
Copyright 0 1984 by Academic Press, Inc. All rights of reproduction in any forni reherqd ISBN 0-12-'J40519-9
62
S e c t . I1
- Pharmacodynamic Agents
Comer, Ed.
l a t i n g and tissue-bound c o n v e r t i n g enzyme. S e v e r a l new C E I modeled a f t e r e i t h e r c a p t o p r i l o r e n a l a p r i l have been r e p o r t e d . P i v a l o p r i l (RHC 3659, 2) h a s been shown e q u i v a l e n t t o c a p t o p r i l -i n v i t r o b u t o n l y 114 as a c t i v e i n man.I5-l7 Z o f e n o p r i l (k) r e p r e s e n t s a second g e n e r a t i o n c a p t o p r i l showing 10-fold g r e a t e r potency and a l o n g e r (WY 44,221) h a s a c t i v i t y d u r a t i o n of a c t i o n . The d i h y d r o i n d o l e analog similar to 6. 9-2 T e t r a h y d r o i s o q u i n o l i n e v a r i a t i o n 2 is e q u i v a l e n t i n act i v i t y t o c a p t o p r i l . 2 2 SA 446 given o r a l l y , i n h i b i t s angiotensin I (i.c.v.)-induced h y p e r t e n s i o n more e f f e c t i v e l y t h a n c a p t o p r i l , implying del i v e r y a c r o s s t h e blood-brain b a r r i e r . The s i d e - c h a i n benzoyl analog 10 i s more p o t e n t t h a n c a p t o p r i l w i t h a l o n g e r d u r a t i o n of a c t i v i t y . 2 4 Lactam 11, 2-fold less a c t i v e t h a n c a p t o p r i l , w a s developed u s i n g a computera s s i s t e d molecular modeling approach.25
1
(z),
FHs
R- S-CHiCH-CO-R‘
-5
b A 12
(c$cc-
-9
Ph-(C%
2al NH A
I?M*qNH
l3 p
Ph-C-
U
* q
A
CHI 8
B=8wH
0 R Ah-Pro
l!i
H-
d
H-
8
-N
COOH
A summary of t h e pharmacology of e n a l a p r i l (MK-421) h a s appeared a l o n g w i t h an account of c l i n i c a l s t u d i e s done w i t h l i s i n o p r i l (MK-521) which s u g g e s t t h i s drug w i l l be s u i t a b l e f o r once-a-day a n t i h y p e r t e n s i v e t h e r a p y . 26-28 Analogs of e n a l a p r i l which have appeared i n c l u d e t h e perhy(SCH 31,846). This compound h a s a q u i c k e r o n s e t of droindole d e r i v a t i v e a c t i o n , b e t t e r a b s o r p t i o n , and g r e a t e r b i l i a r y e x c r e t i o n t h a n e n a l a p r i l b u t i s o t h e r w i s e i n d i s t i n g u i s h a b l e i n vivo. 29-31 S y n t h e s i s of t h e c l o s e l y rel a t e d 2 h a s been r e p o r t e d . 3 2 G l u t a r i c a c i d analog g, m i s s i n g a side-chain n i t r o g e n , i s i n t e r m e d i a t e i n a c t i v i t y i n v i t r o between c a p t o p r i l and enalap r i 1 . 3 3 A r e l a t e d s i m p l i f i e d d e r i v a t i v e 15 (CGS 13,945), i s much l e s s pot e n t t h a n c a p t o p r i l i n man.34 The i n t e r n a l lactam s t r a t a g y h a s a l s o been (CGS 14,831) i s p o t e n t & employed i n t h e e n a l a p r i l series. Benzazepine 7 (CGS 14,8248) h a s a more r a p i d o n s e t of v i t r o (150’3 nM), and i t s ester 1 a c t i o n p l u s greater potency t h a n e n a l a p r i l i n dogs. 35 9 36 The phenethylphosphinamidate 1 9 refinement o f t h e phosphoramidate CEI 3 is 3-fold more po. ~ ~ 20, a d e r i v a t i v e of benzoyl-Phe-Gly-Pro i n which t e n t i n ~ i t r o Compound t h e s c i s s i l e amide bond i s reduced t o a n amine, is a p o o r l y a c t i v e C E I . 3 8
12
16
V a s o d i l a t o r s - The c e l l u l a r